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1
MEGAKARYOPOIESIS AND PLATELET PRODUCTION 
When a blood vessel is damaged due to injury or surgery a process called haemostasis prevents 
signifi cant blood loss. Blood platelets (thrombocytes) are anucleate discoid cells that have a central 
role in this process. Platelets, are derived from large (>150 μm) progenitor cells that reside in the bone 
marrow, called megakaryocytes. Although present at a low frequency of only 1/10000 nucleated cells, 
megakaryocytes produce approximately 1 x 1011 platelets every day. 
Early megakaryopoiesis
Like all blood cells, megakaryocytes are derived from hematopoieti c stem cells (HSCs). In the classical 
model megakaryocytes develop from megakaryocyte-erythrocyte progenitors (MEPs) that are bipotent 
precursors of both the megakaryocyti c and erythroid lineages.1, 2 However, recent studies have 
demonstrated that the commitment to the megakaryocyti c lineage is decided earlier than expected 
previously. The existence of megakaryocyte-biased HSCs suggests that megakaryocytes might be directly 
diff erenti ated from HSCs, possibly bypassing the MEP stage.3 Either way the process of megakaryocyte 
development or megakaryopoiesis starts with early megakaryocytes that undergo a normal proliferati ve 
stage followed by repeated cycles of DNA replicati on without cell division, termed endomitosis, to 
become polyploid up to 128N.4 Endomitosis is believed to occur during megakaryopoiesis in order to 
support the large quanti ty of protein and membrane synthesis necessary for platelet producti on.5
Late megakaryopoiesis
During late events of megakaryopoiesis, an invaginated membrane system (also known as demarcati on 
membrane system) is formed that is conti nuous with the plasma membrane and permeates the 
cytoplasm. This membrane system is thought to functi on as a membrane reservoir for proplatelet 
formati on.6  Furthermore, alpha (α) and dense (δ) granules are produced. δ-granules are the major 
source of small molecules such as calcium, magnesium and adenine nucleoti des that sti mulate platelet 
aggregati on. α-granules, the most abundant platelet organelles, are the major site of protein storage 
(e.g. fi brinogen, platelet factor 4 (PF4), β-thromboglobulin (β-TG), and von Willebrand factor (VWF)) 
needed for coagulati on and haemostasis.4, 7, 8 α-granule proteins can have opposing functi ons. This 
suggests that platelets release diff erent subpopulati ons of α-granules in a regulated manner, depending 
on the functi on to perform. Finally, mature megakaryocytes will express cell surface receptors that 
mediate platelet adhesion and aggregati on such as CD41 (integrin αIIb, GPIIb), CD61 (integrin β3, GPIIIa), 
and CD42b (GPIbα).9
Proplatelet formati on
Mature megakaryocytes will generate multi ple, long branching extensions called proplatelets that 
elongate into the sinusoidal blood vessels of the bone marrow, and functi on as assembly lines of platelet 
producti on.4, 10 Proplatelets are a string of platelet-sized, bead-like swellings, which are connected by 
cytoplasmic bridges. Eventually, the blood fl ow will cause the release of the terminal buds into the 
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bloodstream as platelets.4, 9 In this way, a single megakaryocyte can generate thousands of platelets 
before membrane exhaustion, after which the remaining cell body is degraded.11 
Role of platelets in primary haemostasis
Under normal conditions platelets have a lifespan of about nine days, and do not interact significantly 
with the endothelial cells of the blood vessel. However, when a blood vessel is damaged, the 
subendothelial matrix is exposed, leading to rapid accumulation of platelets at the site of injury to form 
a fibrin rich plug that stops the bleeding. At sites of low shear such as veins and large arteries, platelet 
adhesion is mediated through interaction of platelet receptors with collagen and other adhesive 
proteins. In small arteries or microvasculature, where the shear is high, platelet adhesion is intensified 
through the platelet glycoprotein (GP) Ib-IX-V receptor (containing CD42b) interaction with VWF which 
is bound to collagen in the extracellular matrix. This interaction provides a more stable interaction 
between collagen and its receptors GPVI and integrin α2β1, triggering intracellular pathways that lead to 
remodelling of the cytoskeleton, and aggregation of platelets via fibrinogen and activated integrin αIIbβ3 
(CD41/CD61) receptors.9 Platelets will subsequently release their granule contents (degranulation) e.g. 
VWF from the α-granules and ADP from δ-granules, contributing to coagulation, wound healing and 
inflammation. Simultaneously, the coagulation cascade is activated (secondary haemostasis) resulting 
in fibrin strands, consolidating the platelet aggregate to become a strong fibrin clot. This fibrin clot is 
eventually degraded in a process called fibrinolysis. 
INHERITED BLEEDING AND PLATELET DISORDERS
The above described process of platelet formation and haemostasis is disturbed in inherited bleeding 
and platelet disorders (IBPDs), which is a heterozygous group of diseases. IBPDs can be divided in 
coagulation defects and platelet defects. The most common inherited IBPDs are von Willebrand disease 
(VWD) (1 in 100-1000) and haemophilia A (1 in 5000-10000 males) which are caused by coagulation 
defects, the remaining IBPDs are very rare. IBPDs with a platelet defect are also called inherited platelet 
disorders (IPDs).12 
 IPDs are an extremely heterogeneous group of disorders associated with defective platelet count 
and/or platelet function, and bleeding diatheses of varying severities. This makes them difficult to 
properly diagnose even with standardized platelet function testing and bleeding assessment scores. 
Identification of the pathogenic gene variant is therefore very important in the analysis of these 
patients, as it can provide accurate diagnosis. Genetic variations are nowadays identified using high-
throughput sequencing with targeted gene panels and whole-exome sequencing. Detected variants 
are filtered using their minor allele frequency in the large population cohort database gnomAD and 
prioritized by comparing the patients’ phenotypes with the clinical and laboratory characteristics of 
IPDs. The correct interpretation and pathogenicity scoring of variants is crucial for diagnosis, as usually 
more variants are detected per sequenced sample.13 Guidelines for the interpretation and classification 
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of gene variants have been suggested by the American College of Medical Geneti cs and Genomics 
and the Associati on for Molecular Pathology,14 and we used these guidelines to classify new GFI1B 
variants in Chapter 3. Following these guidelines, variants identi fi ed in pati ents with rare hereditary 
disorders should be classifi ed using the terms ‘pathogenic’, ‘likely pathogenic’, ‘variant of uncertain 
signifi cance (VUS)’, ‘likely benign’, and ‘benign’. These variants can have a parti al or full contributi on to 
the phenotype. For VUS it is sti ll unclear if they are ‘pathogenic’. 
  Unti l now 63 genes have been identi fi ed with variants in IPDs (Figure 1).13 These genes play a role 
in megakaryopoiesis, platelet formati on and platelet functi on. More specifi cally, TPO and MPL signaling, 
transcripti onal regulati on, granule biogenesis and traffi  cking, cytoskeleton regulati on, glycoprotein 
(GP) signaling, and G-protein coupled receptor (GPCR) signaling. Most gene defects result in bleeding 
and thrombocytopenia, but some are also associated with defects in other blood cells or even non-
hematological phenotypes. For instance, mutati ons in RUNX1, ANKRD26 and ETV6 predispose to 
hematological malignancies, MYH9 mutati ons increase the risk of developing kidney failure, cataracts 
and hearing loss at a later stage, while MPL mutati ons almost always evolve into deadly bone marrow 
failure.15
TRANSCRIPTIONAL REGULATION VARIANTS IN IPD
The identi fi cati on of variants causing IPD have given us insight in the proteins important for the producti on 
and functi on of platelets. This is relevant for the development of targeted thrombocytopenia therapies. 
Variants in hematopoieti c transcripti on factors are associated with a multi tude of megakaryocyte and 
platelet defects, suggesti ng they are involved in many processes during megakaryopoiesis and therefore 
ideal to study the molecular pathways underlying megakaryopoiesis.  In my thesis I will focus on the 
transcripti on factor GFI1B because it is one of the most recently identi fi ed genes with variants in IPD 
and therefore less studied. In this chapter I will also discuss the other mutated transcripti on factors to 
illustrate the diff erences and similariti es in phenotypes with GFI1B variants.
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TPO/MPL signaling:   Transcription regulation: Granulopoiesis and traﬃcking:    Cytoskeleton regulation: GP receptor signaling:     GPCR signaling: 
TPO     GATA1                HPS1         MYH9   GP1BA           P2RY12
MPL     RUNX1   AP3B1         WAS   GP1BB           TBXA2R
     FLI1   HPS3         TPM4   GP9           TBXAS1
     ETV6   HPS4         ACTN1  ITGA2B           PLA2G4A
     GFI1B   HPS5         ARPC1B  ITGB3
     HOXA11  HPS6         CDC42  VWF           Other pathways:
     MECOM  DTNBP1         FLNA   RASGRP2           ANO6 
     ANKRD26  BLOC1S3         TUBB1  FERMT3           THBD
     RBM8A   BLOC1S6         DIAPH1  GP6           PLAU
     AP3D1         FYB
     LYST         RNU4ATAC
     VPS33B
     VIPAS39
     STXBP2
     NBEA
     NBEAL2
Pathway incomplete: CYCS, SRC, SLFN14, STIM1, ABCG5, ABCG8, MPIG6B, KDSR, GNE
 
    HSC          Early megakaryocyte         Late megakaryocyte        Proplatelet-forming megakaryocyte      Platelets
Figure 1
Figure 1. Affected genes in inherited platelet disorders. The role of inherited platelet disorder genes in 
megakaryopoiesis, platelet formation, and function. HSC: hematopoietic stem cell, GP: glycoprotein, GPCR: G-protein 
coupled receptor. Figure adapted from Heremans et al. 2018.
Growth Factor Independence 1B (GFI1B) 
GFI1B regulates both megakaryopoiesis and erythropoiesis. Patients with GFI1B variants mainly suffer 
from a bleeding diathesis. Although, there are a few variants for which morphological erythrocyte 
defects have been described. GFI1B contains an N-terminal Snail/GFI1 (SNAG) domain that can interact 
with transcriptional regulators, and six zinc fingers of which 3-5 are essential for DNA binding (Figure 
2).16 For the remaining zinc fingers the function is unknown. Heterozygous truncating variants in the 
DNA binding domain (G272fs, Q287*, H294fs)17-19, result in autosomal dominant bleeding diathesis, 
associated with macro-thrombocytopenia, hypogranular platelets, anisopoikilocytosis, and an increased 
number of megakaryocytes in the bone marrow which are dysplastic. Furthermore, the platelets and 
megakaryocytes express CD34, which is normally only found on stem and progenitor cells. These 
truncating variants are dominant-negative, which means they lost the repressive function of GFI1B and 
inhibit wild type GFI1B.
 In one individual a truncating GFI1B variant (K265*) was found in the DNA binding domain, 
together with a Factor V Leiden variant. This patient had a bleeding diathesis with thrombocytopenia, 
disturbed platelet aggregation and a reduction in α- en δ-granules. K265* caused a reduction in the 
number of megakaryocytes, in contrast to the other truncating variants.20 It needs to be investigated 
whether this variant also acts in a dominant negative manner.  
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 In additi on to truncati ng variants in the DNA-binding domain, there are also variants found that 
disturb the rati o between GFI1B isoforms p37 and p32. GFI1B-p37 is the most common isoform, and 
GFI1B-p32 is formed via alternati ve splicing of coding exon 4. This results in a protein lacking intact 
zinc fi nger 1 and 2. A homozygous inserti on c.551insG within coding exon 4 results in a premature 
stopcodon (S185fs*3), aff ecti ng only GFI1B-p37. De majority of the GFI1B-p37 transcript is broken 
down by nonsense-mediated-mRNA decay, resulti ng in only GFI1B-p32 on protein level. Aff ected 
family members have a very severe bleeding diathesis and hypogranular platelets with a reduced 
aggregati on reacti on. The megakaryocytes are small, dysplasti c, and express CD34 like the platelets.21
There is also a family with a heterozygous splice variant c.648+1_648+8delGTGGGCAC (reported as 
c.2520+1_2520+8delGTGGGCAC by Rabbolini et al.) which is predicted to result in GFI1B-p32 and 
therefore less expression of GFI1B-p37. Aff ected family members have platelet CD34 expression, but 
no bleeding diathesis or thrombocytopenia22 possibly because there is enough GFI1B-p37 as result of a 
heterozygous variant.
 Finally there are missense variants (C165F,23 C168F,22 and L308P (homozygous)20) located in the 
non-DNA-binding zinc fi ngers one and six. Variants C165F and L308P result in a mild bleeding diathesis, 
which is absent in C168F aff ected cases. All three result in macro-thrombocytopenia, either with platelet 
CD34 expression for C165F and C168F, or a reducti on in α- en δ-granules for L308P. Furthermore, the 
bone marrow biopsy of an L308P individual showed increased megakaryocyte numbers, which were 
someti mes immature. Additi onal GFI1B variants located in non-DNA binding domains were reported 
by Chen et al.24 In chapter 3 we performed a molecular and/or clinicopathological characterizati on to 
investi gate if these GFI1B variants are pathogenic.
SNAG
Q287*
znf1       znf2      znf3       znf4      znf5       znf6
K265* G272fs H294fs L308PC165F
DNA binding
S185fs
c.648+1_648+8delGTGGGCAC
GFI1B
C168F
LSD1 binding
Figure 2
Figure 2. GFI1B variants in inherited platelet disorders. Schemati c overview of GFI1B protein structure with 
variants identi fi ed in inherited bleeding and platelet disorders. All variants are heterozygous except for S185fs and 
L308P. There are two isoforms of GFI1B, the full length GFI1B-p37 is presented here, the short isoform GFI1B-p32 
lacks intact zinc fi nger (znf) 1 and 2 due to exon 4 skipping. c.648+1_648+8delGTGGGCAC (NM_004188.6) is a splice 
variant resulti ng in exon 4 skipping and expression of GFI1B-p32. 
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GATA-binding protein 1 (GATA1)
Like GFI1B, GATA1 is crucial in erythrocyte and megakaryocyte development. Inherited (X-linked) 
variants in this gene lead to bleeding diathesis and severe erythrocyte defects in men. The bleeding 
diathesis presents as bruising, petechia, nose bleeds and sustained bleeding after injury or surgery. 
The bleeding diathesis is caused by thrombocytopenia in combination with platelet defects such as 
enlarged platelets, diminished aggregation function, and a reduction of α-granules. Furthermore, the 
bone marrow of several GATA1 mutated patients show dysmegakaryopoiesis with hyperproliferation of 
(sometimes immature) megakaryocytes.25-29
 GATA1 has two zinc fingers. The C-terminal zinc finger binds the consensus DNA sequence (A/T)
GATA(A/G), while the N-terminal zinc finger stabilizes the DNA interaction and binds to co-regulatory 
proteins like Friend of GATA1 (FOG1) and the pentameric complex consisting of TAL1, LMO2, LDB1, 
TAL1, and E2A.9 GATA1 and FOG1 can induce both gene activation and repression,30 in contrast to GATA1 
and the pentameric complex that will only induce transcriptional activation.31
 Until now, all described GATA1 missense variants are located in the N-terminal zinc finger 
(Figure 3). All missense variants cause thrombocytopenia. However, there are differences in additional 
phenotypes depending on the location and amino acid change. The V205M, G208R en D218Y variants 
cause severe dyserythropoietic anemia, G208S, D218G en D218N mild dyserythropoiesis, R216Q 
β-thalassemia, and R216W erythropoietic porphyria. The phenotypes of V205M, G208R, G208S, and 
D218Y are a result of a disturbed interaction with FOG1, and R216Q and D218G disturb the interaction 
with LMO2 (pentameric complex).32 The disease causing mechanism is not studied for R216W. 
 In addition to variants in the N-terminal zinc finger, a rare variant (X414Rext42) was found that 
elongated the GATA1 protein by changing the stopcodon into an arginine. The index patient suffered 
from bruising, mild thrombocytopenia with macro-thrombocytes and a reduction in α-granules.33 For 
this variant it is also not clear how it contributes to the bleeding diathesis. 
   N-TAD N-znf   
DNA binding
   C-TADC-znf   
V205M
G208S
G208R
R216Q
R216W
D218Y 
D218G
D218N
GATA1
X414Rext42
FOG1/LMO2
binding
Figure 3
Figure 3. GATA1 variants in inherited platelet disorders. Schematic overview of GATA1 protein structure with 
variants identified in inherited bleeding and platelet disorders. Different domains are indicated such as the 
N-terminal transactivation domain (N-TAD), N-terminal zinc finger (N-znf), C-terminal zinc finger (C-znf), and 
C-terminal transactivation domain (C-TAD).
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Runt-related transcripti on factor-1 (RUNX1)
There are many diff erent heterozygous variants identi fi ed in RUNX1 (also known as CBFα and AML1), 
ranging from frameshift , missense, and nonsense mutati ons to big deleti ons. These inherited variants 
result in bleeding diathesis, thrombocytopenia, and platelet dysfuncti on such as a reducti on in α- and 
δ-granules or aggregati on defects.34 Like earlier described for GFI1B variants, RUNX1-Q154fs aff ected 
individuals have CD34+ platelets.35 Characteristi c for inherited RUNX1 variants is the increased risk of 
developing acute myeloid leukemia (AML) or myelodisplasti c syndrome (MDS).34 The bleeding diathesis 
is oft en mild and therefore missed resulti ng in only the diagnosis of AML.36
 The majority of RUNX1 variants are located in the RUNT domain (Figure 4), which is responsible 
for nuclear localisati on, DNA binding, and the interacti on with CBFβ. Multi ple studies investi gated the 
in vitro eff ect of RUNX1 variants on the diff erent functi ons of the RUNT domain. To perform its normal 
functi on, RUNX1 should migrate to the nucleus together with CBFβ.37  Truncati ng RUNX1 variants R201* 
and R204* cannot migrate to the nucleus leading to RUNX1 haploinsuffi  ciency. Missense variants at this 
positi on (R201Q and R204Q) do migrate to the nucleus and interact with CBFβ.38 The R201Q variant 
has disrupted DNA binding and inhibits wild type RUNX1 in a dominant-negati ve manner, possibly 
through sequestering CBFβ. This dominant-negati ve eff ect was also observed for the K110E variant.38, 39
Normally, K110 can be ubiquiti nated (mark for proteasomal degradati on). However, this is disturbed by 
the K110E variant resulti ng in a more stable mutant protein that could sequester more CBFβ.40
 Although many RUNX1 variants are located in the RUNT domain, there are also variants found 
in the intermediate domain and the C-terminal transacti vati on domain. RUNX1 can induce acti vati on 
or repression depending on the co-factors binding to the transacti vati on domain.41, 42 The frameshift  
variant T246Rfs, located in the intermediate domain, results in loss of the transacti vati on domain. 
However, the RUNT domain is sti ll intact resulti ng in a mutant protein that inhibits wild type RUNX1 
by occupying the target sites without inducing transcripti onal acti vity.43 Another truncati ng variant 
is located in the transacti vati on domain (Y287*).38 Correcti on of this variant in induced pluripotent 
stem cells (iPSC) rescued the phenotype and restored megakaryopoiesis, proving the pathogenicity of 
Y287*.44
            RUNT
DNA & CBFβ binding          NLS
      ID          TAD   
RUNX1
K110E
c.351+1G>T
A134P
c.442_449del
A156E
R166Q
Q154fs
R201Q, R201*
R204Q, R204*
T246fs Y287* Q335R
Figure 4
Figure 4. RUNX1 variants in inherited platelet disorders. Schemati c overview of RUNX1 protein structure and 
variants identi fi ed in inherited platelet disorders. Diff erent domains are indicated such as the RUNT domain 
important for DNA and CBFβ binding, the transacti vati on domain (TAD), nuclear localizati on signal (NLS), and the 
inhibitory domain (ID). Intronic variants, predicted to interfere with splicing are shown in italics.
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Friend Leukaemia Integration 1 (FLI1)
FLI1 is a transcription factor with a E26 transformation specific (ETS) domain for DNA binding (GGA(A/T) 
motif) and an N-terminal domain important for transactivation. FLI1 acts together with GA binding 
protein transcription factor α subunit (GABPα) which also belongs to the ETS transcription factor 
family.45 FLI1 regulates genes important in megakaryocyte development like C-MPL (TPO-receptor).46  
 FLI1 is located on chromosome 11 (11q23.3) and is monoallelic deleted in Paris-Trousseau and 
Jacobsen syndrome as a result of the 11q deletion.47 These syndromes are characterized by mild 
thrombocytopenia, lack of collagen induced aggregation, and fused α-granules.48, 49 Recently it was 
found that the hemizygotic FLI1 deletion causes the bleeding diathesis in these patients.50 51 
 Individuals with missense and frameshift variants in FLI1 (R324W, N331Tfs*4, R337W, R337Q, 
Y343C, K345E) have a bleeding diathesis with macro-thrombocytopenia, fused α-granules, and reduced 
ATP secretion from the δ-granules. There is no reduction in α-granules like with GATA1, GFI1B, and 
RUNX1 variants. All identified FLI1 variants are located in the ETS domain (Figure 5). As expected, DNA-
binding is disturbed for R324W, R337W, and  Y343C variants. For the remaining variants this is not yet 
studied. 
 Another characteristic of inherited FLI1 defects is increased platelet MYH10 expression.52, 53 
RUNX1 regulates the expression of MYH10 via FLI1, and for several RUNX1 variants MYH10 expression 
was also increased.52  MYH10 might therefore be a good biomarker for both FLI1 and RUNX1 variants.  
            PNT
DNA binding
          ETS   
FLI1
K345ER337W
R337Q
Y343CN331fsR324W
Transactivation
Figure 5
Figure 5. FLI1 variants in inherited platelet disorders. Schematic overview of FLI1 protein structure and variants 
identified in inherited platelet disorders. The pointed (PNT) domain is involved in transactivation and the ETS domain 
in DNA binding.
Ets variants 6 (ETV6) 
ETV6 is, like FLI1, a member of the ETS transcription factor family. In addition to the C-terminal DNA 
binding ETS domain, ETV6 contains a N-terminal PNT domain which mediates dimerization (e.g. with 
FLI1 and ETV6 itself) and nuclear localization. These two domains are separated by a central regulatory 
linker domain. ETV6 specifically acts as a transcriptional repressor that auto-regulates itself and requires 
homodimerization to exert repression.54 The major domains of ETV6 also appear to bind a plethora of 
co-repressors, which interact with the PNT-domain (L3MBTL1, KAP1, SIN3A), central regulatory linker 
domain (HDAC3, N-COR), or ETS-domain (SIN3A, N-COR, SMRT, TIP60).55 
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 Most pati ents with inherited ETV6 variants present with mild to moderate thrombocytopenia. 
Other features such as bleeding symptoms, large platelets, dysmegakaryopoiesis, dyserythropoiesis, 
nuclear hypolobulati on and hypogranulati on of myeloid cells, and increased numbers of circulati ng 
CD34+ cells, were described in a subset of pati ents.54, 55 In general, ETV6 variants predispose to both 
lymphoid and myeloid hematological malignancies. Acute lymphoid leukemia (ALL) is most frequent, 
especially childhood B-ALL. Overall, approximately 30% of all carriers have been diagnosed with a 
hematologic malignancy.54
The hotspot inherited ETV6 variant P214L (present in fi ve families) is located in the central 
regulatory linker domain. The remaining variants are located in the ETS domain (Figure 6). It is thought 
that all variants act in a dominant-negati ve manner either via sequestrati on of the wild type protein to 
the cytoplasm, competi ti on for co-repressors, or reducing the affi  nity of repressive complexes to DNA 
by changing or deleti ng the DNA-binding acti vity of the ETS-domain.55
            PNT                                        Linker
DNA binding
          ETS   
ETV6
Dimerization
Nuclear localization
R418GR369Q
N385fs
R399CW380RR369WR359X
L349P A377T
Y401N
I358M R396G
Y401H
P214L
Figure 6
Figure 6. ETV6 variants in inherited platelet disorders. Schemati c overview of ETV6 protein structure and variants 
identi fi ed in inherited platelet disorders. ETV6 contains a pointed (PNT) domain which mediates homo- and 
heterodimerizati on and is required for nuclear localizati on of the protein, the linker is a central regulatory domain, 
and the ETS domain binds DNA.
EVI1, HOXA11, and RBM8A
EVI1 is encoded by the MECOM gene and has fi ve N-terminal zinc fi ngers that recognize a GATA-like 
moti f and three C-terminal zinc fi ngers that recognize an ETS-like moti f. Through the C-terminal 8th zinc 
fi nger, EVI1 interacts with itself and other transcripti on factors including RUNX1 and GATA1.56 Gain-of-
functi on EVI1 variants (T756A, H751R, and R750W) located in the 8th zinc fi nger have been implicated 
in radioulnar synostosis with amegakaryocyti c thrombocytopenia (RUSAT), which is an inherited bone 
marrow failure syndrome, characterized by severe thrombocytopenia due to absence or  signifi cant 
reducti on of megakaryocytes, and congenital fusion of the radius and ulna. Before, RUSAT was found 
associated with a dominant loss-of-functi on variant in HOXA11 ( N291Tfs*4), which is a transcripti on 
factor implicated in bone morphogenesis and megakaryocyte diff erenti ati on.57, 58 EVI1 is also implicated 
in the pathogenesis of thrombocytopenia–absent radii syndrome. This syndrome is caused by 
compound inheritance, with  a variant in RBM8A on one allele and a variant in an EVI1 regulatory 
region of RBM8A on the other allele.58
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Variants in the regulatory region of ANKRD26
In addition to transcription factor mutations, there are also variants in the 5’UTR of ANKRD26 that 
possibly inhibit binding of RUNX1 and FLI1 causing ANKRD26 related thrombocytopenia. These patients 
show mild to severe thrombocytopenia, mild bleeding diathesis, increased levels of serum TPO and 
dysmegakaryopoiesis in the bone marrow. No defects in platelet function or morphology have been 
found, but several patients displayed defective GPIα expression on platelet surface and a reduction of 
platelet α-granules. Interestingly, about 10% of patients included in this study developed AML, MDS or 
chronic myeloid leukemia (CML).59
TRANSCRIPTIONAL REGULATION BY GFI1B 
GFI1B has an important role in the endothelial to hematopoiesis transition, the process where 
endothelial cells become blood cells and the first hematopoietic stem cells (HSCs) are formed.60 In adult 
hematopoiesis, GFI1B is expressed in HSCs, common myeloid and megakaryocyte/erythroid progenitors, 
and erythroid and megakaryocyte lineages. Moderate GFI1B levels are also found in immature B-cells, 
a subset of  early T-cell precursors, and peripheral blood granulocytes and monocytes.61 Gfi1b knock-
out (KO) mice die because of anemia, and fail to develop megakaryocytes.62 Loss of Gfi1b in adult mice 
increases the absolute numbers of HSCs that are less quiescent,63 ablates erythropoiesis at an early 
progenitor stage, and blocks terminal megakaryocyte differentiation in the polyploid promegakaryocyte 
stage that fail to produce platelets.64 This indicates that GFI1B plays a crucial role in HSCs, erythropoiesis, 
and megakaryopoiesis.
 GFI1B is a repressive transcription factor with an N-terminal SNAG domain for nuclear localization 
and recruitment of co-regulators such as LSD1 and RCOR1. The C-terminus contains six zinc fingers 
of which 3-5 are essential for DNA binding to a TAAATCAC(T/A)GC(A/T) motif.16 Between these two 
domains is a less-studied region of which the function is still unknown. As mentioned before there 
are two GFI1B isoforms, full length GFI1B-p37 and short GFI1B-p32 lacking intact zinc finger 1 and 2. 
This short isoform seems important for erythroid development65 and indispensable for megakaryocyte 
development.24 
 GFI1B target genes have been indentified in different hematopoietic cell types, both myeloid and 
lymphoid. At the DNA level, GFI1B represses its own expression and that of GFI1;66  proto-oncogenes 
Myc, Myb,67 and Meis1;68 tumor suppressor genes Socs1 and Socs3;69 the anti-apoptotic gene BCL2L1;70 
hematopoietic transcription factors GATA271 and SPI1;72 lymphoid regulators GATA373 and RAG1/2;74 cell 
cycle regulator CDKN1A (P21);75 and TGFBR3.76 A few studies specifically investigated GFI1B targets in 
megakaryopoiesis and found regulator of G-protein signaling Rgs18,77 FERMT3 (Kindlin3) which has a 
role in integrin-mediated platelet adhesion,78 and Talin1 involved in integrin-cytoskeleton interactions.78 
These latter two are in line with observations in megakaryocyte-specific Gfi1b KO mice showing loss of 
integrin signaling response, cytoskeleton reorganization, and proplatelet formation. The Gfi1b-deficient 
megakaryocytes exhibit aberrant expression of several components of both the actin and microtubule 
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cytoskeleton, and inhibiti on of PAK, a regulator of the acti n cytoskeleton, completely rescued their 
integrin responsiveness.79
 To regulate hematopoiesis, GFI1B interacts with other transcripti on factors such as the SCL (TAL1) 
core complex (E2A, LMO2, Ldb1) and GATA1.80 Furthermore several co-repressors have been found 
associated with GFI1B, such as LSD1 with its partner RCOR1, histon deacetylase 1/2 (HDAC1/2),81  histon 
methyl transferases SUV39H1 and G9A (EHMT2),82  RUNX1T1 (ETO), and CBFA2T3 (ETO2).83
REGULATION OF GFI1B EXPRESSION
GFI1B expression is controlled by multi ple transcripti on factors binding the promoter, such as GATA1, 
Oct1, NF-Y, HGMB2, and GFI1B itself.84-86 Furthermore Anguita et al. have identi fi ed three multi species 
conserved non-coding elements (CNEs) around 12.5kb, 16kb and 17.5kb downstream of the human 
GFI1B start codon (corresponds to 13, 16 and 17kb in mice). Chromati n immunoprecipitati on studies in 
human (K562) and murine (MEL, L8057, HPC7) cell lines demonstrated that the positi ve regulators of 
GFI1B expression, GATA1, TAL1 (SCL), NF-E2, LDB1, LMO2, MYB, TCF3 (E2A),84 and GATA271 are bound 
to these distant regulatory elements. Interesti ngly, these sites are also bound by repressors of GFI1B
expression, GFI1B, RCOR1, and LSD1, and could behave as negati ve regulatory elements depending on 
the GFI1B levels.84 The three CNEs were validated as hematopoieti c enhancers in transgenic mouse 
assays,71 and looping to the Gfi 1b promoter was shown for the 13 and 17kb CNEs.84
CHAPTER 1
22
OUTLINE OF THIS THESIS
The aim of this thesis is to gain more insight in molecular mechanisms of the transcription factor 
GFI1B in hematological disorders. GFI1B is crucial for megakaryopoiesis, and inherited variants in 
this protein lead to a bleeding diathesis with a multitude of megakaryocyte and platelet defects. In 
chapter 2 we investigated the molecular mechanism of the IPD causing variant GFI1B-Q287*, that was 
earlier identified by our research group. Furthermore, we studied molecular pathways downstream of 
GFI1B-Q287*, to identify GFI1B regulated processes during megakaryopoiesis and platelet formation. 
In chapter 3 we performed a molecular and clinicopathological characterization of eight GFI1B 
variants previously identified in cases with unexplained bleeding and/or platelet defects. To improve 
classification of inherited GFI1B variants we developed assays testing the damaging effect of newly 
identified inherited GFI1B variants on its function. In addition to IPDs, GFI1B has a pathological role 
in myeloid malignancies. For example, deregulated GFI1B expression is associated with hematological 
malignancies including myeloproliferative neoplasms. In chapter 4 we investigated whether the clonal 
hematopoiesis and myeloproliferative neoplasm predisposing G-allele of rs621940, located ~8 kb 
downstream of GFI1B, affects GFI1B expression and GFI1B auto-repression. Finally, chapter 5 provides 
a general discussion and unpublished data related to the research in this thesis.
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ABSTRACT 
Dominant-negative mutations in the transcription factor Growth Factor Independence-1B (GFI1B) like 
GFI1B-Q287*, cause a bleeding disorder characterized by a plethora of megakaryocyte and platelet 
abnormalities. The deregulated molecular mechanisms and pathways are unknown. Here we show that 
both normal and Q287* mutant GFI1B interacted most strongly with the LSD1-RCOR-HDAC co-repressor 
complex in megakaryoblasts. Sequestration of this complex by GFI1B-Q287* and chemical separation 
of GFI1B from LSD1, induced abnormalities in normal megakaryocytes comparable to those seen in 
patients. Megakaryocytes derived from GFI1B-Q287* induced pluripotent stem cells also phenocopied 
abnormalities seen in patients. Proteome studies on normal and mutant induced pluripotent stem cell 
derived megakaryocytes identified a multitude of deregulated pathways downstream of GFI1B-Q287* 
including cell division and interferon signaling. Proteome studies on platelets from GFI1B-Q287* patients 
showed reduced expression of proteins implicated in platelet function, and elevated expression of 
proteins normally downregulated during megakaryocyte differentiation. Thus, GFI1B and LSD1 regulate 
a broad developmental program during megakaryopoiesis, and GFI1B-Q287* deregulates this program 
through LSD1-RCOR-HDAC sequestering.
MOLECULAR CHARACTERIZATION OF THE GFI1B-Q287* MUTATION
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I NTRODUCTION 
Platelets are specialized cell fragments that functi on to prevent excessive bleeding upon blood vessel 
injury.1 During megakaryopoiesis, megakaryoblasts undergo endomitosis followed by cytoplasmic 
maturati on, during which α- and δ-granules are formed. Subsequently, mature megakaryocytes migrate 
to blood vessels in the bone marrow or lung, where they form protrusions and shed proplatelets into 
the bloodstream.2, 3
 The identi fi cati on of inherited bleeding and platelet disorder mutati ons has provided insight into 
proteins crucial for platelet producti on and functi on. Genes mutated in these disorders range from 
proteins involved in α-granule biology like NBEAL2, to transcripti on factors controlling a wide range of 
megakaryocyte processes.4 One of the transcripti on factors mutated in inherited bleeding  and platelet 
disorders is Growth Factor Independence 1B (GFI1B). To date, truncati ng mutati ons aff ecti ng DNA 
binding,5-8 missense mutati ons,9-11 and mutati ons that change the amount and rati o of the two naturally 
occurring GFI1B isoforms (p37 and p32) have been described.11, 12 Bleeding tendencies may vary 
depending on the type of mutati ons, being severe for cases that express only GFI1B-p32,12 moderate 
to severe for dominant-negati ve truncati ng mutati ons,5-8  and mild to even absent for the missense 
mutati ons.9-11 Most, but not all mutati ons associate with macrothrombocytopenia, a reducti on in 
platelet α-granules, and increased CD34 expression. For some mutati ons, a reducti on in CD42b 
expression, paucity of platelet δ-granules, and an increase in morphologically abnormal megakaryocyte 
numbers in the bone marrow have been described as well. Based on these observati ons it can be 
concluded that normal GFI1B regulates a multi tude of megakaryocyte-specifi c processes, and that the 
molecular mechanisms causing the abnormaliti es may diff er.
 GFI1B is a transcripti onal repressor containing six C-terminal zinc fi ngers (in case of the GFI1B-p37 
isoform) and an N-terminal Snail/GFI1 (SNAG) domain, important for lysine specifi c demethylase (LSD1/
KMD1A), REST Corepressor 1 (CoREST/RCOR1) recruitment.13 The GFI1B-p32 isoform that lacks intact 
zinc fi nger 1 and 2, also associates with LSD1-RCOR1 and is suffi  cient for erythropoiesis.12, 14 In additi on 
to LSD1, GFI1B recruits histone methyl transferases and histone deacetylases (HDACs) to target gene 
promoters and enhancers to induce transcripti onal repression, among which GFI1B itself.15, 16 Of the 
co-factors, LSD1 may be especially important because the majority (80%) of Gfi 1b bound regions in 
murine MEL cells are also enriched for Lsd1 occupancy, suggesti ng a strong interdependency.13 LSD1 is 
an essenti al gene in mammalian diff erenti ati on and functi on, including hematopoiesis. In vitro and in 
vivo Lsd1 knockdown studies showed that normal granulopoiesis, erythropoiesis and megakaryopoiesis 
all depend on Lsd1.13, 17, 18
 Inherited mutati ons in GFI1B disrupti ng its DNA binding zinc fi ngers, such as GFI1B-Q287*, are 
known to act in a dominant-negati ve manner.5 The GFI1B p.Q287* mutati on is located within the fi ft h 
zinc fi nger of GFI1B and leads to a protein truncated in its DNA-binding region. As a consequence, 
GFI1B-Q287* is disrupted in its ability to bind GFI1B sequence moti fs.8 Importantly, its SNAG domain, 
crucial for LSD1 binding, remains intact. In this study we use the dominant-negati ve GFI1B-Q287*
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mutant to unravel the mechanism by which it inhibits wild type GFI1B and identify GFI1B regulated 
pathways during megakaryopoiesis.
METHODS 
Mass spectrometry analysis of GFI1B interacting proteins in MEG-01 cells
MEG-01 cells were lentivirally transduced with FUW, FUW-GFI1B-GFP and FUW-GFI1B-Q287*-GFP 
and nuclear extracts were prepared as described in Dignam et al.19 Label-free GFP-pulldowns were 
performed using GFP-Trap beads (ChromoTek) as described in Smits et al.20 Subsequently, the proteins 
were subjected to on-bead trypsin digestion and peptides were acidified and desalted using C18-
Stagetips.21 Peptides were recorded with an LC-MS/MS Orbitrap Fusion Tribrid mass spectrometer 
(ThermoFisher Scientific). Raw data were analyzed by MaxQuant (version 1.5.7.0). Differential proteins 
between empty vector and GFI1B or GFI1B-Q287* were determined using a t-test with FDR<0.01 and 
fold change (FC)>9.2. The stoichiometry of the identified complexes was determined by dividing the 
iBAQ intensity in the GFI1B/GFI1B-Q287* samples with the iBAQ intensity in the empty vector samples. 
Proliferation of GFI1B transduced MEG-01 cells
MEG-01 cells were retrovirally transduced with pMIGR1-GFI1B variant-flag-IRES-GFP resulting in mixed 
cultures of GFP positive and negative cells. The GFP% was followed using flow cytometry for 26 days. 
GFP% were normalized to the starting point of the culture (day 5) using the following formula: (GFP% 
day X/(100 – GFP% day X))/(GFP% day 5/(100 – GFP% day 5)). On day 23, GFP positive cells were FACS-
sorted to determine total and endogenous GFI1B expression using quantitative RT-PCR. 
Primary megakaryocyte cultures
CD34+ hematopoietic stem and progenitor cells were isolated from mobilized peripheral blood of healthy 
donors. Informed consent was given in accordance with the Declaration of Helsinki and the Dutch 
national and Sanquin internal ethical review boards. CD34+ cells were differentiated to megakaryocytes 
in modified IMDM (HEMAdef)22 supplemented with 50 ng/ml stem cell factor (SCF), 50 ng/ml TPO, 1 
ng/ml IL-3 and 20 ng/ml IL-6 for 4 days, followed by culturing in 50 ng/ml TPO and 10 ng/ml IL-1β for 
7 more days (Peprotech).23 Where indicated, 4 µM GSK-LSD1 (Sigma) was added subsequently and 
cells were cultured for an additional 2-6 days depending on the read out (2 days: expansion, CD34 and 
CD42b expression; 2-6 days: prolonged effect on CD42b expression and proplatelet formation).
Proteomics mass spectrometry analysis of platelets and megakaryocytic cells
Blood was taken from healthy donors and patients to generate induced pluripotent stem cells (iPSC) 
and isolate platelets. The study was approved by the Medical Ethical Committee of the Radboudumc 
Nijmegen (2013/064) and conducted in accordance with the Declaration of Helsinki. The control iPSC 
line MML-6838-Cl224 and GFI1B-Q287* patient iPSC lines BEL-5-Cl1 and Cl2 (Supplementary Figure S1) 
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were diff erenti ated towards megakaryocytes as described before.25 For label-free quanti fi cati on proteins 
were reduced, alkylated, trypsin-digested, desalted and concentrated. Trypti c pepti des were separated 
by nanoscale C18 reverse phase chromatography coupled on-line to an Orbitrap Fusion Tribrid mass 
spectrometer (ThermoFisher Scienti fi c) via a nanoelectrospray ion source (Nanospray Flex Ion Source, 
ThermoFisher Scienti fi c). All mass spectrometry data were acquired with Xcalibur soft ware (Thermo 
Scienti fi c) and processed with MaxQuant computati onal platf orm, 1.5.2.8. The RAW fi les, MaxQuant 
search results, and details about the setti  ngs are available in the PRIDE repository database26 with the 
dataset identi fi er PXD009020. 
Stati sti cal analysis
Stati sti cal analysis for non-mass spectrometry experiments was performed in GraphPad Prism.
For more details see Supplementary Methods.
RESULTS
GFI1B and GFI1B-Q287* interact with LSD1-RCOR1-HDAC1/2 complex.
Several GFI1B variants have been identi fi ed in inherited bleeding and platelet disorders.5, 6, 8, 9 The 
majority of the pathogenic variants, like GFI1B p.Q287*, result in a truncati on disrupti ng the DNA 
binding capacity. Truncated GFI1B inhibits the wild type protein in a dominant-negati ve manner.5, 8
With the SNAG domain intact, we hypothesized that GFI1B-Q287* can compete with GFI1B for the 
recruitment of epigeneti c modifi ers. To test this hypothesis, we fi rst identi fi ed proteins interacti ng with 
GFI1B and GFI1B-Q287*. To this end, C-terminally GFP-tagged GFI1B and GFI1B-Q287* were expressed 
in megakaryoblasti c MEG-01 cells. GFP-pull down followed by on-bead trypsin digesti on and mass 
spectrometry analysis identi fi ed the following GFI1B interacti ng proteins: LSD1, RCOR1/3, HDAC1/2, 
GSE1, HMG20B, PHF21A, and GFI1 (Figure 1A). Of the detected GFI1B interactors, LSD1 was most 
abundant together with RCOR1/3 and HDAC1/2 (Figure 1B). The proteins GSE1, HMG20B, and PHF21A 
are all known to be subunits of the LSD1-RCOR-HDAC complex, also known as the CoREST (RCOR1) 
complex.27 The identi fi ed interactome of GFI1B-Q287* was highly similar to GFI1B, with ZMYM3 as the 
only signifi cant diff erenti al interactor (Figure 1C; Supplementary Figure S2), indicati ng that the DNA-
binding defecti ve GFI1B-Q287* mutant recruits virtually the same co-factors as GFI1B. 
GFI1B-Q287* functi ons in a dominant-negati ve manner by sequestering LSD1
The GFI1B p.Q287* mutati on results in an increase in megakaryocyte expansion in vivo and in vitro.5 To 
investi gate whether sequestering of LSD1 by GFI1B-Q287* is important for this eff ect, we introduced a 
P2A or K8A mutati on in the SNAG domain, previously described to disrupt effi  cient LSD1 recruitment to 
GFI1 and GFI1B.13, 28 We confi rmed impaired LSD1 recruitment in GFI1B-P2A/K8A-GFP transduced MEG-
01 cells, using GFP-trap bead mediated pull down (Figure 1D). Further, GFI1B-Q287*, GFI1B-
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Figure 1. GFI1B and GFI1B-Q287* interact with the LSD1-RCOR-HDAC complex. (A,C) Nuclear extracts of MEG-01 
cells transduced with empty vector (EV), GFI1B-GFP, or GFI1B-Q287*-GFP were analyzed by mass spectrometry. 
Stati sti cally enriched proteins are identi fi ed by a permutati on-based false discovery rate (FDR)-corrected t-test 
(FDR<0.01). The volcano plot shows the diff erence between label free quanti fi cati on (LFQ) intensiti es of the GFI1B-
GFP or GFI1B-Q287*-GFP pulldown and the EV control (log2-transformed fold change (FC)) on the x-axis, and the 
-log10-transformed p-value on the y-axis. Dott ed grey lines represent the stati sti cal cut-off s, which were chosen such 
that no proteins were present as outliers on the empty vector control side of the volcano plot. The proteins in the 
upper right corner represent the bait (GFI1B) and its interactors. We cannot exclude the possibility that we missed 
interacti ons due to steric hindrance by the GFP-tag, especially at the C-terminal end.  (B) Stoichiometry analysis of  >> 
MOLECULAR CHARACTERIZATION OF THE GFI1B-Q287* MUTATION
35
2
GFI1B interactors in MEG-01 showing relati ve abundances. Discriminati on between GFI1B;GFI1, HDAC1;HDAC2, and 
RCOR1;RCOR3 was not possible because of the presence of common pepti des. The iBAQ value of each interacti ng 
protein is graphed with GFI1B;GFI1 set to 1. GFI1 was identi fi ed as interactor of both GFI1B (all three replicates) and 
GFI1B-Q287* (two/three replicates, therefore fi ltered out). As pepti des common to GFI1B and GFI1 were included 
in the normalizati on this may aff ect stoichiometry values. Data are shown as mean ± standard deviati on of three 
pulldowns. (D) Western blot analysis of co-immunoprecipitated (IP) LSD1 aft er GFP-trap bead pulldown in MEG-
01 cells transduced with GFI1B-GFP (WT), GFI1B-Q287*-GFP (Q287*), GFI1B-P2A-GFP (P2A), GFI1B-K8A-GFP (K8A). 
Non-transduced (NT) cells were used as negati ve control. The upper panel shows LSD1 (~90kDa) and the lower panel 
GFI1B variants-GFP (~58kDa). The left  side of the blot shows LSD1 and GFI1B-GFP expression in the input samples. 
(E) Western blot analysis of MEG-01 cells transduced with empty vector (EV), and GFI1B-GFP, GFI1B-Q287*-GFP, 
GFI1B-P2A-GFP, and GFI1B-K8A-GFP stained with an anti body against GFI1B, identi fying both exogenous GFI1B-GFP 
fusions (~58kDa) and endogenous GFI1B (~37kDa). Acti n staining was used as loading control. (F) Endogenous GFI1B
expression (qPCR on 5’UTR GFI1B that is not present in overexpression constructs) relati ve to GAPDH expression 
following exogenous expression of empty vector (EV) or indicated fl ag-tagged GFI1B variants in MEG-01 cultures 
from Figure 2. Results show mean ± standard deviati on (n=3-11).
P2A and GFI1B-K8A failed to inhibit endogenous GFI1B expression in MEG-01 cells, in contrast to wild 
type GFI1B (Figure 1E-F). Next, we used MEG-01 as a megakaryoblast model to study the eff ect of 
GFI1B-Q287* on cell expansion. In expansion-competi ti on cultures containing transduced and non-
transduced cells, GFI1B overexpressing cells were rapidly overgrown by non-transduced cells, while 
the opposite was observed following expression of dominant-negati ve GFI1B-Q287* (Figure 2A). Thus, 
forced GFI1B expression inhibits MEG-01 expansion and dominant-negati ve GFI1B-Q287* results in 
enhanced expansion, the latt er being in line with observati ons in GFI1B p.Q287* aff ected individuals. 
 To determine whether the interacti on with LSD1 is important for the inhibitory eff ect on expansion 
of GFI1B, we separately introduced the P2A and K8A mutati ons in GFI1B. Expression of GFI1B-P2A or 
GFI1B-K8A nullifi ed the inhibitory eff ect of GFI1B on expansion (Figure 2B-C; Supplementary Figure S3). 
Thus, an intact LSD1 interacti ng SNAG domain is required for both inhibiti on of MEG-01 expansion and 
repression of the endogenous GFI1B locus.
 To investi gate whether the LSD1 interacti on is relevant for the dominant-negati ve eff ect in MEG-
01, we introduced the P2A and K8A mutati ons into GFI1B-Q287*. This showed that similar levels of 
ectopic GFI1B-P2A+Q287* and GFI1B-K8A+Q287* expression did not aff ect MEG-01 expansion, in 
contrast to GFI1B-Q287* (Figure 2D-E; Supplementary Figure S3). Together, these data indicate that 
GFI1B limits MEG-01 expansion through the LSD1 interacti ng SNAG domain. GFI1B-Q287* may aff ect 
this functi on in a dominant-negati ve manner by sequestering LSD1. 
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Figure 2. GFI1B and GFI1B-Q287* regulate MEG-01 expansion via LSD1 recruitment. (A) Normalized GFP% of 
MEG-01 cells transduced with empty vector (EV)-IRES-GFP, GFI1B-IRES-GFP and GFI1B-Q287*-IRES-GFP for 26 days 
(n=8). GFP percentages were normalized to day 5 after transduction (starting point of the culture) as described in the 
Methods. Results show mean ± standard error of the mean. (B) Normalized GFP% of MEG-01 cells transduced with 
empty vector (EV)-IRES-GFP, GFI1B-IRES-GFP, and GFI1B-P2A-IRES-GFP (n=4). (C) Normalized GFP% of MEG-01 cells 
transduced with empty vector (EV)-IRES-GFP, GFI1B-IRES-GFP, and GFI1B-K8A-IRES-GFP (n=3). (D) Normalized GFP% 
of MEG-01 cells transduced with empty vector (EV)-IRES-GFP, GFI1B-Q287*-IRES-GFP, and GFI1B-P2A+Q287*-IRES-
GFP (n=3). (E) Normalized GFP% of MEG-01 cells transduced with empty vector (EV)-IRES-GFP, GFI1B-Q287*-IRES-
GFP, and GFI1B-K8A+Q287*-IRES-GFP (n=4). *P<0.05, **P<0.01 ***P<0.001.
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Chemical disrupti on of the GFI1B-LSD1 interacti on in normal megakaryocytes 
results in abnormaliti es seen in GFI1B p.Q287* mutated megakaryocytes. 
LSD1 sequestering by GFI1B-Q287* in MEG-01 resulted in enhanced proliferati on. To determine 
whether LSD1 sequestrati on is relevant for other megakaryocyte abnormaliti es, we inhibited the GFI1B-
LSD1 interacti on during megakaryocyte diff erenti ati on by treati ng CD34+ cell-derived megakaryoblasts 
with the small molecule GSK-LSD1. This inhibitor binds covalently to LSD1 cofactor FAD, and thereby 
sterically hinders binding of GFI1B.29 We confi rmed the disrupted LSD1-GFI1B binding by the absence 
of co-precipitated LSD1 upon GFP-trap bead mediated pulldown in the presence of GSK-LSD1 (Figure 
3A). To study eff ects on megakaryopoiesis, CD34+ cells were diff erenti ated towards megakaryocytes 
in the presence of GSK-LSD1 for 48 hours. Quanti fi cati on of cell surface marker expression showed 
sustained CD34 expression and impaired CD42b expression compared to mock-treated cells (Figure 
3B-D). Besides this, a 2-fold increase in megakaryoblast expansion was observed in the presence of GSK-
LSD1 (Figure 3E). CD42b expression remained low aft er 3-6 days exposure to GSK-LSD1 (Supplementary 
Figure S4C) and we observed that these cells were unable to form proplatelets aft er 6 days (Figure 
3F, Supplementary Figure S4). These phenotypes are in line with observati ons in individuals with the 
GFI1B p.Q287* mutati on.5 Together with data presented in the previous secti on, this strongly suggests 
that mutant GFI1B-Q287* functi ons in a dominant-negati ve manner by sequestering LSD1, resulti ng in 
developmental megakaryocyte abnormaliti es. 
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Figure 3. Chemical disrupti on of the GFI1B-LSD1 interacti on by GSK-LSD1 recapitulates GFI1B-Q287* hallmarks 
in vitro. (A) Western blot on co-immunoprecipitated (IP) LSD1 aft er GFP-trap bead pulldown in DMSO control or  >> 
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GSK-LSD1 treated MEG-01 cells transduced with GFI1B-GFP (WT). Non-transduced (NT) cells were used as negati ve 
control. The upper panel shows LSD1 (~90kDa) and the lower panel GFI1B variants-GFP (~58kDa). The left  side of 
the blot shows LSD1 and GFI1B-GFP expression in the input samples. (B) Cell surface expression of megakaryocyte 
associated markers CD34, CD41a, and CD42b, to measure megakaryocyte maturati on. Represented are results from 
megakaryocyti c cultures 2 days aft er additi on of DMSO control or 4µM GSK-LSD1. (C) CD34 nMFI from CD34+/CD41a+
megakaryoblasts. (D) Percentage of CD42b positi vity on CD41a+ megakaryoblasts. The connecti ng lines (C-D) indicate 
which samples are from the same experiment. (E) Expansion of CD34+/CD41a+ megakaryoblasts during two days of 
DMSO control or GSK-LSD1 treatment. (F) Absolute number of proplatelet forming megakaryocyti c cells per view 
(based on Supplementary Figure S4A-B) 6 days aft er additi on of DMSO or 4 µM GSK-LSD1, n=6. *P<0.05, ***P<0.001.
GFI1B-Q287* iPSC-derived megakaryocyti c cells show disturbed megakaryocyte 
diff erenti ati on.
The morphological megakaryocyte abnormaliti es, their increased expansion, and sustained CD34 
expression, indicates that megakaryocyte diff erenti ati on is severely disturbed in GFI1B-Q287* mutated 
individuals. As the availability of CD34+ progenitors and megakaryocytes from pati ents is limited, 
we generated iPSC lines from a control individual (MML-6838-Cl2)24 and an individual harboring the 
GFI1B-Q287* mutati on (BEL-5-Cl1/2) to study megakaryopoiesis in more detail (Supplementary Figure 
S1). iPSC colonies were diff erenti ated towards megakaryocytes using a 2D diff erenti ati on protocol.25
May-Grünwald Giemsa stained cytospins and fl ow cytometry revealed enlarged cells with someti mes 
polyploidizati on for control megakaryocyti c cells, with co-expression of CD41a and CD42b confi rming 
megakaryocyte diff erenti ati on (Figure 4A-B). In contrast, diff erenti ati on of GFI1B-Q287* iPSCs resulted 
in a homogeneous appearance of small and pale cells (Figure 4A). In additi on, GFI1B-Q287* iPSC-
derived megakaryocyti c cells expressed elevated levels of CD34 in line with primary GFI1B-Q287*
megakaryocytes,5 while CD41a and CD42b expression was not diff erent (Figure 4C-E). Quanti fi cati on of 
the total number of CD41a+ cells between day 14-18 of iPSC diff erenti ati on showed that GFI1B-Q287* 
iPSCs produced 55-fold more megakaryocyti c cells compared to control iPSCs (Figure 4F), in line with 
the increased bone marrow megakaryocyte numbers observed in GFI1B-Q287* aff ected individuals. 
Electron microscopy of control and GFI1B-Q287* megakaryocyti c cells showed the presence of 
α-granules in both conditi ons (Supplementary Figure S5). Together, these data indicate that the 
GFI1B-Q287* iPSC-derived megakaryocyti c cells resemble micromegakaryocytes that exhibit some 
phenotypes (CD34 expression, increased expansion) also observed in aff ected individuals. 
CHAPTER 2
40
A      B
C            D
E                F  
                                                           Control
                                                      GFI1B-Q287*
GFI1B-Q287*
Control
CD
34
CD
34
CD
42
b
CD
42
b
CD41a CD41a
CD41aCD41a
4.47%                       26.2%                                 2.69%                42.0%
48.9%                       20.4%                                  51.7%                      3.69%
7.93%                      62.6%                                   1.20%                     44.6%
28.4%                       1.04%                                  35.1%                    19.0%
Control GFI1BQ287*
1,000
10,000
100,000
nM
FI
CD
34
****
Control GFI1BQ287*
0
10,000
20,000
30,000
40,000
50,000
nM
FI
CD
42
b
Control GFI1BQ287*
0
10,000
20,000
30,000
40,000
nM
FI
CD
41
a
Control GFI1BQ287*
10
100
1,000
10,000
100,000 **
Ce
ll
ex
pa
ns
io
n
(F
C)
Figure 4 
Figure 4. GFI1B-Q287* of iPSC derived megakaroid cells phenocopy disease characteristi cs (A) Cytospins of 
control and GFI1B-Q287* iPSC lines diff erenti ated towards megakaryocytes and stained with May-Grünwald Giemsa. 
Pictures were taken at 40x magnifi cati on using a Zeiss Scope.A1 microscope (Zeiss) and images were processed 
with Zen blue editi on. (B) Representati ve fl ow-cytometric analysis of control and GFI1B-Q287* iPSC derived cells for 
surface expression of megakaryocyte associated markers CD34, CD41a and CD42b. (C) nMFI of CD34 and (D) CD42b. 
(E) CD41a (F) Quanti fi cati on of CD41a+ megakaryocyti c cells per seeded iPSC to measure expansion potenti al. >> 
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CD41a+ cells were negati ve for erythroid, myeloid and endothelial makers indicati ng that these cells represent true 
megakaryocyti c cells (data not shown) **P<0.01, ****P<0.0001
Identi fi cati on of GFI1B-regulated processes in early megakaryocyte 
diff erenti ati on.
To determine deregulated protein expression downstream of GFI1B-Q287*, we compared the 
proteomes of GFI1B-Q287* iPSC-derived CD41a+ megakaryocyti c cells (n=6) with those of controls 
(n=6). In total 2906 proteins were quanti fi ed (Supplementary Table 1). We detected CD34 expression in 
GFI1B-Q287* iPSC-derived cells, while it was not detected in control cells (Supplementary Table 1).  The 
mass spectrometer was not sensiti ve enough to detect the lower CD34 expression on control cells versus 
GFI1B-Q287* cells observed with fl ow cytometry. The results confi rm the increased CD34 expression 
observed in the iPSC model system and pati ent platelets (Figure 4C). Major platelet receptors, including 
glycoprotein (GP)-IB, GPIX, and integrin αIIbβ3, as well as α-granule proteins such as Von Willebrand 
Factor (VWF) and thrombospondin-1 (THBS1), were not diff erenti ally expressed between control and 
GFI1B-Q287* iPSC-derived megakaryocyti c cells. However, a total of 396 proteins were diff erenti ally 
expressed between the GFI1B-Q287* and control iPSC-derived megakaryocyti c cells, of which 252 were 
up-regulated and 144 down-regulated (Figure 5A-B; Supplementary Table 1). One of the most strongly 
down-regulated proteins in GFI1B-Q287* iPSCs was the interferon-induced GTP-binding protein MX1, 
showing high expression in control iPSC derived cells but no detectable levels in GFI1B-Q287* iPSC-
derived cells (Supplementary Figure S6B). Other proteins related to interferon signaling, i.e. STAT1, 
IFI16, IFI30, IFI35, IFIT1, IFIT3, OAS2, and OAS3 were also signifi cantly reduced in GFI1B-Q287* iPSC-
derived megakaryocyti c cells compared to controls (Supplementary Table 1). Because the control and 
GFI1B-Q287* lines are derived from diff erent individuals, diff erences in individual protein expression 
might be caused by variati on in geneti c makeup of the lines. Therefore, gene ontology (GO) term analyses 
were performed to identi fy multi ple diff erenti ally expressed proteins assigned to specifi c pathways/
functi ons. This identi fi ed down-regulated proteins related to diverse functi ons, including mitochondria, 
response to sti muli, and transmembrane transport (Figure 5C; Supplementary Table 2). On the other 
hand, strongly enriched proteins in the GFI1B-Q287* iPSC-derived megakaryocyti c cells were all 
members of the minichromosome maintenance complex (DNA replicati on licensing factor proteins, 
MCM2-7; Supplementary Figure S6A, D) and structural maintenance of chromosome proteins (SMC1A, 
SMC2-4, SMCHD; Supplementary Table 1), which are required for DNA replicati on and chromosome 
condensati on, respecti vely (Figure 5D; Supplementary Table 2). Furthermore, MEIS1, a key player in 
megakaryocyte diff erenti ati on which is normally down-regulated at fi nal stages of megakaryocyte 
diff erenti ati on,30 showed consistent expression in GFI1B-Q287* iPSC-derived megakaryocyti c cells while 
it was never detected in control iPSC-derived cells (Supplementary Figure S6C). Thus, the GFI1B-Q287* 
protein infl uences the expression of a large number of proteins during megakaryopoiesis. 
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Figure 5. Diff erenti al protein expression between GFI1B-Q287* and control iPSC-derived megakaryocyti c cells. 
(A) Protein levels in control and GFI1B-Q287* iPSC-derived megakaryocyti c cells were determined using label free 
quanti fi cati on (LFQ) and diff erenti ally expressed proteins were determined using a two-sided t-test (p<0.05 and 
s0=0.5). The volcano plot shows the -log10-transformed p-value against the log2 fold change (FC) in relati ve protein 
levels between control and GFI1B-Q287* iPSC-derived megakaryocyti c cells, with each protein represented by a 
single point in the graph. Dashed lines represent the stati sti cal cut-off . A negati ve FC indicates proteins with reduced 
levels and a positi ve FC indicates elevated proteins in GFI1B-Q287* iPSC-derived cells. (B) Heat-map and hierarchical 
clustering of the 396 diff erenti ally expressed proteins between control and GFI1B-Q287* iPSC-derived cells. >>
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Heat-map colors are based on the z-scored (log2) LFQ values. Blue shades correspond to decreased expression levels 
and yellow shades to increased expression levels. Imputed values are shown in case a protein was not detected. (C) 
Enrichment of GO terms based on biological process, molecular functi on and cellular components was assessed as 
described in Materials and Methods. The overlap heatmap shows signifi cant GO terms related to down-regulated 
proteins in GFI1B-Q287* iPSC-derived megakaryocyti c cells. For each cluster, one or two summarizing terms are 
indicated. For a full list of signifi cant GO-terms see Supplementary Table 2. (D) The signifi cant GO-terms with 
corresponding p-values for up-regulated proteins in GFI1B-Q287* iPSC-derived megakaryocyti c cells are shown. 
Proteome changes in GFI1B p.Q287* platelets are not limited to α-granule 
protein depleti on.
GFI1B-Q287* iPSC derived megakaryocyti c cells show phenotypes that indicate aberrant diff erenti ati on. 
With platelets representi ng the fi nal stage of megakaryopoiesis, we asked how this is translated to the 
platelet proteome. To identi fy the deregulated proteins, platelet protein levels of four GFI1B-Q287* 
aff ected individuals were compared to those of four healthy individuals using label free quanti tati ve 
mass spectrometry. Out of 2550 quanti fi ed proteins, 1005 proteins were diff erenti ally expressed 
between normal and GFI1B-Q287* platelets, with 395 proteins being reduced and 610 elevated in 
case of the GFI1B-Q287* mutati on (Figure 6A-B; Supplementary Table 3). In line with the reported 
α-granule defi ciency,5 α-granule proteins such as VWF, THBS1, and platelet factor 4, showed markedly 
reduced levels in GFI1B-Q287* platelets (Figure 6C). Of note, NBEAL2, which is mutated and causati ve 
for the α-granule defi ciency in classical Gray Platelet Syndrome,31-33 was not among the reduced 
proteins in GFI1B-Q287* platelets, but in fact mildly elevated (Supplementary Table 3). In additi on, 
strongly elevated expression of CD34 was observed in GFI1B-Q287* platelets, compati ble with 
fi ndings reported above and published reports.5, 8 Other proteins enriched in GFI1B-Q287* platelets 
were proteasomal, ribosomal, and mitochondrial proteins (Supplementary Figure S7; Supplementary 
Table 3). GO terms associated with down-regulated proteins in GFI1B-Q287* platelets were strongly 
related to platelet functi ons and α-granules, including wound healing, chemotaxis, immune response, 
and vesicle secreti on (Figure 6D; Supplementary Table 2). Proteins elevated in GFI1B-Q287* platelets 
were parti cularly enriched for GO terms on mitochondrial functi on and the respiratory electron 
transport chain (Figure 6E; Supplementary Table 2). In additi on, a multi tude of other cellular processes 
associated with underrepresented (e.g. the Golgi and ER systems, adhesion, and the cytoskeleton) 
and overrepresented proteins (e.g. ubiquiti nati on, RNA processing, hematopoieti c diff erenti ati on, and 
several metabolic functi ons) were observed (Figure 6D-E; Supplementary Table 2). Thus, in additi on to 
a major reducti on in α-granule proteins, GFI1B-Q287* platelets exhibit aberrant expression of many 
other proteins with various functi ons.
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Figure 6. Diff erenti al protein levels between GFI1B-Q287* and control platelets. Platelets from four GFI1B-Q287* 
pati ents and four healthy individuals were isolated and protein levels were assessed using mass spectrometry. 
Diff erenti ally expressed proteins were determined using a two-sided t-test (p<0.05 and s0=0.5). (A) Volcano plot 
showing the -log10-transformed p-value against the log2 fold change (FC) in relati ve protein levels between control and 
GFI1B-Q287* platelets. Dashed lines represent the stati sti cal cut-off . A negati ve FC indicates proteins with reduced 
levels and a positi ve FC indicates increased levels in GFI1B-Q287* platelets. (B) Heat-map with hierarchical clustering 
for the 1007 diff erenti ally expressed proteins between control and GFI1B-Q287* platelets. Heat-map colors are 
based on the z-scored (log2) LFQ values. Blue shades correspond to decreased expression levels and yellow shades 
to increased expression levels. Imputed values are shown in case a protein was not detected. (C) Relati ve protein 
levels (log2 LFQ values) of selected α-granule proteins in platelets of healthy controls (circles) and GFI1B-Q287* 
pati ents (squares). ANGPT1, Angiopoieti n-1; FGA, Fibrinogen alpha chain; SPARC, Secreted protein acidic and rich in 
cysteine; PF4, Platelet Factor 4; THBS1, Thrombospondin-1; VWF, Von Willebrand Factor. (D-E) GO term enrichment 
analysis of the signifi cantly expressed proteins in GFI1B-Q287* platelets. Overlap heatmaps of signifi cant GO terms 
associated with (D) down-regulated and (E) up-regulated proteins in GFI1B-Q287* platelets. For each cluster, one or 
two summarizing terms are indicated. For a full list of signifi cant GO-terms see Supplementary Table 2. 
The GFI1B-Q287* platelet proteome resembles early megakaryoblasts.
As both platelets and cultured megakaryocyti c cells harboring the GFI1B-Q287* mutati on express the 
early progenitor marker CD34, we next asked whether GFI1B-Q287* platelets also express other early 
megakaryocyte proteins that are normally down-regulated upon terminal diff erenti ati on. To study 
this, we compared protein profi les of healthy maturing megakaryocytes with GFI1B-Q287* pati ent 
derived platelets. To this end, CD34+ cells were diff erenti ated to megakaryocytes and harvested for 
mass spectrometry analysis between days 4 and 14 of diff erenti ati on. A total of 3733 proteins were 
quanti fi ed, of which 1668 proteins showed signifi cantly diff erent expression levels during megakaryocyte 
maturati on (Figure 7A; Supplementary Table 4). Two main clusters of proteins showed strong up-
regulati on (578 proteins) or down-regulati on (1026 proteins) towards the late stages of megakaryocyte 
diff erenti ati on. Compati ble with the role of megakaryocytes as the platelet progenitor cells, platelet 
α-granule proteins and receptors were strongly increased during megakaryocyte diff erenti ati on (Figure 
7B-C). GO term analyses showed that up-regulated proteins were indeed strongly related to platelet 
biogenesis and functi on, including wound healing, (alpha) granules, the cytoskeleton, and cell acti vati on 
(Supplementary Figure S8A; Supplementary Table 2). Down-regulated proteins were associated with 
several GO terms related to ribosome functi on, RNA processing, DNA replicati on (including the MCM 
proteins) and other metabolic and biosyntheti c processes (Supplementary Figure S8B; Supplementary 
Table 2). Next, the over- and underrepresented proteins in GFI1B-Q287* platelets were compared with 
the protein profi les of the maturati ng megakaryocytes. The majority of down-regulated proteins in 
GFI1B-Q287* platelets showed a clear patt ern of up-regulati on in diff erenti ati ng megakaryocytes (~80%; 
Figure 7D), whereas the proteins that showed up-regulati on in GFI1B-Q287* platelets were generally 
down-modulated during megakaryocyte diff erenti ati on (~60%; Figure 7E). As platelets represent the 
terminal stage of megakaryocyte maturati on, our proteomic data show that the GFI1B-Q287* platelets 
resemble poorly diff erenti ated megakaryocytes.
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Figure 7. The GFI1B-Q287* platelet proteome reveals impaired megakaryocyte diff erenti ati on. The proteome 
of in vitro-diff erenti ati ng megakaryocytes (MK) was analyzed by label-free mass spectrometry (see Methods). 
Diff erenti ally expressed proteins were determined using ANOVA (false discovery rate <0.05, s0=0.5). (A) Heat-map 
with hierarchical clustering of the 1,668 proteins showing signifi cantly expression between any of the analyzed days 
of MK diff erenti ati on, i.e. day 4, 5, 6, 7, 8, 9, 10, 11, and 14 of diff erenti ati on (from left  to right) with three replicates 
per day of culture. Relati ve protein levels [z-scored log2 label-free quanti fi cati on (LFQ)] are shown with imputed 
values in the case a protein was not detected. (B) Expression levels in cultured MK of platelet α-granule proteins 
during MK diff erenti ati on. (C) Expression levels in cultured MK of platelet receptors during MK diff erenti ati on. (D-E) 
Relati ve expression levels in cultured MK of proteins with signifi cantly increased or decreased levels in GFI1BQ287* >> 
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platelets: 272 of the 395 downregulated proteins (D) and 503 of the 610 upregulated proteins (E) in GFI1BQ287*
platelets were identi fi ed in the MK. Magenta/blue shades in the heat-maps correspond to decreased expression 
levels and yellow/orange shades to increased expression levels; a gray color indicates that a protein was not 
identi fi ed in a given MK sample (Panels D and E only). THBS1: thrombospondin-1; VWF: von Willebrand factor; PF4: 
platelet factor 4; ANGPT1: angiopoieti n-1; SELP: selecti n P; ITGA2B: integrin subunit alpha 2b; ITGB: integrin subunit 
beta; CD36: cluster of diff erenti ati on 36; GP1BA: glycoprotein Ib platelet subunit alpha; GP9: glycoprotein 9.
DISCUSSION
The work presented here furthers our understanding on deregulated and disease-causing processes 
in GFI1B-related bleeding and platelet disorders. Earlier we proposed that GFI1B-Q287*, observed in 
individuals with an inherited bleeding diathesis, may inhibit the functi on of wild type GFI1B in a dominant-
negati ve manner by sequestering co-repressors.5 Indeed, mutant GFI1B-Q287* sti ll interacts with LSD1 
and its associated proteins in MEG-01. Unlike GFI1B causing a decrease in proliferati ve capacity, forced 
expression of GFI1B-Q287* in MEG-01 resulted in increased proliferati on. This increase was nullifi ed 
upon introducti on of single point mutati ons in GFI1B-Q287* that abrogate the interacti on with LSD1. 
In line with these fi ndings we observed that disrupti on of the GFI1B-LSD1 interacti on using GSK-LSD1 
induces GFI1B-Q287*-like phenotypes in CD34+ cell derived megakaryocytes, including the down-
regulati on of CD42b. Yet, GFI1B-Q287* iPSC-derived megakaryocytes did not show impaired CD42b 
expression. This could be explained by variati on in CD42b expression observed in aff ected individuals, 
with highest levels being comparable to those observed in non-aff ected individuals.5 Alternati vely, this 
may be explained by diff erences in in vivo and in vitro diff erenti ati on cues. Nevertheless, we propose 
that GFI1B-Q287* inhibits wild type GFI1B by inhibiti ng LSD1-dependent processes through competi ti ve 
sequestrati on of LSD1 and its binding partners. 
 The relevance of the GFI1B-LSD1 interacti on in megakaryoblast expansion is substanti ated 
by observati ons in mice following in vivo Lsd1 silencing. This resulted in Meis1 overexpression and 
increased megakaryocyte numbers in the bone marrow as well. Of note, here we found MEIS1 only in 
GFI1B-Q287*iPSC-derived megakaryocyti c cells but not in control iPSC-derived cells, indicati ng elevated 
expression in the former. Interesti ngly, Lsd1-silenced mice also exhibited megakaryocyte abnormaliti es, 
thrombocytopenia and a reducti on of platelet granules, similar to the phenotypes of pati ents harboring 
the dominant-negati ve GFI1B-Q287* mutati on.18 This could mean that the functi onal interplay between 
GFI1B and LSD1 is not limited to controlling megakaryoblast proliferati on and diff erenti ati on, but that 
it is also required for terminal maturati on and the generati on of granules and platelets. In additi on, 
this interplay is not restricted to megakaryopoiesis, but has also been shown to be essenti al for the 
transiti on of endothelial to hematopoieti c stem cells (HSCs) and erythrocyte development.13, 14, 34
 In additi on to GFI1B-Q287*, two other truncati ng GFI1B mutati ons have been identi fi ed that 
disrupt the DNA binding domain: G272fs8 and H294fs,6 both leading to a similar bleeding and platelet 
disorder. These GFI1B mutati ons also act in a dominant-negati ve manner. Thus, LSD1 sequestrati on by 
mutant GFI1B that cannot bind its transcripti onal targets may be a general mechanism through which 
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a collection of GFI1B mutations is acting. In these cases, the mutation is present in both GFI1B isoforms 
and they will inhibit wild-type GFI1B-p37 and GFI1B-p32. However, because GFI1B-p32 expression is 
much lower than GFI1B-p37,14 LSD1 sequestration by GFI1B-Q287*-p32 will be less than that for GFI1B-
Q287*-p37. The molecular mechanisms causing megakaryocyte and platelet defects for other reported 
GFI1B mutations are likely different because the DNA binding and LSD1-interacting domains remain 
intact in these mutants.
 We observed that GFI1B mainly associates with the LSD1-RCOR-HDAC repressor complex (also 
called BRAF-HDAC complex in neural development) containing LSD1, RCOR1, HDAC1/2, PHF21A 
(BHC80), and HMG20B (BRAF35).35 The other proteins found, GSE1, RCOR3, and ZMYM2/3, are also 
known LSD1 interactors,36 of which ZMYM2/3 have not been reported in complex with GFI1B before. 
ZMYM3 was identified as the only significantly different interacting protein between GFI1B and 
GFI1B-Q287*. Whether this is relevant for disease pathogenesis remains to be seen. Most interactors 
(LSD1, RCOR1/3, HDAC1/2, GSE1, ZMYM2/3) are detected in differentiating megakaryocytes as well 
(Supplementary Table 4), suggesting that they may be relevant for megakaryocyte development. 
 Proteome comparison of different iPSC-derived megakaryocytic cell cultures showed a uniform 
expression pattern in GFI1B-Q287* cells compared to wild type cells. The latter might be more 
variable due to differences in megakaryocytic differentiation stages between cultures. GFI1B-Q287* 
megakaryocytes exhibit a more uniform, micromegakaryocyte-like appearance, suggesting that they 
are arrested before polyploidization. This is in contrast with megakaryocytes observed in GFI1B-Q287* 
individuals5 and conditional GFI1B knockout mice,37 where a block after polyploidization but before 
cytoplasmic maturation is observed. Possibly, environmental cues that are absent in in vitro cultures 
may stimulate differentiation of GFI1B-Q287* megakaryocytes in vivo.
 In GFI1B-Q287* iPSC-derived megakaryocytic cells we observed a down-regulation of 
downstream IFN-γ signaling targets like STAT1, MX1, IFI16, IFI30, IFI35, IFIT3, OAS2, and OAS3. IFN-γ and 
its downstream effector STAT1 stimulate megakaryocyte differentiation and platelet production. STAT1 
promotes polyploidization, and loss of STAT1 in JAK2 V617F mice resulted in reduced platelet numbers 
through interference with megakaryocyte development.38, 39 The failure to activate interferon target 
genes in GFI1B-Q287* megakaryocytes may inhibit differentiation and explain the micromegakaryocyte-
like appearance of iPSC-derived megakaryocytes. 
 GFI1B-Q287* iPSC-derived megakaryocytic cells further revealed significantly increased levels of 
the MCM complex and MEIS1. This might be relevant as the MCM complex is involved in DNA replication/
cell cycle progression and, in accordance with several studies,40, 41 we observed that MCM proteins 
are downregulated upon megakaryocyte differentiation (Supplementary Figure S6D).40, 41 In addition, 
we showed earlier that forced MEIS1 expression in CD34+ cells results in larger and more colonies 
in CFU-MK assays.30 Thus, failure of down-modulation of DNA-replication associated genes by GFI1B 
as a consequence of sequestering LSD1 and associated proteins by GFI1B-Q287* might contribute to 
increased proliferation and lack of polyploidization.
 The platelets of GFI1B-Q287* patients showed a major reduction in α-granule proteins, ranging 
from a mild <2-fold decrease (e.g. SPARC, fibrinogen α and β chains) to a severe >10-fold depletion (e.g. 
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VEGF, P-selecti n). To our surprise, NBEAL2 showed signifi cantly increased expression in both platelets 
and iPSC-derived cells harboring the GFI1B-Q287* mutati on. Inacti vati ng mutati ons in NBEAL2 cause 
recessive gray platelet syndrome, a bleeding disorder characterized by a severe paucity in α-granules.31-33
Although its exact functi on is sti ll unclear, NBEAL2 is thought to be required for the biogenesis and/or 
retenti on of α-granules in megakaryocytes.42-44 Other proteins with putati ve roles in α-granule formati on, 
such as VPS33B45 and VIPAS3946, and proposed NBEAL2 interactors DOCK7, SEC16A and VAC1447 were 
mostly unaff ected in both GFI1B-Q287* platelets and iPSC derived cells, except SEC16A and VAC14, 
which showed a mild (<2-fold) decrease and increase in GFI1B-Q287* platelets, respecti vely. Possibly, 
these proteins are under diff erenti al control of GFI1B. In contrast to the GFI1B-Q287* platelets there 
was no change in α-granule proteins observed in GFI1B-Q287* iPSC derived megakaryocyti c cells. This 
could suggest that the observed α-granule defect in primary GFI1B-Q287* platelets may not be caused 
by defecti ve protein expression, but possibly originates from defecti ve transport from proteins to 
α-granules and/or defecti ve traffi  cking of α-granules to proplatelets.
 In additi on to the reducti on in α-granule proteins, the proteome of GFI1B-Q287*platelets showed 
additi onal abnormaliti es including increased expression of ribosomal, proteasomal and mitochondrial 
proteins. These fi ndings imply that proplatelet forming megakaryocytes of GFI1B-Q287* pati ents 
may diff er from normal mature megakaryocytes at the metabolic level. Part of the up-regulated 
platelet proteins, in parti cular the ribosome subunits, showed signifi cant down-regulati on during in 
vitro megakaryocyte diff erenti ati on, in line with the presumed maturati on defect in GFI1B-Q287*
megakaryocytes. Indeed, early megakaryocytes exhibit high protein synthesis rates to support their 
increasing cellular mass, while this is ceased at fi nal maturati on stages.48 In additi on, proteasomal 
and mitochondrial acti viti es are closely related to the regulati on of cell fate decisions.49, 50 Highly 
proliferati ng cells, including cancer cells and (hematopoieti c) stem cells, show disti nct mitochondrial 
acti viti es, and proliferati ng HSCs have increased mitochondrial mass compared to quiescent HSCs.51, 
52 Thus, the increase in mitochondrial proteins might support the hyperproliferati on of GFI1B-Q287* 
megakaryocytes.
 In conclusion, GFI1B regulates protein expression in megakaryocytes through recruitment of 
the LSD1-RCOR-HDAC co-repressor complex. During megakaryopoiesis many proteins are regulated 
by GFI1B, that associate with expected but also new processes. GFI1B-Q287* may inhibit GFI1B by 
specifi cally sequestering the LSD1-RCOR-HDAC complex, making it less available for GFI1B. The normal 
and aff ected megakaryocyte and platelet proteomes reported here may serve as a reference to bett er 
understand other platelet disorders and the molecular pathways that drive megakaryopoiesis and 
platelet development.
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SUPPLEMENTARY METHODS
Lentiviral transduction of MEG-01 cells with GFI1B-GFP and GFI1B-Q287*-GFP 
GFI1B variant-GFP fusions (wild type GFI1B, Q287*, P2A, and K8A) were cloned in the FUW lentiviral 
vector. Lentivirus was produced using 293FT cells. After seeding 293FT cells onto 9 cm dishes, cells 
were transfected at 60% confluency with calcium phosphate. Transfection was performed using 3.68 µg 
pLP1, 1.84 µg pLP2, and 2.30 µg pLP/VSVG packaging vectors and 14.4 µg FUW construct. After 16-18 
hours, the medium was replaced with 5 ml fresh medium. Viral supernatant was harvested ~48 hours 
after transfection. MEG-01 cells were transduced with FUW, FUW-GFI1B-GFP or FUW-GFI1B-Q287* 
viral supernatant by spinning down the virus on a retronectin coated 6-wells plate. Subsequently, the 
MEG-01 cells were added and incubated with virus for 24 hours. 
Nuclear extracts MEG-01 and GFP-pull down GFI1B interacting proteins
Nuclear extracts from 100 million lentivirally transduced MEG-01 cells were generated according to 
Dignam et al.1 Cells were harvested and washed twice with PBS. Cells were incubated for 10 minutes at 
4°C in 5 volumes of Buffer A (10 mM Hepes KOH pH 7.9, 1.5 mM MgCl2, and 10 mM KCl), and then pelleted 
at 400g for 5 minutes at 4°C. Swollen cells were resuspended in 2 volumes of buffer A supplemented 
with complete protease inhibitors (Roche) and 0.15% NP40 (Sigma), followed by homogenization on ice 
using 30 strokes with a type B (tight) pestle. The nuclei were pelleted and washed two times with PBS 
at 3200g, 4°C for 15 minutes. This was followed by incubation in 2 volumes of Buffer C (420 mM NaCl, 
20 mM Hepes KOH pH 7.9, 20% v/v glycerol, 2 mM MgCl2, 0.1% NP40, complete protease inhibitors, 
and 0.5 mM DTT) for 1 hour at 4°C to extract nuclear proteins. The nuclear extract (supernatant) was 
obtained by centrifugation at 21.000g for 30 minutes at 4°C. 
Label-free GFP-pulldowns were performed in triplicate as described in Smits et al.2 For GFP-pulldowns, 
0.6 mg of nuclear extract was incubated with 7.5 µl GFP-Trap beads (ChromoTek) in incubation buffer 
(300 mM NaCl, 20 mM Hepes KOH pH 7.9, 20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.25% NP40, 
complete protease inhibitors, and 0.5 mM DTT) in the presence of 50 µg/ml ethidium bromide (Sigma) 
to prevent indirect DNA mediated interactions. Beads were washed twice with incubation buffer 
(0.5% NP40), twice with PBS (0.5% NP40) and finally twice with PBS. Subsequently, the proteins were 
subjected to on-bead trypsin digestion and peptides were acidified and desalted using C18-Stagetips. 
Mass spectrometry and data analysis GFI1B interacting proteins
Just before mass spectrometry analysis, peptides were eluted from the C18 Stagetips and recorded 
with LC-MS/MS LTXQ-Orbitrap Fusion Tribrid mass spectrometer (ThermoFisher Scientific) at top speed 
mode of 3 seconds cycle. Raw data were analyzed by MaxQuant (1.5.7.0) using default settings and 
blasted against the Human Uniprot database downloaded on 17-02-2017. Statistical outliers for the 
GFP-pulldown of the empty vector compared to wild type GFI1B or GFI1B-Q287* were determined using 
a two-tailed t-test. Multiple testing correction was applied by using a permutation-based false discovery 
rate (FDR) method in Perseus (from MaxQuant package). Statistical cut-offs (FDR<0.01 and fold change 
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>9.2) were chosen such that no proteins were present as outliers on the empty vector control side of 
the volcano plot. To determine the stoichiometry of the identi fi ed complexes, we compared the relati ve 
abundance of interactors by calculati ng iBAQ intensiti es (sum of all identi fi ed pepti de intensiti es for a 
certain protein, divided by the number of theoreti cally observed pepti des). Next, the iBAQ intensiti es 
were compensated for the iBAQ intensity in the empty vector samples representi ng the background 
binding level. Finally, these relati ve abundance values were normalized by setti  ng the abundance of 
GFI1B;GFI1 to 1.
Co-immunoprecipitati on and western blotti  ng
MEG-01 cells were lenti virally transduced with FUW-GFI1B-(WT, Q287*, P2A, or K8A)-GFP, and when 
indicated treated with 4μM GSK-LSD1 (Sigma) for 48 hours. Nuclear extracts were made using the NE-PER 
Nuclear and Cytoplasmic Extracti on Kit (ThermoFisher). Co-immunoprecipitati on was performed with 
GFP-Trap beads. For normal western blot, whole cell extracts were prepared in SDS gel-loading buff er 
(2% SDS, 0.1% bromphenol blue, 50 mM Tris-HCl (pH 6.8), 100 mM DTT, 10% glycerol, water). PVDF 
membranes were stained with rabbit anti -LSD1 (Abcam), mouse anti -GFI1B (Santa Cruz Biotechnology), 
or rabbit anti -Acti n (Sigma). Luminescence signal was visualized using a ChemiDox XRSþ (Bio-Rad).
Proliferati on of GFI1B and GFI1B mutant transduced MEG-01 cells
Flag-tagged GFI1B constructs were cloned into the retroviral vector pMIGR1-IRES-GFP to generate 
pMIGR1-GFI1B-fl ag-IRES-GFP. Retrovirus was produced using PhoenixA cells, which were cultured 
in DMEM supplemented with 10% heat inacti vated FCS at 37˚C supplied with 5% CO2. Aft er seeding 
onto 9cm dishes, cells were transfected at 60% confl uency with calcium phosphate. Transfecti on was 
performed using 3.15 µg pCL-Ampho retroviral packaging vector and 18.4 µg pMIGR1 construct. Aft er 
16-18 hours, the medium was replaced with 5ml fresh medium. Viral supernatant was harvested 30 
hours aft er transfecti on. MEG-01 cells were maintained between 2x105 and 8x105 cells/ml in RPMI 
1640 (GIBCO) supplemented with 10% heat inacti vated FCS, at 37˚C and 5% CO2. MEG-01 cells were 
transduced with 2.5 ml pMIGR1 virus. Briefl y, 1.25 ml viral supernatant plus 2x105 MEG-01 cells (in 
1ml) were added to retronecti n (Takara Bio Inc.)-coated non-ti ssue culture treated 33 mm dishes. 
Aft er 24 hours, 1.25 ml medium was removed from the plates and 1.25 ml fresh viral supernatant was 
added. Aft er an additi onal 24 hours MEG-01 cells were harvested from retronecti n plates, spun down 
and resuspended in 1 ml fresh culture medium. The GFP% was followed using fl ow cytometry for 26 
days with 2-3 day intervals. GFP percentages were normalized to the start point of the culture (day 5 
aft er transducti on) using the following formula: (GFP% day X/(100 - GFP% day X))/(GFP% day 5/(100 - 
GFP% day 5)) to correct for diff erences in start GFP%. On day 23, 2x105 GFP+ cells were FACS-sorted to 
determine GFI1B expression using quanti tati ve RT-PCR. 
Quanti tati ve RT-qPCR 
RNA was isolated using the Quick-RNATM kit (Zymo Research). RNA was treated with DNAse (Zymo 
Research) and reverse transcribed using M-MLV reverse transcriptase (Invitrogen). For quanti tati ve Real 
CHAPTER 2
56
Time Polymerase Chain Reaction (RT-qPCR), cDNA was amplified using Taqman 2x Universal PCR Master 
Mix (Applied biosystems) as recommended by the manufacturer. GFI1B expression was determined 
using the following primers and probe: forward primer 5’-CCCGTGTGCAGGAAGATGA, reverse primer 
5’-CAGGCACTGGTTTGGGAATAGA, probe 5’-FAM-TTACCCCGGTGCCCAGA-MGB. Endogenous GFI1B 
expression (5’UTR) was determined using TaqMan Gene Expression Assay Hs01062474_m1 (Applied 
Biosystems). GAPDH expression was determined using Human GAPDH mix (FAMTM Dye/MGB Probe) 
(Applied biosystems) to correct for differences in input. RT-qPCR was performed on the 7500 Real Time 
PCR System (Applied Biosystems). Data were analyzed using 7500 Fast System Software (version 1.3.1).
BEL-5-Cl1/2 iPSC line generation  
To generate blood-derived induced pluripotent stem cells (iPSC), patient blood (5-10ml) was collected 
after written informed consent. Peripheral blood mononuclear cells were expanded and differentiated 
to erythroblasts within 8 days as described in Heideveld et al.3 The polycystronic Oct4/KLF4/SOX2/c-
Myc lentiviral plasmid4, 5 was used to transduce erythroblasts for reprogramming as described in Hansen 
et al.6 After transduction, cells were cultured in IMDM (Biochrome, Merk) supplemented with 1U/ml 
erythropoietin, 100ng/ml SCF, 1uM Dexamethason, 10µg/ml polybrene (Sigma) and 2mmol/ml valproic 
acid (VPA, Sigma) for 1 day. Cells were subsequently plated on 0.1% gelatine (Sigma) coated plates 
containing a confluent layer of irradiated mouse embryonic fibroblasts (iMEF, GlobalStem). Cells were 
incubated with VPA for an additional 7 days. The medium was changed to E8 (ThermoFisher Scientific) 
on day 10 and iPS colonies were harvested between days 14-20. iPSCs were tested for pluripotency as 
we previously described in Hansen et al.6
iPSC megakaryocytic differentiation
iPSC lines MML-6838-Cl26 and BEL-5-Cl1/2 were maintained on Matrigel coated (BD Biosciences) plates 
in E8 medium (ThermoFisher Scientific) following manufacturer’s instructions. For differentiation, iPS 
colonies were made single cell with TrypleSelect (ThermoFisher Scientific), and 120-250 cells were 
seeded in E8 with RevitaCell (ThermoFisher Scientific) on 6cm matrigel coated dishes. Colonies were 
grown until a size of 400-600µm. Differentiation was initiated with StemLine II (Sigma) supplemented 
with 50ng/ml bFGF, 40ng/ml VEGF, 20ng/ml BMP4 and insulin transferrin selenium (1:100, ITS) 
(ThermoFisher Scientific). At day 6 of differentiation, medium was changed to IMDM (Biochrom, Merck) 
with 10ng/ml VEGF, 20ng/ml BMP4, 10ng/ml IL-1β, 1ng/ml IL-3, 10ng/ml IL-6, 50ng/ml TPO, 50ng/ml 
SCF and 1:100 ITS. All growth factors were purchased from PeproTech. Cells were harvested from the 
supernatant between days 14-18, for flow cytometry and on day 18 for sorting CD41a+ cells for mass 
spectrometry.
Electron Microscopy (EM) iPSC-derived megakaryocytic cells
For EM, tissue culture samples were fixed in Karnovsky’s fixative. Postfixation was done with 1% 
Osmiumtetroxide in 0,1 M cacodylatebuffer, after washing tissues were stained en bloc with Ultrastain 
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1 (Leica, Vienna, Austria),  followed by ethanol dehydrati on series. Finally the samples were embedded 
in a mixture of  DDSA/NMA/Embed-812 (EMS, Hatf ield, U.S.A), secti oned and  stained with Ultrastain 
2 (Leica, Vienna, Austria) and analyzed with a CM10 electron microscope (Thermo Fisher, Eindhoven, 
the Netherlands).
Primary megakaryocyte culture 
Mobilized peripheral blood was provided by the Sanquin Laboratory for Cell Therapy and obtained 
from leukopheresis material of healthy donors treated with G-CSF (2x5 µg/kg/day subcutaneously, 
Filgastrim, Amgen) as described.7 Informed consent was given in accordance with the Declarati on of 
Helsinki and the Dutch nati onal and Sanquin internal ethical review boards. CD34+ hematopoieti c stem 
and progenitor cells were isolated from mobilized peripheral blood using CD34 Microbeads (Miltenyi 
Biotec) and magneti c-acti vated cell sorti ng according to the manufacturer’s instructi ons. CD34+ cells 
were diff erenti ated to megakaryocytes in modifi ed IMDM (HEMAdef8) supplemented with 50 ng/ml 
stem cell factor (SCF), 50 ng/ml TPO, 1 ng/ml IL-3 and 20 ng/ml IL-6 for 4 days, followed by culturing in 
50 ng/ml TPO and 10 ng/ml IL-1β for 7 more days.3 All growth factors were from Peprotech. To study the 
eff ect of LSD1 inhibiti on on megakaryocyte diff erenti ati on,  4 µM GSK-LSD1 (Sigma) was added to the IL-
1β and TPO culture at day 7, and cells were followed for 2-6 days. CD34/CD41a/CD42b expression and 
expansion was measured aft er 2 days of GSK-LSD1 treatment. In the experiment with 6 days exposure 
to GSK-LSD1, CD42b expression and proplatelet formati on was analyzed. The number of proplatelet 
forming  megakaryocytes was based on 6 photos from each culture (n=3) and quanti fi ed by ImageJ 
counti ng.
Flow cytometry
The Coulter FC500 fl ow cytometer (Beckman Coulter) was used to determine the percentage of GFP 
positi ve MEG-01 cells, and the BD FACSAria (BD Bioscience) to sort these GFP positi ve cells. Expression 
of surface molecules on cultured megakaryocytes either originati ng from mobilized blood CD34+ cells 
or iPSCs were analyzed by staining with the following fl uorochrome-conjugated anti bodies: CD34-APC 
(Biolegend), ITGA2B/CD41a-PE-Cy7 (Biolegend), and GP1BA/CD42b-FITC (Sanquin). Aft er staining, 
cells were analyzed using the LSR-II (BD Bioscience). FACS beads (BD Bioscience) were taken along to 
determine the expansion of the CD34+/CD41a+ megakaryoblast populati on. Geometric mean fl uorescent 
intensity (MFI) was normalized to isotype control geometric MFI, generati ng nMFI for normalized MFI.
Platelet isolati on
The study was approved by the Medical Ethical Committ ee of the Radboudumc Nijmegen (2013/064) 
and conducted in accordance with the Declarati on of Helsinki. Venous blood was collected from 
healthy volunteers and from GFI1B-Q287* pati ents aft er obtaining writt en informed consent. The 
clinical parameters of the GFI1B-Q287* pati ents have been described previously.9 Platelet-rich plasma 
was obtained via centrifugati on of whole blood for 20 min at 120g. Platelets were spun down by 
centrifugati on for 10 minutes at 2000g, washed and resuspended in a buff er comprising 36 mM Citric 
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acid, 103 mM NaCl, 5 mM KCl, 5 mM EDTA, 5.6 mM D-glucose, 1 nM Prostaglandin E1 (PGE1) and 10% 
(v/v) ACD-A (BD-Plymouth) at pH 6.5. Platelets were again washed and resuspended in the same buffer 
but with 0.1 nM PGE1. Finally, platelets were collected by centrifugation for 10 minutes at 2000g and 
processed for MS analysis.
Sample preparation for proteomics mass spectrometry. 
All fine chemicals were from Thermo Scientific unless indicated otherwise. 100 x 10⁶ washed platelets 
per donor or 1 x 106 cultured megakaryocytic cells were lysed in 100 μl 8 M Urea, 100 mM Tris-HCl 
(Life Technologies) at pH 8. For iPSC MK, sorted CD41a+ cells were used. Samples were sonicated 
for 10 minutes and centrifuged at 12000g to remove insoluble material. The protein concentration 
of the lysates was measured using a Bradford assay. For label-free quantification, three replicates of 
5 µg protein from platelets or from cultured megakaryocytic cells were taken. The same amount of 
protein was used for each iPSC sample. Samples were diluted at least 7-fold (v/v) in 50 mM ammonium 
bicarbonate (Fluka). Proteins were reduced for 60 minutes at 25°C in 10 mM dithiothreithol (DTT) and 
alkylated using 55 mM iodoacetamide (IAM) for 45 minutes at room temperature in the dark. Finally, 
proteins were proteolysed by trypsin (Promega) overnight at 25°C using a protein:trypsin ratio of 1:20 
(mg/mg). Protein samples were acidified with 5 μl 99% formic acid, and prepared for MS analysis using 
Empore-C18 StageTips.10
Proteomics mass spectrometry data acquisition.
Tryptic peptides were separated by nanoscale C18 reverse phase chromatography coupled on-line to 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific) via a nano-electrospray ion source 
(Nanospray Flex Ion Source, Thermo Scientific). Peptides were loaded on a 20 cm 75–360 µm inner-
outer diameter fused silica emitter (New Objective) packed in-house with ReproSil-Pur C18-AQ, 1.9 
μm resin (Dr Maisch GmbH). The column was installed on a Dionex Ultimate3000 RSLC nanoSystem 
(Thermo Scientific) using a MicroTee union formatted for 360 μm outer diameter columns (IDEX) and 
a liquid junction. The gradient that was employed to separate the peptides as well as the top-speed 
method to acquire MS/MS spectra on the Fusion are described previously.11 All MS data were acquired 
with Xcalibur software (Thermo Scientific).
Proteomics mass spectrometry data analysis
The RAW mass spectrometry files were processed with the MaxQuant computational platform, 1.5.2.8. 
Proteins and peptides were identified using the Andromeda search engine by querying the human 
Uniprot database (89796 entries; downloaded February 2015). Standard settings with the additional 
options ‘match between runs’, ‘Label Free Quantification (LFQ)’, and ‘unique peptides for quantification’ 
were selected. The RAW files, MaxQuant search results, and details about the settings are available in 
the PRIDE repository database12 with the dataset identifier PXD009020. The generated ‘proteingroups.
txt’ table was imported into Perseus 1.5.1.6 and filtered for ‘only identified by site’ and reverse hits. 
The LFQ values were transformed in log2 scale and potential contaminant proteins were removed, 
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except for ALB and THBS1. For primary cultured megakaryocyte and platelet samples, the three 
technical replicates of samples were grouped, and the proteins were fi ltered for three valid values in at 
least one of these groups. The three replicates of the control and GFI1B-Q287* platelet samples were 
then averaged. For the analysis of diff erenti ally expressed proteins between GFI1B-Q287* and control 
platelets, only proteins that were detected in four pati ent and/or four control platelet samples were 
included. For iPSC-derived samples, proteins detected in at least fi ve control and/or fi ve GFI1B-Q287* 
samples were included. Missing values were imputed by normal distributi on (width = 0.3, shift  = 1.8), 
assuming these proteins were close to the detecti on limit. 
Gene ontology term enrichment analysis.
Enrichment of gene ontology (GO) terms based on biological processes, molecular functi ons and 
cellular components was performed and visualized with the R package gogadget13, by comparing up- 
and down-regulated proteins against the background of total detected proteins. For comparison of 
signifi cantly enriched proteins to all identi fi ed proteins, a p-value cut-off  of 0.05 was used. Heatmaps 
were generated based on overlapping proteins between GO terms, and k-means was determined 
separately for each clustering. One or two overlapping terms were assigned for each cluster of GO 
terms. The full lists of GO terms, including cluster numbers, is provided in Supplementary Table 2.   
Supplementary Tables can be found in the online publicati on of this paper at www.haematologica.org.
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Figure S1. Generati on of the GFI1B-Q287* iPSC BEL-5-Cl.2 (A) Morphology of BEL-5-Cl2, 4x magnifi cati on, EVOS XL 
(Thermo Fisher Scienti fi c). (B) Silencing of the reprogramming cassett e measured by fl ow cytometry as the absence 
of green fl uorescent protein (GFP; left ); an episomal reprogramed iPSC SANi003-B serves as negati ve control (right). 
(C) Expression of pluripotency associated markers SSEA4, OCT4, SOX2 and TRA1-81 by fl ow cytometry. Gati ng was set 
based on isotype control. (D) Alkaline phosphatase staining showing bright fi eld (left ) and green fl uorescence channel 
(right). (E) Sanger sequencing showing the heterozygous GFI1B-Q287* mutati on in BEL5 Cl.2 (F) Representati ve 
G-banded karyogram. (G) Teratomas stained for mesoderm (Alpha-SMA, red), endoderm (cytokerati n, green), and 
(H) ectoderm (Beta Tubulin Class III, green) and Dapi (blue).
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Figure S2
Figure S2. ZMYM3 binds signifi cantly diff erent to GFI1B-Q287* compared to GFI1B. Nuclear extracts of MEG-01 
cells transduced with GFI1B-GFP, or GFI1B-Q287*-GFP were analyzed by mass spectrometry. Stati sti cally enriched 
proteins are identi fi ed by a permutati on-based false discovery rate (FDR)-corrected t-test (FDR<0.01). The volcano 
plot shows the diff erence between label free quanti fi cati on (LFQ) intensiti es of GFI1B-GFP and GFI1B-Q287*-GFP 
pulldown (log2-transformed fold change (FC)) on the x-axis, and the -log10-transformed p-value on the y-axis. Dott ed 
grey lines represent the stati sti cal cut-off s, which were kept the same as in the other volcano plots in Figure 1. 
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Figure S3. Overexpression of GFI1B in MEG-01 competition cultures. GFI1B RNA expression in sorted GFP positive 
MEG-01 cells transduced with empty vector (EV), GFI1B-flag, GFI1B-Q287*-flag, GFI1B-H294fs-IRES-GFP, GFI1B-
P2A-flag, GFI1B-P2A+Q287*-flag, GFI1B-K8A-flag, or GFI1B-K8A+Q287*-flag at day 23 after transduction. GFI1B 
expression is normalized to GAPDH and endogenous GFI1B expression in empty vector (EV). Error bars represent 
mean ± standard deviation (n=3-11).  
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Figure S4. LSD1 is essenti al for proplatelet formati on. CD34+ cells were diff erenti ated towards megakaryocytes and 
treated with GSK-LSD1 for 6 days. On day 6 aft er additi on of GSK-LSD1 photos were taken of (A) DMSO and (B) GSK-
LSD1 megakaryocyte cultures. (C) During GSK-LSD1 treatment the percentage of CD42b cell surface expression was 
monitored by fl ow cytometry (n=3, control , GSK-LSD1 ). 
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Figure S5. Granule formation in iPSC derived megakaryocytic cells. (A)Control iPSC derived megakaryocytic cells 
have characteristics of a mature megakaryocyte such as the demarcation membrane system (DMS) on the outside of 
the cell and an intermediary zone close to the nucleus rich of organelles including α-granules . (B) In the GFI1B-Q287* 
iPSC derived megakaryocytic cells the DMS is more pronounced and there are also some α-granules present.  Some 
of the α-granules are indicated with black arrows. The scale bars represent 2 μm except for the zoomed in picture 
of (A), here it represents 500 nm.
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Figure S6. MCM complex proteins are elevated in GFI1B-Q287* iPSC derived megakaryocyti c cells. Relati ve protein 
levels (log2 LFQ values) of (A) the minichromosome maintenance (MCM) complex subunits 2-7, (B) MX1, and (C) 
MEIS1 in control and GFI1B-Q287* iPSC-derived megakaryocyti c cells. In case the protein was not detected in one or 
more of the samples, fewer than six points are shown. N.D. indicates the protein was not detected at all in a sample 
group. (D) Expression patt erns of the MCM proteins during the diff erenti ati on of cultured primary megakaryocytes. 
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Figure S7. GFI1B-Q287* platelets show elevated levels of proteasomal, ribosomal, and mitochondrial proteins.
Relati ve protein levels (log2 LFQ values) are shown for the indicated proteins of (A) proteasomal, (B) ribosomal, and 
(C) mitochondrial complexes in the platelets of control individuals and GFI1B-Q287* pati ents. 
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LETTER TO THE EDITOR
Several types of GFI1B variants have been identi fi ed in pati ents with inherited bleeding and platelet 
disorders. This includes dominant-negati ve truncati ng variants aff ecti ng DNA binding,1-4 missense 
variants of which the molecular mechanism is unclear,5-7 and variants changing the amount and 
rati o of GFI1B isoforms (Figure S1).7, 8 The severity of the bleeding disorder may diff er depending 
on the type of variant, but frequent abnormaliti es include macrothrombocytopenia, a reducti on in 
α-granule numbers, and platelet CD34 expression. In this study we performed a molecular and/or 
clinicopathological characterizati on of eight GFI1B variants in non-DNA binding domains (Figure S1). 
These variants were previously identi fi ed by the NIHR BioResource rare disease study in cases with an 
assumed inherited bleeding or platelet disorder.9 Molecular characterizati on was not performed for 
D23N, since the minor allele frequency in the gnomAD database deemed too high for a causal variant. 
From the characterizati on of the other variants we can conclude that although some have a clear eff ect 
on GFI1B functi on, they are not necessarily suffi  cient to cause bleedings on their own.
 Previously, we used the megakaryoblast cell line MEG-01 to study the eff ect of GFI1B and the 
proven pathogenic GFI1B-Q287* variant on cell expansion. In expansion-competi ti on cultures containing 
transduced and non-transduced cells, MEG-01 cells ectopically expressing GFI1B were overgrown by 
non-transduced cells, while the opposite was observed following expression of GFI1B-Q287* (Figure 
1; manuscript resubmitt ed September 2018). Thus, forced GFI1B expression inhibits MEG-01 cell 
expansion whereas dominant-negati ve GFI1B-Q287* results in enhanced expansion. The latt er is in 
line with elevated megakaryocyte numbers observed in a bone marrow specimen of a GFI1B p.Q287* 
aff ected individual.1 To investi gate the (functi onal) eff ect of GFI1B variants, we retrovirally expressed 
them in MEG-01 cells and performed the expansion-competi ti on culture described above. GFI1B and 
GFI1B-Q287* were taken along as references. Two variants, one in the intermediate domain (G139S) 
and one in zinc fi nger (znf) 2 (G198S), did not aff ect the inhibitory functi on of wild type GFI1B on MEG-
01 proliferati on (Figure 1A, Figure 1B). The R190W variant, located between znf1 and znf2, rendered 
the protein less eff ecti ve at inhibiti ng MEG-01 proliferati on (Figure 1C), whilst both the znf1 variant 
C168F and the truncated variant Q89fs rendered the protein completely inacti ve (Figure 1D, Figure 
1E). Interesti ngly, expression of znf1 H181Y and R184P variants resulted in increased MEG-01 cell 
proliferati on, although to a lesser extent than cells expressing GFI1B-Q287* (Figure 1F, Figure 1G). To 
further study H181Y and R184P, we introduced these variants separately in GFI1B-Q287*. This led to 
parti al inhibiti on of the growth sti mulati ng eff ect of GFI1B-Q287* (Figure 2A, Figure 2B), indicati ng 
that amino acids H181 and R184 are important for the eff ect of GFI1B-Q287* on MEG-01 proliferati on. 
These fi ndings clearly demonstrate that diff erent variants have qualitati vely disti nct eff ects on the 
functi on of GFI1B, and that znf1 is important in regulati ng MEG-01 proliferati on. 
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Figure 1
A            B
C          D
E          F
G
Figure 1. GFI1B variants have different effects on GFI1B function. Expansion competition cultures of MEG-01 cells 
transduced with flag-tagged GFI1B variants (A) G139S (B) G198S (C) R190W (D) C168F (E) Q89fs (F) H181Y (G) R184P. 
GFI1B-Q287*-flag, GFI1B-p37-flag wild type (WT), and empty vector (EV) were taken along as controls. Fold change 
of GFP% to GFP% at day 5 (first GFP measurement) is presented on the y-axis. Results show mean ± standard error 
of the mean, and two-tailed paired t-tests were performed on day 26 to determine statistical significance *P<0.05, 
**P <0.01. Of note, all MEG-01 transduced cells showed increased GFI1B mRNA expression indicating expression of 
the retroviral vector (Figure S2). 
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 The increased MEG-01 expansion caused by GFI1B-H181Y and GFI1B-R184P suggests that these 
variants, like GFI1B-Q287*, act in a dominant-negati ve manner. However, the molecular mechanism 
might be diff erent, because these variants are not located in the DNA binding domain like GFI1B-Q287*. 
GFI1B is a repressive transcripti on factor that inhibits its own transcripti on and that of its paralogue 
GFI1.10, 11 GFI1B-Q287* has lost this repressive functi on.1 To study if the variants aff ect the repressive 
functi on of GFI1B, we performed gene reporter assays using the Gfi 1 promoter. Remarkably, all tested 
GFI1B missense variants, including GFI1B-H181Y and GFI1B-R184P, repressed the Gfi 1 promoter to a 
similar extent as wild type GFI1B (Figure 2C). However, results obtained in transient gene repression 
assays may not refl ect eff ects on endogenous target genes. We therefore analyzed the eff ects of 
GFI1B-H181Y and GFI1B-R184P on endogenous GFI1B expression. Wild type GFI1B, GFI1B-Q287*, 
GFI1B-H181Y, and GFI1B-R184P were expressed in MEG-01 cells, followed by endogenous GFI1B
mRNA expression analysis. In line with earlier reports, wild type GFI1B inhibited endogenous GFI1B
expression.12 In contrast, GFI1B-Q287*, as well as GFI1B-H181Y and GFI1B-R184P did not repress 
endogenous GFI1B expression to the same extent as wild type GFI1B (Figure 2D). This indicates that not 
only the DNA binding znfs, but also amino acids H181 and R184 are required for effi  cient repression of 
endogenous GFI1B.
 The LSD1-RCOR1-HDAC co-repressor complex is one of the main epigeneti c regulatory complexes 
recruited by GFI1B to induce transcripti onal repression. To study whether GFI1B-H181Y- and GFI1B-
R184P-induced MEG-01 expansion depends on an interacti on with this complex, we co-introduced 
a P2A mutati on in the GFI1B-H181Y or GFI1B-R184P variants. The P2A mutati on in the N-terminal 
SNAG domain of GFI1B abrogates its interacti on with LSD1,13 and nullifi es the inhibitory eff ect of wild 
type GFI1B and sti mulatory eff ect of GFI1B-Q287* on MEG-01 proliferati on (manuscript resubmitt ed 
September 2018). Expression of the P2A-H181Y and P2A-R184P double mutants resulted in expansion 
rates similar to empty vector transduced cells (Figure 2E). This strongly suggests that H181Y and R184P 
variants require the LSD1 interacti on to exert their eff ect on MEG-01 expansion. 
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Figure 2
A          B
C          D
E        
Figure 2. Functional effect of GFI1B variants H181Y and R184P. (A-B) Expansion competition cultures of MEG-
01 cells transduced with flag-tagged GFI1B-H181Y+Q287* (A), or GFI1B-R184P-Q287* (B). Empty vector (EV) and 
GFI1B-Q287*-flag transduced cells taken along as reference. (C) Dual luciferase reporter assays in HEK293FT cells 
transfected with Renilla luciferase construct, Gfi1 promoter Firefly luciferase construct, and empty vector (EV), wild 
type GFI1B-p37-flag (WT-p37), wild type GFI1B-p32-flag (WT-p32, lacking coding exon 4 and therefore amino acids 
171-216 corresponding to zinc finger 1 and 2), or GFI1B-flag variants. Firefly/Renilla luciferase ratios are normalized 
to EV transfected cells. Results show mean ± standard deviation, and two-tailed paired t-tests were performed to 
determine statistical significance between WT-p37 and the other conditions. Corresponding Western blots showing 
expression of the flag-tagged GFI1B proteins and the GAPDH loading control are depicted below the graph. (D) 5’UTR 
GFI1B expression in GFP positive cells from MEG-01 expansion competition cultures, FACS-sorted 23 days after 
transduction. GFI1B expression is normalized to GAPDH expression. Results show mean ± standard deviation, and >> 
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two-tailed paired t-tests were performed to determine stati sti cal signifi cance.  (E) Expansion competi ti on cultures of 
MEG-01 cells transduced with fl ag-tagged GFI1B-H181Y+P2A, or GFI1B-R184P-P2A. EV transduced cells taken along 
as reference.  *P<0.05, **P <0.01, ***P <0.001
 The functi onal data were subsequently correlated with clinical and laboratory features of pati ent 
samples to improve classifi cati on of the GFI1B variants according to ACMG guidelines14 (Table S1). A 
minimal set of geneti c, clinical and laboratory features have already been published in Chen et al., 
supplementary table ST15.9 For this study, we expanded clinical and laboratory phenotype studies for 
the H181Y and R184P variants, because these GFI1B variants had similar functi onal eff ects in the MEG-
01 cell models as the proven pathogenic GFI1B-Q287* variant. In additi on, we performed clinical and 
laboratory phenotype studies for R190W variant carriers.
 The variants G139S and G198S were classifi ed as ‘Benign’ as they showed similar inhibiti on of 
MEG-01 expansion as wild type GFI1B, and have a relati vely high minor allele frequency in gnomAD. 
Further, the thrombocytopenia in pati ent P9 with G198S was explained by a pathogenic ACTN1 
variant (p.R46Q)15. Variants R190W, C168F and Q89fs did not inhibit MEG-01 expansion to the same 
extent as wild type GFI1B (loss of functi on eff ect). R190W platelets were weakly CD34-positi ve, but 
R190W in pati ents P8.1 and P8.2 did not co-segregate with bleeding or result in abnormal α-granules 
(Table S1; Figures S3-5). Moreover, pati ent P7 with the same R190W variant was explained by a 
pathogenic variant in WAS (p.R364*), resulti ng in a ‘Benign’ classifi cati on for R190W. Pati ent P4 with 
a homozygous C168F variant suff ered from clinical bleeding symptoms with thrombocytopenia and 
platelet aggregati on dysfuncti on. Unlike P4, heterozygous C168F pati ents studied by Rabbolini and 
colleagues only displayed macrothrombocytopenia with platelet CD34 expression (parti al eff ect on 
the phenotype).7 C168F is predicted to disrupt znf1 structure and thereby GFI1B functi on.9 This was 
confi rmed in functi onal experiments performed here (Figure 1D) and by Rabbolini et al. showing that 
C168F disrupts the repressive functi on of GFI1B gene expression.7 C168F was classifi ed as a ‘variant 
of unknown signifi cance’ (VUS); further studies in the aff ected pati ent or of family members was not 
possible. A 90-year old woman (deceased) carrying the Q89fs variant and without aff ected siblings 
had mild thrombocytopenia with bleeding, platelet dysfuncti on and signifi cantly reduced α-granule 
numbers; a phenotype very similar to previously described GFI1B pathogenic variants (Table S1; Figure 
S5).1, 2, 4 The Q89fs variant does not repress the Gfi 1 promoter to the same degree as wild type GFI1B 
and the missense variants. However, it must be noted that we could only detect the truncated protein 
aft er proteasome inhibiti on, suggesti ng it is instable (Figure S6). If this is also the case in pati ent cells, 
the Q89fs variant would lead to haploinsuffi  ciency. This variant was classifi ed as VUS.
 The R184P and H181Y variants sti mulated MEG-01 proliferati on and failed to repress endogenous 
GFI1B expression in a similar way as the pathogenic Q287* variant. These missense variants were absent 
from the gnomAD database and co-segregati on studies were performed (Figure 3). Both the propositus 
(P6.1) and her father (P6.2), who are carriers of R184P, showed a small number of hypogranular 
platelets and platelet CD34 expression (Table S1; Figures S3-4). P6.1 had a normal platelet count 
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whereas her father (P6.2) had mild thrombocytopenia. Importantly, neither parent had clinical bleeding 
symptoms or platelet dysfunction (Table S1; Figure 3A). Following ACMG criteria, the R184P variant 
was classified as VUS. For the propositus (P5.1) with the H181Y variant, three affected relatives (P5.2, 
P5.4-5) and one non-affected (P5.3) relative were screened and the variant co-segregated with clinical 
bleeding symptoms, platelet dysfunction and CD34-positive platelets (Table S1; Figure S3; Figure 3B). 
Affected individuals P5.1 and P5.2 had normal platelet counts with few large platelets and a significant 
reduction of α-granules (Table S1; Figures S4-5). The functional and segregation data suggest that the 
H181Y variant is causal of bleeding and platelet dysfunction but does not result in thrombocytopenia. 
Following ACMG guidelines, H181Y was classified as a VUS (Table S1). 
P6.3
R184P
PLT 196
CD34 high
P6.4
PLT 200
CD34 absent
P6.1
WT
PLT 242
CD34 absent
P6.2
R184P
PLT 124
CD34 high
WT
P5.1
H181Y
PLT 184
CD34 high
P5.2
H181Y
PLT 152
CD34 high
P5.3
WT
PLT 237
CD34 ND
P5.4
H181Y
PLT 178
CD34 high
P5.5
H181Y
PLT 257
CD34 ND
Figure 3
A
B
BAT 10          BAT 11                                   BAT 4
BAT 8
BAT -1
BAT 7                                          
BAT 0                                         
Figure 3. Pedigrees for families harboring GFI1B variants H181Y (A) and R184P (B). The propositus (arrow) and 
the family members with signs of pathological bleeding are indicated with a black filled symbol. GFI1B variant status, 
patient identifier, platelet count (PLT), platelet CD34 expression, and the ISTH bleeding assessment tool (BAT) score 
are indicated for each patient. Normal range for the ISTH BAT score is <4 in adult males, <6 in adult females and <3 
in children. P5.4 has less haemostatic challenges than the other siblings. ND= not determined. Additional clinical and 
laboratory data obtained in patient samples can be found in Table S1. 
CHARACTERIZATION OF GFI1B VARIANTS
79
3
 We conclude Q89fs, C168F, H181Y, and R184P aff ect GFI1B functi on, but are not necessarily 
suffi  cient to cause bleedings on their own. Sti ll, their identi fi cati on and documentati on, even when 
classifi ed as VUS, will help to disti nguish pathological from non-pathological GFI1B variants and increase 
our understanding of GFI1B functi onal domains. The identi fi cati on of additi onal pati ents with similar 
variants will be essenti al to clarify their exact role for platelet phenotypes and bleeding.
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SUPPLEMENTARY METHODS
Pati ent recruitment and ethics 
The NIHR BioResource (NBR) – Rare Disease Study is a multi -centre whole-exome and whole-genome 
sequencing study including approximately 10,000 pati ents. The NBR–Rare Diseases study was approved 
by the East of England Cambridge South nati onal research ethics committ ee (REC) under reference 
number: 13/EE/0325. The inclusion and exclusion criteria were as described before.1 In short, the 
inclusion criteria for enrolment are: (i) positi ve history of bleeding, (ii) abnormal platelets (abnormal 
count, volume, aggregati on, morphology). In additi on, pati ents were only included when their disease 
was highly likely of geneti c eti ology (e.g. early onset, informati ve pedigrees, absence of acquired cause). 
Variant classifi cati on was performed according to the ACMG criteria19 and using SapientaTM soft ware 
(Congenica).
Clinical evaluati on and laboratory tests 
The clinical and laboratory phenotypes including electron microscopy and CD34 expression were 
determined as previously described.1, 2 Pati ents from the pedigrees with the H181Y, R184P, and R190W 
variants were recalled for this study.
Expansion of GFI1B variant transduced MEG-01 cells 
MEG-01 cells were maintained in RPMI 1640 (GIBCO) supplemented with 10% heat inacti vated FCS and 
retrovirally transduced with pMIGR1-GFI1B variant-fl ag-IRES-GFP constructs. The GFP% was measured 
on the Coulter FC500 fl ow cytometer (Beckman Coulter) for 26 days with 2-3 day intervals. GFP 
percentages were normalized to the FACS measurement of day 5 using the following formula: (GFP% 
day X/(100 - GFP% day X))/(GFP% day 5/(100 - GFP% day 5)). On day 23, GFP+ cells were sorted using the 
BD FACSAria (BD Bioscience) to determine total and endogenous GFI1B expression using quanti tati ve 
RT-PCR. GFI1B exon 1-2 primers and probe are as follows: forward 5’-CCCGTGTGCAGGAAGATGA, reverse 
5’-CAGGCACTGGTTTGGGAATAGA, probe 5’-FAM-TTACCCCGGTGCCCAGA-MGB. 5’UTR GFI1B expression 
was determined using the TaqMan gene expression assay Hs01062474_m1. GAPDH expression was 
determined using Human GAPDH mix Hs99999905_m1 (FAMTM Dye/MGB Probe) (Applied biosystems). 
GFI1B variant reporter assays 
To determine GFI1B transcripti onal acti vity, we performed Dual-Luciferase Reporter Assays (Promega) 
in 293FT cells. 293FT cells were maintained in DMEM (GIBCO) supplemented with 10% non-heat 
inacti vated fetal calf serum (FCS), 1% glutamine, 1% non-essenti al amino acids, 1% pyruvate, and 
1% penicillin/streptomycin (MP Biomedical). 293FT cells were transfected using Lipofectamine 2000 
(Invitrogen). A total of 2μg DNA was used for transfecti on consisti ng of 0.5μg pcDNA3.1 fl ag-tagged 
wild type or variant GFI1B, 0.5μg pcDNA3.1-empty vector, 0.8μg pGL3-basic Firefl y Luciferase vector 
harboring the Gfi 1 promoter, and 0.2μg pGL3-basic Renilla Luciferase vector. Forty-eight hours aft er 
transfecti on, cells were washed with PBS and lysed in 100μl of passive lysis buff er (Dual-Luciferase 
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Reporter Assay System, Promega) for 1 hour. Luciferase signal from 1.5μl lysate was detected using 10μl 
LAR II and 10μl Stop&Glo (Dual-Luciferase Reporter Assay System, Promega) on the Fluostar Optima 
(BMG LABTECH). Experiments were performed at least three times, in duplicate. Firefly Luciferase 
activity was normalized to Renilla activity and each condition was normalized to empty vector. 
Statistics 
Two-tailed paired t-tests or one-way Anova testing was performed with Graphpad Prism version 5.03 to 
determine statistically significant differences.
GFI1B-Q89fs-flag expression after MG132 treatment 
293FT cells were transfected in duplo with 20μg pcDNA3.1 (empty vector), pcDNA3.1-GFI1B-Q89fs-flag, 
or pcDNA3.1-GFI1B-Q287*-flag using calcium phosphate. Sixteen hours after transfection, the medium 
was refreshed, and 24 hours after transfection 5μM MG132 or 1μl DMSO was added to the cells. After 
16 hours of MG132 proteasome inhibitor treatment cells were lysed in passive lysis buffer (Promega) 
and loaded on a SDS-PAGE gel. The proteins were transferred to a PVDF membrane which was stained 
with mouse α-flag (SIGMA-ALDRICH, Merck) and mouse α-GAPDH (Abcam) followed by probing with 
goat α-mouse HRP-conjugated secondary antibody (Santa Cruz Biotechnology). Luminescence signal 
was visualized using a ChemiDox XRSþ (Bio-Rad). 
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SUPPLEMENTARY FIGURES
SNAG
Q287*
Q89fs G139S C168F H181Y R184P R190W G198S
znf1       znf2      znf3       znf4      znf5       znf6
K265* G272fs H294fs L308PC165F
D23N
DNA binding
S185fs
c.648+1_648+8delGTGGGCAC
Figure S1
Figure S1. Overview of reported GFI1B variants. Schematic overview of GFI1B protein structure with variants 
identified in inherited bleeding and platelet disorders. The variants displayed below are analyzed in this study 
(C168F also identified in another study1). The upper variants have been published and studied before: C165F,4 
S185fs (homozygous, GFI1B-p37 transcript is mostly degraded and the short GFI1B-p32 isoform, lacking intact zinc 
finger (znf) 1 and 2, is unaffected),5 c.648+1_648+8delGTGGGCAC7 (NM_004188.6; splice variant resulting in coding 
exon 4 skipping and expression of GFI1B-p32),3 K265*,6 G272fs,7 Q287*,8 H294fs,9 and L308P.6 GFI1B contains an 
N-terminal SNAG domain and six C-terminal znfs, of which znf 3-5 are involved in DNA binding.Figure S2
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Figure S2. Expression of GFI1B in MEG-01 expansion cultures. GFI1B expression in FACS-sorted GFP positive 
MEG-01 cells transduced with empty vector (EV) or GFI1B variant-flag at day 23 following transduction. These data 
correspond to the cultures in Figures 1 and 2. GFI1B expression is normalized to GAPDH and endogenous GFI1B 
expression in the empty vector (EV) condition. Error bars represent mean ± standard deviation of at least three
experiments.
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0.0009
L1 L2
Figure S3
Figure S3. CD34 expression on platelets. Flow cytometry of CD34 expression on pati ents’ platelets carrying GFI1B 
H181Y, R184P, or R190W variants. Measurements were performed in two laboratories (L1 and L2) using 169 (L1) 
and three (L2) unrelated healthy individuals as controls (see Table 1). Subjects P6.1 and P6.4 are wild type for GFI1B 
(R184R) and do not have bleeding symptoms or platelet defects. Error bars represent mean ± standard deviati on. P 
values were determined by one-way ANOVA (Tukey’s multi ple comparisons test).
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H181Y (P5.4)  
Control 
H181Y (P5.1)  
WT (P6.1)  
H181Y (P5.2)   
R184P (P6.2)  R184P (P6.3)  
R190W (P8.1)   R190W (P8.2)   
Figure S4 
Figure S4. May-Grünwald-Giemsa stained peripheral blood smears of control and patients with the H181Y, 
R184P, or R190W variant. Overall analysis of the blood smears is presented in Table 1. Representative photos are 
depicted. Several macrothrombocytes and/or hypogranular platelets are indicated by arrows. Photo P6.3 is a 100x 
magnification. The remaining photos are a 40x magnification.
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R190W (P8.1)   R190W (P8.2)   
Q89fs (P2)   Control 
H181Y (P5.2)   H181Y (P5.1)   
Figure S5 
Figure S5. Platelet electron microscopy for control and pati ents with Q89fs, H181Y, and R190W variants. Platelet 
area and α- granule number was quanti fi ed and reported in Table 1. Representati ve photos are depicted. α-granule 
numbers were reduced in P2 (Q89fs), P5.1 (H181Y) and P5.2 (H181Y). Platelet area was in the normal range for all 
presented cases.
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NT   EV  Q287*  Q89fs NT   EV  Q287*  Q89fs 
~ 32 kD 
~ 17 kD 
α-GAPDH 
DMSO MG132 
α-flag 
Figure S6 
Figure S6. GFI1B Q89fs is only detected after proteasome inhibition treatment. Protein expression of transfected 
GFI1B-Q287*-flag (~32kD) and GFI1B-Q89fs-flag (~17kD) in HEK293FT cells 24 hour after treatment with 5μM 
MG132 or DMSO (solvent control). PVDF membrane was stained with α-flag and α-GAPDH antibodies.
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ABSTRACT 
Transcription factor GFI1B suppresses its own gene expression, and deregulated GFI1B expression 
contributes to myeloid neoplasms. The DNA polymorphism rs621940 located 8 kb downstream of 
GFI1B predisposes for clonal hematopoiesis and myeloproliferative neoplasms. Whether rs621940 
affects GFI1B expression is unknown. We observed clear GFI1B binding around the rs621940 locus in 
megakaryoblast MEG-01 cells using ChIP-seq. Pull-downs using DNA-sequences with either rs621940-
allele followed by protein identification using mass spectrometry detected 24 differentially bound 
proteins in MEG-01 cells, but GFI1B was not among these. Also, GFI1B auto-repression was not different 
between either rs621940-allele in transient gene reporter assays. Deletion of an 1.6 kb fragment 
encompassing rs621940 in K562 cells did not alter GFI1B expression nor GFI1B auto-repression. 
In primary peripheral blood mononuclear cells from healthy donors, absolute GFI1B expression did 
not differ consistently between the rs621940 alleles. Finally, GFI1B haplotyping using long range 
DNA sequencing detected 3’ non-coding polymorphisms on the same chromosome as the rs621940 
polymorphism. Yet, targeted deep RNA sequencing did not detect consistent effects of  rs621940 on 
allelic GFI1B expression. These studies find no evidence that rs621940 affects GFI1B expression nor 
GFI1B auto-repression. 
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INTRODUCTION 
Genome wide associati on studies (GWAS) have identi fi ed numerous common single nucleoti de 
polymorphisms (SNPs) associated with human diseases, including cancer. These SNPs are located 
in genes, promoters, and undefi ned geneti c regions. Several studies have shown that the latt er 
can modulate gene transcripti on through long range cis eff ects.1 Recently a GWAS was conducted 
that identi fi ed eight predisposing alleles for JAK2 V617F+ clonal hematopoiesis and Philadelphia 
chromosome-negati ve myeloproliferati ve neoplasms (MPN). One of these SNPs was located in an 
undefi ned region ~8 kb downstream of the startcodon of GFI1B.2 It is unclear whether this SNP aff ects 
GFI1B gene expression.
 The transcripti on factor Growth Factor Independence-1B (GFI1B) regulates dormancy and 
proliferati on of hematopoieti c stem cells (HSCs),3 and sti mulates the development of erythroid and 
megakaryocyti c cells,4-7 as well as B and T cells.8-10 Inherited GFI1B variants result in a bleeding diathesis 
with quanti tati ve and qualitati ve platelet defects. In additi on, bone marrow from individuals with the 
inherited dominant-negati ve GFI1B-Q287* variant showed increased megakaryocyte expansion.11
Furthermore, GFI1B is found upregulated in peripheral blood cells from pati ents with both leukemia and 
MPN,12 and leukemic cell lines.13 GFI1B silencing in these cell lines resulted in decreased proliferati on 
and increased apoptosis.13 In contrast, reduced levels or absence of GFI1B negati vely infl uences 
the prognosis of myelodysplasti c syndrome (MDS) and acute myeloid leukemia (AML) pati ents. 
Furthermore, in diff erent human AML mouse models loss or reduced expression of Gfi 1b promotes 
AML development and leads to a higher number of leukemic stem cells.14 This is in line with a somati c 
dominant-negati ve GFI1B mutant found to contribute to AML development,15 and conditi onal Gfi 1b
knockout mice showing increased proliferati on of HSCs.3 Summarizing, GFI1B expression needs to be 
ti ghtly controlled as both too much and too litt le expression is associated with hematological disorders.
 GFI1B is a transcripti onal repressor that regulates its own gene expression via the N-terminal 
SNAG domain. This domain recruits epigeneti c modifi ers such as LSD1, RCOR1, HDAC1/2 and G9a to 
induce deacetylati on of H3K9, demethylati on of H3K4, and/or methylati on of H3K916, 17 (van Oorschot 
et al in press). Furthermore, multi ple other transcripti on factors bind to the GFI1B promoter, such 
as GATA1, Oct1, NF-Y, and HGMB2.5, 18, 19 In additi on, Anguita et al. have identi fi ed three multi species 
conserved non-coding elements around 12.5 kb, 16 kb and 17.5 kb downstream of the human GFI1B 
start codon (corresponding to 13 kb, 16 kb and 17 kb in mice). Chromati n immunoprecipitati on (ChIP)-
PCR studies in human (K562) and murine (MEL, L8057, HPC7) cell lines demonstrated that positi ve 
regulators of GFI1B expression including GATA1, TAL1 (SCL), NF-E2, LDB1, LMO2, MYB, TCF3 (E2A),18 and 
GATA220 are bound to these regulatory elements. Interesti ngly, these sites are also bound by repressors 
of GFI1B expression, such as GFI1B, RCOR1, and LSD1 (KDM1A), and hence could behave as negati ve 
regulatory elements depending on the GFI1B levels.18 The three regulatory elements were validated as 
hematopoieti c enhancers in transgenic mouse assays,20 and looping to the Gfi 1b promoter was shown 
for the elements 13 kb and 17 kb downstream of Gfi 1b.18
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 The GWAS described above, identified rs621940[C/G] which is located 8 kb downstream of GFI1B.2 
The minor G allele occurs with a frequency of 0.15 in different populations, and is among the identified 
polymorphisms that also associate with higher JAK2 V617F burden and risk of uniparental disomy of 
chromosome 9p. Since deregulated GFI1B expression is associated with MPN, we investigated whether 
rs621940 and the relevant surrounding region contributes to regulation of GFI1B expression.
METHODS
GFI1B ChIP-seq in MEG-01 cells 
Chromatin from MEG-01 cells was isolated as described by Mandoli et al.21 Sonicated chromatin was 
centrifuged at maximum speed for 10 minutes followed by overnight incubation at 4°C in incubation 
buffer supplemented with 0.1% BSA, protein A Dynabeads (ThermoFisher Scientific) and 2 µg of GFI1B 
B7 antibody (Santa Cruz, sc-28356). Beads were washed with four different buffers at 4°C: TEE (10 mM 
Tris pH 8, 0.1 mM EDTA and 0.5 mM EGTA) + 0.1% SDS, 0.1% DOC, 1% Triton, and 150 mM NaCl, the 
former buffer with 500 mM NaCl, TEE + 0.25 M LiCl, 0.5% DOC, 0.5% NP-40, and TEE. Subsequently, 
precipitated chromatin was eluted from the beads with 400 ul elution buffer (1% SDS, 0.1 M NaHCO3) at 
room temperature for 20 minutes. Protein-DNA complexes were decrosslinked at 65°C for 4 hours, after 
which DNA was isolated by Qiagen column (QIAquick MinElute PCR Purification Kit). ChIP-seq libraries 
were prepared as followed; end repair was performed using Klenow and T4 PNK, a 3’ A-overhang 
was generated using Taq polymerase, and adaptors were ligated. The DNA was loaded on E-gel and 
fragments corresponding to ~300 bp were excised being the length of ChIP-fragment plus adaptors. 
The DNA was isolated, amplified by PCR, and used for cluster generation and sequencing on the HiSeq 
2000 (Illumina).
Biotin labeled oligo pull-down and mass spectrometry
Biotin labeled double strand oligos harboring either the C- or G-allele of rs621940 (Supplementary Table 
S1) were prepared and bound to streptavadin sepharose beads. Pull-downs for the C- and G-alleles 
were performed in duplo. Nuclear extracts from MEG-01 cells were generated according to Dignam et 
al.22 450 ug MEG-01 nuclear extract in a total volume of 600 ul protein incubation buffer (150 mM NaCl, 
50 mM Tris pH 8.0, 0.25% NP-40, 1 mM DTT, 1x Complete proteinase inhibitor) supplemented with 5 µg 
dIdC, 5 µg dAdT and 5 µg tRNA was added to the beads and incubated for 1.5 hours at 4°C on a rotating 
wheel. Subsequently the beads were washed, and the proteins on-bead digested with trypsin. After 
this the proteins were eluted from the beads and further digested overnight. The next day, the digested 
samples were loaded on C18 stage tips and labelled with light (10 mM monosodium phosphate, 35 
mM disodium phosphate, 16.2 μl 37% CH2O, 6 mg NaBH3CN) or medium dimethyl labeling (10 mM 
monosodium phosphate, 35 mM disodium phosphate, 30 μl 20% CD2O, 6 mg NaBH3CN). After labeling 
the tips were washed and stored at 4°C. For mass spectrometry analysis C-allele pull-down light was 
combined with G-allele pull-down medium (“forward experiment” and the other way around (“reverse 
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experiment”). Mass spec runs and raw data analysis was performed as described for standard dimethyl 
pull down.23 Raw data were processed by MaxQuant soft ware, and scatt er plots were generated using 
Perseus. 
Dual-Luciferase Reporter Assay in HEK293FT cells
Dual-Luciferase Reporter Assay (Promega) were performed according to the manufacturers’ 
recommendati ons.  HEK293FT cells were transfected using Lipofectamine 2000 (Invitrogen) with 0.2 µg 
pGL3-basic Renilla Luciferase vector, 0.8 µg pGL3-basic Firefl y Luciferase vector with diff erent inserts, 
0.5 µg pcDNA3.1-GFI1B-fl ag or pcDNA3.1-HA-GATA1, and 0.5 µg pcDNA3.1-empty vector. In the empty 
vector conditi on, the 0.5 µg pcDNA3.1-GFI1B-fl ag/pcDNA3.1-HA-GATA1 was replaced by an additi onal 
0.5 µg pcDNA3.1-empty vector. The pGL3-basic Firefl y Luciferase vector contains the GFI1B promoter 
(GRCh37/hg19 Chr9: 135,853,012 – 135,854,484) with or without a 645 bp region containing rs621940 
C/G-allele (GRCh37/hg19 Chr9: 135,869,978 – 135,870,622). Experiments were performed four ti mes, 
in duplicate. Luciferase signal was detected on the Fluostar Opti ma (BMG LABTECH). Firefl y Luciferase 
acti vity was normalized to Renilla Luciferase acti vity.
CRISPR-Cas9 mediated deleti on of rs621940 locus in K562
Two pairs of single guide RNAs (sgRNAs) to delete a 1.6 kb region encompassing rs621940 and located ~8 
kb downstream of GFI1B were designed using CRISPR Design (Zhang lab, MIT 2013, crispr.mit.edu). For 
each guide an oligo pair (Supplementary Table S1) was ligated into the BbsI digested pSpCas9(BB)-2A-
GFP (PX458) backbone vector according to Ran et al.24 Subsequently, 1*106 K562 cells were nucleofected 
with either sgRNA1.1-PX458 and sgRNA2.1-PX458 or sgRNA1.2-PX458 and sgRNA2.2-PX458 plasmids 
using Amaxa cell line nucleofector kit V and program T-016 of the Nucleofector II device (LONZA). 
Three days aft er nucleofecti on, GFP positi ve cells were single cell FACS sorted in a 96-wells plate and 
expanded in RPMI medium supplemented with 10% heat inacti vated FCS to generate clones. DNA was 
isolated using the QIAamp DNA Blood mini kit (QIAGEN). Deleti on of the 1.6 kb region was validated 
using PCR and Sanger sequencing with primers outside the expected deleted region (Supplementary 
Table S1). For the clones with a deleti on, a Sybr Green qPCR (on DNA) with primers inside the deleted 
region (Supplementary Table S1) was used to confi rm that all alleles were deleted. An albumin qPCR 
(Hs00910225_m1; Applied Biosystems) was performed to check for equal input in this qPCR. 
Allele specifi c GFI1B expression in peripheral blood mononuclear cells
Peripheral blood was collected in EDTA tubes from 30 healthy volunteers (SPB1-30) aft er informed 
consent was obtained (Sanquin blood supply, 2006-10-bc-MAS). For DNA and RNA isolati on see 
Supplementary Methods. The SPB panel was genotyped for rs621940 with a Sybr Green qPCR using 
allele specifi c primers (Supplementary Table S1). SNPs in the GFI1B 3’UTR were genotyped using a PCR 
and Sanger sequencing (Supplementary Table S1). The same GFI1B 3’UTR PCR was performed on cDNA 
followed by Ion Torrent next generati on sequencing to determine allele specifi c GFI1B expression using 
the heterozygous SNPs present in the 3’UTR. A long range PCR (Supplementary Table S1) was performed 
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with PrimeSTAR GXL DNA Polymerase according to the manufacturers’ recommendations, to haplotype 
the SNPs in samples where heterozygous rs621940 and heterozygous GFI1B 3’UTR SNPs co-occur. The 
long range PCR product was sequenced with Single Molecule Real-Time (SMRT) sequencing on the 
Sequel system (ICS v.5.1, Pacific Biosciences) (Neveling et al. in preparation). 
For more details see Supplementary Methods.  
RESULTS
GFI1B and many other epigenetic regulators bind the rs621940 locus in leukemia 
cell lines.  
The minor G-allele of rs621940, located ~8 kb downstream of GFI1B, associates with MPN and JAK2 
V617F+ clonal hematopoiesis.2 Here, we investigated the consequence of rs621940 on GFI1B expression 
regulation. As part of a negative feedback loop, the GFI1B protein represses its own gene expression 
through multiple sites.18 To investigate if the rs621940 locus is bound by GFI1B, we generated a genome 
wide binding profile in the GFI1B expressing cell line MEG-01, which is homozygous for the major 
C-allele of rs621940 (Supplementary Table S2). We observed clear GFI1B enrichment at the rs621940 
locus and confirmed earlier identified binding of GFI1B to the regulatory elements 12.5 kb, 16 kb, and 
17.5 kb downstream of human GFI1B (Figure 1). The latter three loci were earlier identified as GFI1B 
regulatory elements based on multispecies conservation, binding of erythrocyte and megakaryocyte 
transcription factors like GFI1B and GATA1, histon 4 acetylation, and looping to the GFI1B promoter.18 
To investigate if the rs621940 locus represents a putative regulatory element, we analyzed publically 
available chromatin data of the GFI1B expressing cell line K562, generated by the ENCODE Consortium. 
The rs621940 locus was hypersensitive for DNAseI, had strong enrichment for H3K4me1, and weak 
enrichment for H3K27ac (Supplementary Figure S1). However, compared to the earlier identified 
regulatory elements that show both enrichment of H3K4me1 and H3K27ac, the latter signal was 
clearly lower at the region containing rs621940. Furthermore, binding of erythrocyte/megakaryocyte 
transcription factors (EGR1, TAL1, CMYC, GATA1/2) and histon modifiers (LSD1, HDAC1/2) was 
observed. The Chromatin State Segmentation prediction from ENCODE/Broad institute suggested that 
the rs621940 region is an enhancer (Supplementary Figure S1). 
Scale
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Figure 1. GFI1B binds to the rs621940 locus in MEG-01 cells. GFI1B ChIP profile in MEG-01 cells (GRCh37/hg19). 
The location of rs621940 is indicated, MEG-01 cells are homozygous for the major C-allele. Previously identified 
GFI1B regulatory elements at 12.5 kb, 16 kb, and 17.5 kb downstream of GFI1B are indicated with the asterisks. 
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Diff erenti al transcripti on factor binding to the rs621940 C- and G-allele.
The region encompassing the rs621940 C-allele is bound by GFI1B in MEG-01 cells. To investi gate if 
GFI1B binding is altered by the G-allele, we performed a pull-down experiment with bioti n labeled 
oligonucleoti des containing either the C- or G-allele using MEG-01 nuclear extracts, followed by dimethyl 
labeling and mass spectrometry analysis. This approach is specifi cally suited to identi fy diff erenti ally 
bound factors. Indeed, a total of 24 diff erenti ally bound proteins were identi fi ed; 7 binding stronger 
to the C-allele and 17 binding more effi  cient to the G-allele (Figure 2). However, GFI1B was not among 
them, suggesti ng that GFI1B binding is not aff ected by either rs621940 allele. All enriched interactors of 
the C-allele, except BANP/BEND1, are transcripti on factors (NFIA, NFIX, NFIC, KLF3, SOX4, MBD4) known 
to be involved in hematopoiesis.25-31 The 17 proteins enriched for the G-allele contain 9 transcripti on 
factors of which ZBTB7A and ZNF148/ZBP-89 have a described role in hematopoiesis.25, 32, 33 None of the 
diff erenti ally binding interactors are known to bind GFI1B, currently. However, ZBTB7A and ZNF148 do 
interact with GATA1,32, 33 a known interacti on partner of GFI1B and regulator of its gene expression.34
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Figure 2. Diff erenti al protein binding between rs621940 C- and G-allele. Mass spectrometry analysis on bioti n-
tagged oligo pull-down in MEG-01 nuclear lysates. One oligo contained the major C-allele and the other the minor 
G-allele. In the “Forward” sample the pepti des from the C-allele pull-down are light (L) dimethyl labeled and the 
pepti des from the G-allele medium (M) dimethyl labeled. This is vice versa in the “Reverse” sample. Presented here 
are the proteins binding diff erenti ally to the C- and G-allele of rs621940. Proteins binding more effi  ciently to the 
C-allele are red and the ones binding more effi  ciently to the G-allele are blue. NFIX is presented twice because there 
are NFIX two isoforms in the Uniprot database, which is used to map the pepti des.
CHAPTER 4
100
Rs621940 alleles do not differentially affect GFI1B promoter activity in gene 
reporter assays.
To study if the rs621940 alleles affect GFI1B promoter activity we used luciferase reporter assays in the 
context of forced GFI1B and GATA1 expression. To this end, HEK293FT cells were transfected with the 
pGL3 vector containing the GFI1B promoter followed by the luciferase reporter, or the GFI1B promoter 
and the reporter followed by a ~645 bp element containing rs621940 either with the C- or G-allele. 
For all conditions we observed  that GFI1B repressed, and that GATA1 stimulated the promoter (Figure 
3). The addition of the region containing rs621940 resulted in lower basal promoter activity with the 
C-allele having a more pronounced effect than the G-allele. However, both constructs were equally well 
repressed and activated by GFI1B and GATA1, respectively.  Thus, the region encompassing rs621940 
negatively affects GFI1B promoter activity in gene reporter assays, with a stronger effect for the C- than 
the G-allele. Yet, these alleles do not affect the ability of GFI1B nor GATA1 to influence gene expression. 
The rs621940 locus does not affect GFI1B expression nor GFI1B auto-repression 
in K562 cells.
To investigate the contribution of the rs621940 locus on GFI1B expression and auto-repression in a 
physiological model, we deleted a ~1.6 kb fragment encompassing rs621940 by CRISPR-Cas9 DNA 
editing in K562 cells. We used K562 cells because they highly express GFI1B, are easily gene-edited, and 
have been extensively studied by the ENCODE consortium. Cells were electroporated with two sgRNA-
Cas9 constructs and single cells were subsequently sorted using the FACS BD Aria sorter. Clones with 
deletion of the rs621940 locus were identified using a PCR with primers encompassing  the expected 
deletion followed by Sanger sequencing (Supplementary Figure S2A-B). Subsequently, a DNA based 
qPCR amplifying ~120 bp within the deleted region was performed to validate that the rs621940 locus 
was deleted in all alleles (Supplementary Figure S2A, C). This identified three clones with complete loss 
of the rs621940 locus (1-9, 1-11, and 2-10).
 Compared to wild type K562 cells, basal GFI1B expression did not differ consistently in cells 
lacking the rs621940 region (Figure 4A). Because the variation in GFI1B expression was almost 2-fold 
between the different clones, we determined GFI1B expression variation in cloned wild type K562 
cells. This showed that GFI1B expression relative to bulk K562 cells ranged between 0.55-2.0 (Figure 
4B), indicating that the GFI1B expression variation in the rs621940 deleted clones is within the normal 
range. Subsequently, we studied if auto-repression is disturbed in the rs621940 deleted clones by 
overexpressing GFI1B using retroviral transduction (Figure 4C). The auto-repression observed in the wild 
type K562 cells appeared to be unchanged in the rs621940 deleted clones (Figure 4D). In conclusion, 
we did not find a functional consequence of the rs621940 locus deletion on GFI1B expression and auto-
repression in K562 cells.
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Figure 3. Rs621940 does not aff ect GFI1B promoter acti vity in luciferase reporter assays. (A) Schemati c 
representati on of used pGL3 fi refl y luciferase contructs. The GFI1B promoter is cloned upstream, and the ~645 bp 
region encompassing rs621940[C/G] downstream of the fi refl y luciferase gene. (B) Gene reporter luciferase assays 
in HEK293FT cells transfected with pGL3 backbone only, or pGL3 with either the GFI1B promoter, GFI1B promoter 
+  rs621940[C], or GFI1B promoter +  rs621940[G]. For every promoter construct three conditi ons were tested, 
overexpression of empty vector, GFI1B, or GATA1. On the y-axis are the Firefl y Luciferase signals normalized with 
Renilla Luciferase signals (n=4).
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Figure 4. Deletion of the rs621940 locus does not influence GFI1B expression or GFI1B auto-repression in K562 
cells. (A) Relative GFI1B expression in K562 CRISPR-Cas9 genome edited clones that have a complete deletion of the 
~1.6 kb region encompassing rs621940. GFI1B expression in the deleted clones is presented relative to the GFI1B 
expression in the wild type (WT) bulk K562 cells. Results show mean with standard deviation (n=2). (B) Relative GFI1B 
expression in K562 WT clones. GFI1B expression in the clones is presented relative to the GFI1B expression in the 
WT bulk K562 cells. (C) GFI1B expression in rs621940 deleted clones retrovirally transduced with GFI1B, relative to 
the same clone transduced with empty vector (EV).  (D) Endogenous GFI1B expression in rs621940 deleted clones 
retrovirally transduced with GFI1B, relative to endogenous GFI1B expression in the same clone transduced with EV. 
GFI1B expression was normalized to GAPDH expression in all sub panels.
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Rs621940 does not aff ect allele-specifi c GFI1B expression in mononuclear cells.
Finally, we investi gated if the rs621940 G-allele infl uences GFI1B expression in peripheral blood 
mononuclear cells from 30 healthy donors. Genomic DNA from these individuals was fi rst genotyped for 
rs621940 using a Sybr Green qPCR with allele specifi c primers for the C- and G-allele. Sanger sequencing 
was used for validati on. This identi fi ed 10 individuals with rs621940[C/G] and 20 individuals that were 
homozygous C (Supplementary Table S2). GFI1B expression was not signifi cantly diff erent between the 
two groups (Figure 5A). Because the rs621940 G-allele carrying individuals were heterozygous, subtle 
eff ects on GFI1B expression by the G-allele might be missed. Therefore, we examined allele specifi c 
GFI1B expression in rs621940[C/G] and [C/C] cases based on non-coding SNPs present in the 3’UTR of 
the GFI1B transcript (rs4962034, rs667805, and rs15906).  First, we genotyped the 3’UTR of GFI1B by 
genomic PCR followed by Sanger sequencing. Next, we selected samples with informati ve  3’UTR SNPs 
(5 with rs621940[C/G] and 9 with rs621940 [C/C]). Subsequently, the 3’UTR SNPs and rs621940 were 
haplotyped using long range PCR and SMRT sequencing to determine which alleles of the 3’UTR SNPs 
are on the same chromosome as the rs621940[G] minor allele. Having established this, we measured 
allele specifi c expression by performing an RT-PCR of the expressed informati ve 3’UTRs followed by Ion 
Torrent next generati on sequencing to determine the variant allele frequency of the polymorphisms. 
We observed no consistent eff ect of the rs621940 minor allele on allelic GFI1B expression. Among 
the rs621940[C/G] samples was one sample where the C-allele and two samples where the G-allele 
correlated with higher GFI1B expression. In additi on, in two samples there was no expression diff erence 
between the two alleles. In controls lacking the minor allele [C/C], variant allele frequencies also diff ered 
indicati ng that other factors than rs621940 determine allelic GFI1B expression (Figure 5B).   
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rs4962034 rs667805 rs15906 rs621940 haplotyping rs621940 allele associated 
sample ID c.*211C>G c.*256A>G c.*530T>A C>G with higher GFI1B 
G-allele % G-allele % A-allele % expression
SPB001 53%   CC
SPB006 21%   54%   CC
SPB007 14%   CC
SPB009 45%    45%   CC
SPB013 35% CC
SPB019 59% CC
SPB020 40% 56% 42% CC
SPB024 29%  CC
SPB028 23%   74% CC
SPB003 24%    CG C-A-T-G G-allele
SPB005 80%    CG C-A-T-G C-allele 
SPB010 53%    CG G-A-T-G 50/50
SPB014 68% CG G-A-T-G G-allele 
SPB021 45%  52%  50%  CG G-A-T-G 50/50
Figure 5. Rs621940 does not influence (allele specific) GFI1B expression in mononuclear cells of healthy donors. 
(A) Total GFI1B expression in donors with CC or CG at the rs621940 locus normalized to GAPDH expression. (B) The 
second column shows the variant allele frequency (frequency of minor allele) of heterozygous GFI1B 3’UTR SNPs 
(rs4962034, rs667805, rs15906) in cDNA of mononuclear cells from healthy donors. Rs621940 genotype is presented 
in the third column. Haplotype of 3’UTR SNP with rs621940 G-allele is shown in the fourth column. The order of 
alleles is rs4962034, rs667805, rs15906, and rs621940. Informative GFI1B 3’UTR SNP alleles are indicated in red. 
The last column shows which rs621940 allele is associated with higher GFI1B expression based on the variant allele 
frequency of the GFI1B 3’UTR SNPs and haplotyping. For example, in SPB003 the informative SNP is rs15906[T>A]. 
The minor A-allele is present in 24%, meaning that the major T-allele is higher expressed. Rs15906 T-allele is on the 
same chromosome as rs621940 G-allele, so rs621940 G-allele is associated with higher GFI1B expression. 
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DISCUSSION
The G-allele of rs621940 located ~8 kb downstream of GFI1B associates with JAK2 V617F+ clonal 
hematopoiesis in healthy individuals and MPN.2 GFI1B regulates HSC proliferati on, and diff erenti ati on 
of erythrocyte and megakaryocyte lineages.3-7 GFI1B expression is deregulated in various hematological 
malignancies, including MPN.12 Here, we investi gated whether the G-allele of rs621940 aff ects GFI1B
expression. We observed that GFI1B binds the rs621940 locus in MEG-01 cells, being homozygous for 
the major C-allele. However, GFI1B was not among the 24 MEG-01 expressed proteins that diff erenti ally 
bind to either rs621940 allele. Luciferase gene reporter assays suggested that the rs621940 locus inhibits 
GFI1B promoter acti vity in HEK293FT cells. This eff ect is stronger for the C-allele than the G-allele. 
However, there was no signifi cant diff erence in GFI1B auto-repression (and GATA1 acti vati on) between 
the C- and G-allele. Thus, if the rs621940 alleles aff ect GFI1B expression this is likely not mediated by 
GFI1B itself. 
 In chronic myeloid leukemia K562 cells, the rs621940 locus exhibits an open chromati n architecture 
and is bound by many transcripti on factors. Yet, deleti on of an 1.6 kb fragment encompassing rs621940 
in these cells did not alter GFI1B expression nor GFI1B-mediated auto-repression. Importantly, we 
also did not observe altered GFI1B expression in mononuclear leukocytes from healthy individuals 
heterozygous for the minor rs621940 G-allele compared to individuals homozygous for the major allele. 
Likewise, we did not detect consistent diff erences in allele specifi c GFI1B expression in mononuclear 
leukocytes of healthy donors with rs621940[C/G]. In fact, diff erences in allelic GFI1B expression were 
observed in mononuclear leukocytes from healthy individuals homozygous for the major rs621940-C 
allele. Thus, we fi nd no evidence that the rs621940 G-allele has a dominant eff ect on GFI1B expression, 
although in K562 cells the locus is accessible and bound by many transcripti onal regulators. 
 Regarding histone modifi cati ons, the rs621940 locus is specifi cally enriched for H3K4me1 but 
not H3K27ac in K562 cells (Supplementary Figure S1), suggesti ng that this region is a poised enhancer 
that is not required for GFI1B expression in cycling K562 cells. Possibly, the earlier identi fi ed elements 
12.5 kb, 16 kb and 17.5 kb  downstream of GFI1B are suffi  cient to maintain GFI1B expression. Other 
possibiliti es are that the rs621940 locus regulates GFI1B expression in other cell types and/or diff erent 
hematopoieti c developmental phases. It is also possible that this locus regulates other genes. To test 
this, we measured expression of TSC1 and GTF3C5, the genes respecti vely up- and downstream of 
GFI1B but did not observe any diff erences in the K562 clones (Supplementary Figure S3). Genome-wide 
chromati n capture experiments using the rs621940 locus as viewpoint could show which genes might 
be regulated through this region. This may be relevant as we observed interesti ng proteins binding 
diff erenti ally to the rs621940-alleles. The transcripti on factors ZBTB7A (a.k.a LRF) and ZNF-148 (a.k.a. 
ZBP-89) specifi cally bind the minor allele and interact with GATA1 at regulatory elements of key erythroid 
genes.32, 35 GATA1 is a regulator of GFI1B expression, and can be an acti vator or repressor depending on 
the presence of other co-(transcripti on)factors.34 It would be interesti ng to study if ZBTB7A and ZNF-148 
regulate GFI1B expression together with GATA1. Furthermore, ZBTB7A mutati ons occur in ~23% of AML 
pati ents that harbor the translocati on t(8;21).36 These mutati ons disrupt the transcripti onal repressor 
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potential and the anti-proliferative effect of ZBTB7A. NFIX, binding more efficient to the C-allele, can also 
be mutated in acute erythroid leukemia (ASH 2018 abstract, Lacobucci et al). Possibly, changed ZBTB7A 
and/or NFIX binding due to rs621940 can contribute to myeloid transformation. Further studies are 
warranted to test the contribution of these factor in GFI1B expression regulation during hematopoiesis.
Data availability
Raw ChIP sequencing data of the GFI1B binding profile in MEG-01 cells has been deposited with the 
Gene Expression Omnibus (GEO)  database under accession number GSE125246.
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SUPPLEMENTARY METHODS
Cell culture
K562 and MEG-01 cells were cultured in RPMI 1640 (GIBCO) supplemented with 10% heat inacti vated 
FCS, at 37˚C and 5% CO2. PhoenixA cells were cultured in DMEM (GIBCO) supplemented with 10% heat 
inacti vated FCS, at 37˚C supplied with 5% CO2. HEK293FT cells were maintained in DMEM  supplemented 
with 10% non-heat inacti vated FCS, 1% glutamine, 1% non-essenti al amino acids, 1% pyruvate, and 1% 
penicillin/streptomycin (MP Biomedical).
Chromati n isolati on from MEG-01 cells 
Chromati n from ~18 million MEG-01 cells was isolated as described by Mandoli et al.1 Briefl y, cells were 
crosslinked with 1% formaldehyde for 10 minutes at room temperature. The crosslinking reacti on was 
stopped by adding 0.125 M glycine, followed by washing with three diff erent buff ers to isolate the 
nuclei (1) PBS, (2) 0.25% Triton X 100, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6 and (3) 0.15 M 
NaCl, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6. Nuclei were then incubated in ChIP incubati on 
buff er (0.15% SDS, 1% Triton X 100, 150 mM NaCl, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6) 
and sonicated using Bioruptur sonicator (Diagenode) for 20 minutes at high power, 30 seconds on and 
30 seconds off . 
UCSC genome browser screenshot
Profi les of DNAseI, histone modifi cati ons, binding of transcripti onal regulators, and Chromati n State 
Segmentati on by Hidden Markov Model in K562 cells were presented in UCSC Genome Browser 
with genome assembly GRCh37/hg19.2, 3 The epigeneti c K562 data was generated by the ENCODE 
Consorti um.4
Bioti n labeled oligo pull-down and mass spectrometry
Double strand oligos harboring either the C or G allele of rs621940 were prepared by annealing 5 ul 
(100 uM) of bioti nylated sense oligo and 7.5ul (100 uM) of anti sense oligo in 12.5 ul annealing buff er 
(100 mM NaCl, 20 mM Tris pH8, 2 mM EDTA). See Supplementary Table S1 for oligo sequences. This 
mixture was heated for 10 minutes at 95°C and cooled down in the heatblock to room temperature. 
Subsequently the bioti nylated double strand oligos were bound to streptavadin sepharose beads. Pull-
downs for the C- and G-allele were performed in duplo, per pull-down 20 ul streptavadin sepharose 
beads (50% slurry) was used. Beads were washed once with PBS + 0.1% NP40 and once with DNA 
binding buff er (DBB) (1 M NaCl + 10 mM Tris pH 8.0 + 1 mM EDTA + 0.05% NP40). To the beads, 575 ul 
DBB and 25 ul bioti nylated double strand oligos was added. The mixture was incubated for 30 minutes 
to let the oligos anneal to the beads. Aft erwards the beads were washed once with DBB and twice with 
protein incubati on buff er (PIB) (150 mM NaCl, 50 mM Tris pH 8.0, 0.25% NP-40, 1 mM DTT, 1x Complete 
proteinase inhibitor). 
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 Nuclear extracts from MEG-01 cells were generated according to Dignam et al.5 450 ug MEG-01 
nuclear extract in a total volume of 600 ul PIB supplemented with with 5 µg dIdC, 5 µg dAdT and 5 µg 
tRNA was added to the beads and incubated for 1.5 hours at 4°C on a rotating wheel. Subsequently the 
beads were washed thrice with 1 ml PIB and twice with 1 ml PBS. After which the PBS was removed 
completely with 30G needles. Beads were resuspended in 50 ul elution buffer (2M urea, 100 mM 
ammonium bicarbonate, 10 mM DTT) and incubated for 20 minutes in a shaker at 1400 rpm and room 
temperature. Subsequently IAA was added to a final concentration of 50 mM and incubated for 10 
minutes in shaker in the dark at 1400 rpm and room temperature. Proteins were on-bead digested by 
adding 0.25 ug trypsin and two hour incubation in a shaker at 1400 rpm and room temperature. The 
beads were spun down and the supernatant transferred to a new tube. Again 50 ul of elution buffer was 
added to the beads and incubated for 5 minutes. The beads were spun down and the supernatant was 
combined with the previous one. Digestion was continued over night using 0.1 ug trypsin. 
 The next day, C18 stage tips were prepared and washed once with 50 ul MeOH, once with 50 ul 
buffer B, and twice with 50 ul buffer A. Subsequently, the digested samples were loaded on the stage 
tip and washed once with 50 ul buffer A. Of the duplos, one was treated with light dimethyl labelling 
(10 mM monosodium phosphate, 35 mM disodium phosphate, 16.2 μl 37% CH2O, 6 mg NaBH3CN) and 
one with medium dimethyl labelling (10 mM monosodium phosphate, 35 mM disodium phosphate, 
30 μl 20% CD2O, 6 mg NaBH3CN). After labeling the tips were washed with 100 ul buffer A and stored 
at 4°C. For mass spectrometry analysis C-allele pull-down light was combined with G-allele pull-down 
medium and the other way around. Mass spec run and raw data analysis was performed as described 
for standard dimethyl pull down.6 Raw data were processed by MaxQuant software, and scatter plots 
were generated using Perseus.  
RT-qPCR
RNA was isolated using the Quick-RNATM kit (Zymo Research). RNA was treated with DNAse (Zymo 
Research) and reverse transcribed using M-MLV reverse transcriptase (Invitrogen). For RT-qPCR, cDNA 
was amplified using Taqman 2x Universal PCR Master Mix (Applied biosystems) as recommended by 
the manufacturer. Primer-probe sets for total GFI1B expression  and endogenous GFI1B expression 
are presented in Supplementary Table 1. Endogenous GFI1B expression was determined using primers 
targeting the 5’UTR which is not present in the overexpression construct.  TSC1 expression was 
determined with Taqman gene expression assay Hs01060648_m1. GTF3C5 expression was determined 
with Taqman gene expression assay Hs01034267_m1. GAPDH expression was determined using GAPDH 
Endogenous Control (Hs99999905_m1) (Applied biosystems) to correct for differences in input. RT-
qPCR was performed on the 7500 Real Time PCR System (Applied Biosystems). Data were analyzed 
using 7500 Fast System Software (version 1.3.1).
Retrovirus production and transduction K562 cells
Retrovirus of  pMIGR1-IRES-GFP and pMIGR1-GFI1B-flag-IRES-GFP was produced using PhoenixA cells. 
Cells were transfected using calcium phosphate with 3.15 µg pCL-Ampho retroviral packaging vector 
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and 18.4 µg pMIGR1 construct. Aft er 16-18 hours, the medium was replaced with 5 ml fresh medium. 
Viral supernatant was harvested 30 hours aft er transfecti on. Subsequently, 2.5 ml viral supernatant 
was spun down on retronecti n (Takara Bio Inc.)-coated non-ti ssue culture treated 6-wells plates for 1.5 
hours at maximum speed and 4°C. Aft er which the viral supernatant was removed from the plates and 
1*106 K562 cells were added per well. The plate with K562 cells was spun down for 5 minutes at 500g 
and room temperature. Aft er 2 days the cells were harvested from the retronecti n and cultured for an 
additi onal 2 days. Finally GFP+ cells were sorted using the BD FACSAria (BD Bioscience) and prepared 
for RNA isolati on.   
DNA and RNA isolati on from peripheral blood mononuclear cells
Peripheral blood was collected in EDTA tubes from 30 healthy volunteers (SPB1-30) aft er informed 
consent (Sanquin blood supply, 2006-10-bc-MAS). The tubes were centrifuged for 10 minutes at 1800 
rpm. This created three phases, of which the middle phase was taken containing the mononuclear 
cells. Remaining red cells were lysed at 4°C using 0.9xNH4Cl soluti on. Mononuclear cells were washed 
in PBS+0.5%FCS and divided for DNA and RNA isolati on. RNA was isolated from 60*106 cells using 4 ml 
RNAbee. DNA from 20-100*106 cells was isolated using Nucleospin Blood XL kit (MACHEREY-NAGEL) 
according to the manufactures’ recommendati ons. 
Single molecule real-ti me (SMRT) sequencing
Long-range amplicons were purifi ed using AMPure BP beads (Pacifi c Biosciences). Library preparati on 
was performed according to protocol ‘Procedure and Checklist – Preparing SMRTbell Libraries using 
PacBio Barcoded Adapters for Multi plex SMRT Sequencing’ (Pacifi c Biosciences, Part Number 100-538-
700-02), using barcoded hairpin adapters. During library preparati on, the here described amplicons 
were pooled equimolarly with other amplicons that were sequenced on the same sequencing run. 
The concentrati on of the fi nal SMRTbell library was measured by Qubit 3.0 (ThermoFisher Scienti fi c). 
To generate polymerase-bound SMRTbell complexes, both sequencing primers and sequencing 
polymerase were annealed to the SMRTbell library. Sequencing was performed on a Sequel system (ICS 
v.5.1, Pacifi c Biosciences), with an on-plate concentrati on of 4.5 pM, a 600 minutes movie ti me and 
pre-extension. Following sequencing, demulti plexing and CCSmapping (circular consensus sequencing, 
mapped against hg19) was performed using SMRTLink 5.1. For more detailed descripti on of the used 
sequencing workfl ow, see Neveling et al (in preparati on). 
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Table S1. Oligos and primers
Application Orientation Sequence
pull-down 
rs621940[C]
forward 
reverse
Biotin-TCCTTCTTTGTCGACTGAGGTTTGGCGAGATCGAGATTAAGCTTGTCG
GG CCCGACAAGCTTAATCTCGATCTCGCCAAACCTCAGTCGACAAAGAAGGA
pull-down 
rs621940[G]
forward 
reverse
Biotin-TCCTTCTTTGTCGACTGAGGTTTGGGGAGATCGAGATTAAGCTTGTCG
GG CCCGACAAGCTTAATCTCGATCTCCCCAAACCTCAGTCGACAAAGAAGGA
sgRNA1.1* forward 
reverse
CACCGCCAAAAAGATAGCCTCAACT               
AAACAGTTGAGGCTATCTTTTTGGC
sgRNA1.2* forward 
reverse
CACCGCTGGTTCCCAAATTAACCTT      
AAACAAGGTTAATTTGGGAACCAGC
sgRNA2.1* forward 
reverse
CACCGACGAGTCCCCATTCAATCCT   
AAACAGGATTGAATGGGGACTCGTC
sgRNA2.2* forward 
reverse
CACCGGGGGTCAGTGCCACAGTCTA      
AAACTAGACTGTGGCACTGACCCCC
CRISPR-Cas9 check 
PCR
forward 
reverse
GGGTTCGTTTGCTTTAGACG        
TGTCACCACGAACAGGACAT
CRISPR-Cas9 check 
qPCR
forward 
reverse
CTGACTCATCTCTTACACACACATG      
CGATACTGGTTTGGTTTTGTTTAG
GFI1B RT-qPCR forward 
reverse
probe
CCCGTGTGCAGGAAGATGA     
CAGGCACTGGTTTGGGAATAGA              
FAM-TTACCCCGGTGCCCAGA-MGB
endogenous GFI1B 
RT-qPCR
forward 
reverse probe
CCGAGAGAGGCTTTGCAGTT     
TGTGAGCCTTCTTGCTCTTCAC          
FAM- CCACCTCGGGAAGC-MGB
genotyping 
rs621940[C] qPCR
forward 
reverse
GCATACTCCCTGTTTGCTAAACAAA     
CGACAAGCTTAATCTCGATCTCG
genotyping 
rs621940[G] qPCR
forward 
reverse
CTTTGTCGACTGAGGTTTGGG       
CCCTCTTTCTCTGCTGTATGCA
genotyping GFI1B 
3’UTR SNPs
forward 
reverse
CTACCAGCTTGTTTTGAGACTCAT           
TATTGACAGCAGTTGAGAGAACAG
haplotyping 
rs621940+GFI1B 
3’UTR SNPs
forward  
reverse
CTACCAGCTTGTTTTGAGACTCAT     
CCCTCTTTCTCTGCTGTATGCA
*All four sgRNA guides are targeted to the antisense strand. The bold sequences will generate the restriction sites 
that anneal to a BbsI cut pSpCas9(BB)-2A-GFP (PX458) backbone vector.
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Table S2. Genotyping rs621940 of peripheral blood mononuclear cell samples and cell lines.
sample ID Sybr green qPCR Sanger sequencing 
SPB001 CC CC
SPB002* CC CC
SPB003 CG CG
SPB004* CG CG
SPB005 CG
SPB006 CC
SPB007 CC
SPB008* CC
SPB009 CC
SPB010 CG
SPB011* CC
SPB012* CC CC
SPB013 CC
SPB014 CG
SPB015* CC
SPB016* CC
SPB017 CC
SPB018* CG
SPB019 CC
SPB020 CC
SPB021 CG
SPB022* CG CG
SPB023* CG CG
SPB024 CC CC
SPB025* CC
SPB026 CC
SPB027* CC
SPB028 CC
SPB029* CG
SPB030* CC
MEG-01* CC
K562* CC
* no heterozygous GFI1B 3’UTR SNPs
CHAPTER 4
114
SUPPLEMENTARY FIGURES
Scale
chr9:
K562 ChromHMM
10 kb hg19
135,855,000 135,860,000 135,865,000 135,870,000 135,875,000 135,880,000
100 vertebrates Basewise Conservation by PhyloP
Chromatin State Segmentation by HMM from ENCODE/Broad
GFI1B
GFI1B
100 Vert. Cons
4.88 _
-4.5 
0 -
K562 DNAseI
UW 
127 _
0 
K562 H3K4me1
ENCODE/SYDH
200 _
0 
K562 H3K4me1
ENCODE/Broad
200 _
0 
K562 H3K4me2
ENCODE/Broad
200 _
0 
K562 H3K4me3
ENCODE/Broad
200 _
0 
K562 H3K9ac
ENCODE/Broad
200 _
0 
K562 H3K9me1
ENCODE/Broad
200 _
0 
K562 H3K9me3
ENCODE/Broad
200 _
0 
K562 H3K27ac
ENCODE/Broad
200 _
0 
K562 H3K27me3
ENCODE/Broad
200 _
0 
K562 H3K36me3
ENCODE/Broad
200 _
0 
K562 H3K79me2
ENCODE/Broad
200 _
0 
K562 H4K20me1
ENCODE/Broad
200 _
0 
K562 HDAC1
200 _
0 
K562 HDAC2
200 _
0 
K562 LSD1
ENCODE/Broad
200 _
0 
K562 PLU1
ENCODE/Broad
200 _
0 
K562 RBBP5
ENCODE/Broad
200 _
0 
K562 P300
ENCODE/Broad
200 _
0 
K562 Pol2
ENCODE/Broad
200 _
0 
K562 CTCF
ENCODE/Broad
200 _
0 
K562 EGR1 
HudsonAlpha
200 _
0 
K562 TAL1 
Stanford
200 _
0 
K562 CMYC 
Standford
200 _
0 
K562 HDAC2 
HudsonAlpha
200 _
0 
K562 GATA1 
UCD
200 _
0 
K562 GATA2
UCD 
200 _
0 
K562 MAX 
HudsonAlpha
200 _
0 
K562 ZBTB7A
HudsonAlpha 
200 _
0 
ENCODE/Broad
ENCODE/Broad
rs621940
*                    *      *
Figure S1
Figure S1. Rs621940 is located in a predicted regulatory element downstream of GFI1B. UCSC genome browser 
screenshot https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&lastVirtModeType=default&lastVirtModeExtra >> 
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State=&virtModeType=default&virtMode=0&nonVirtPosition=&position=chr9%3A135849904-135883721) 
showing 100 vertebrates Basewise Conservati on by PhyloP; Chromati n State Segmentati on by Hidden Markov Model 
(HMM) from ENCODE/Broad (the colors indicate the diff erent states such as weak/strong promoter (pink/red), weak/
strong enhancer (yellow/orange), transcripti onal transiti on/transcripti onal elongati on/weak transcribed (green)); 
DNaseI signal of open chromati n from University of Washington (UW); histone modifi cati ons by ChIP signal from 
ENCODE/SYDH and ENCODE/Broad; binding of transcripti onal regulators by ChIP-seq signal from ENCODE/Broad, 
UCD, Stanford, and HudsonAlpha. All experiments were performed in K562 cells. The rs621940 locus is indicated 
with a black line. Previously identi fi ed GFI1B regulatory elements at 12.5 kb, 16 kb, and 17.5 kb downstream of the 
GFI1B start codon are indicated with asterisks.  
  1-2   1-3   1-6   1-9   1-11  2-4  2-10  WT
A
B         C
GFI1B 
F     sgRNA1.1  sgRNA2.1              qPCR primers                    gRNA1.2   sgRNA2.2       R
rs621940 encompassing element
albumin rs621940 locus
Ct-value Ct-value
WT bulk 24,77 21,76
1-2 24,63 22,21
1-3 24,97 23,27
1-6 24,66 22,9
1-9 24,24 >40
1-11 24,29 39,42
2-4 24,01 23,11
2-10 24,17 >40
Figure S2
Figure S2. Selecti on of homozygous rs621940 locus deleted clones. (A) Schemati c overview of sgRNA locati ons 
used to delete the rs621940 locus in K562 cells, and primer locati ons to validate if the rs621940 locus was deleted 
in all alleles. sgRNA1.1 was combined with sgRNA1.2 to generate 1-x clones, and sgRNA2.1 was combined with 
sgRNA2.2 to generate 2-x clones. A PCR with primers (F and R) outside the deleted region was used to select clones 
that at least had one allele deleted. A Sybr Green qPCR was performed with primers inside the deleted region to 
validate if the deleti on had occurred on all alleles. (B) Agarose gel with PCR products (primers F and R) from K562 
clones. K562 wild type (WT) bulk DNA was taken along as negati ve control. PCR product size 1-x clones: ~440 bp, 2-x 
clones: ~360 bp, and WT: 2025 bp. Lack of 2025 bp WT fragment amplifi cati on in clones 1-2, 1-3, 1-6, and 2-4 could 
be caused by preferenti al amplifi cati on of the smaller fragment. (C) Ct values of Sybr Green qPCR with primers in 
rs621940 locus deleti on on DNA of K562 clones. K562 WT bulk DNA was taken along as control.  An albumin qPCR 
was performed to check for equal input. 
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Figure S3
Figure S3. Deletion of rs621940 locus does not affect expression of other close by genes. Relative TSC1 (A) and 
GTF3C5 (B) expression in K562 CRISPR-Cas9 genome edited clones that have a deletion of the ~1.6 kb rs621940 locus 
(n=2). K562 wild type (WT) bulk cells were taken along as control, and TSC1 and GTF3C5 expression was normalized 
to GAPDH expression. TSC1 is the gene upstream of GFI1B and its first exon is ~50 kb upstream of rs621940. GTF3C5 
is the downstream gene of GFI1B and its first exon is ~36 kb downstream of rs621940. 
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THESIS OBJECTIVE
Thrombocytopenia and platelet dysfuncti on resulti ng in bleedings is a frequent occurring problem in 
the clinic and can have various causes. To bett er prevent and treat these platelet defects we need more 
insight in the molecular pathways underlying megakaryocyte development and platelet formati on. GFI1B 
is one of the transcripti on factors crucial for megakaryopoiesis, and inherited variants in this protein 
lead to a bleeding diathesis with a multi tude of megakaryocyte and platelet defects. In this thesis we 
investi gated the molecular mechanism of the bleeding disorder causing GFI1B-Q287* variant that was 
earlier identi fi ed by our research group. Furthermore, we studied the molecular pathways downstream 
of GFI1B-Q287*, to identi fy GFI1B regulated processes during megakaryopoiesis and platelet formati on. 
The identi fi cati on of GFI1B-Q287* molecular mechanisms and downstream pathways may eventually 
contribute to targeted drug development for thrombocytopenia and thrombopathy, and help to 
understand and maybe prevent drug-induced thrombocytopenia.
 There are sti ll many cases with inherited bleeding and platelet defects for which the underlying 
geneti c defect is unknown. The identi fi cati on of molecular pathways driving megakaryopoiesis can 
expand the panel of possible mutated genes in inherited platelet disorders and thereby improve 
molecular diagnosis. When a variant is found, determinati on of its pathogenicity is challenging especially 
in small families. To improve classifi cati on of inherited GFI1B variants we developed assays testi ng the 
damaging eff ect of newly identi fi ed inherited GFI1B variants on its functi on. These assays were used to 
gain insight in the molecular mechanisms of the newly identi fi ed GFI1B variants.
 GFI1B is not only pathologically involved in inherited bleeding and platelet disorders, but also 
in hematological malignancies. Deregulated GFI1B expression and a somati c mutati on disrupti ng 
GFI1B functi on are associated with myeloid malignancies. This highlights the importance of balanced 
GFI1B expression, which is normally mediated by multi ple epigeneti c regulators binding the GFI1B
promoter and downstream regulatory elements. In this thesis we also investi gated whether the clonal 
hematopoiesis and myeloproliferati ve neoplasm (MPN) predisposing G-allele of rs621940, located ~8 
kb downstream of GFI1B, aff ects GFI1B expression and GFI1B auto-repression.
  In the rest of this chapter I will touch upon several topics related to our research stated above and 
presented in chapters 2-4. Furthermore, I will show some additi onal non-published data and highlight 
important remaining research questi ons.
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MOLECULAR MECHANISMS OF GFI1B VARIANTS IDENTIFIED IN CASES WITH 
INHERITED BLEEDING AND PLATELET DISORDERS. 
Nonsense and frameshift variants causing a truncation of the DNA binding 
domain
In the last five years several types of GFI1B variants have been identified in patients with inherited 
bleeding and platelet disorders.1-8 The first identified variants cause a heterozygous truncation of the 
DNA binding domain. These proven pathogenic variants (G272fs4, Q287*1, H294fs2) act in a dominant-
negative manner over wild type GFI1B, likely by sequestering the LSD1 containing CoREST co-repressor 
complex with its N-terminal SNAG domain (Chapter 2, Figure 1A-B). At the protein level there are at least 
two GFI1B isoforms expressed, full length GFI1B-p37 and the shorter isoform GFI1B-p32. GFI1B-p32 
lacks intact zinc finger 1 and 2 due to (coding) exon 4 skipping. The dominant-negative truncating 
variants will be present in both GFI1B isoforms, as they are located in DNA-binding zinc finger 5 and 
the loop between zinc finger 4 and 5. The SNAG domain is still intact in both isoforms and GFI1B-p32 
also interacts with the CoREST complex,9 suggesting that mutant GFI1B-p37/p32 will inhibit wild type 
GFI1B-p37/p32. In line with this, overexpression of GFI1B–p32-Q287* resulted in a similar increase of 
MEG-01 expansion as GFI1B-p37-Q287* (Figure 2). 
Variants affecting expression of GFI1B isoforms p37 and p32
Furthermore, a pathogenic homozygous truncating variant has been described in non-DNA binding 
zinc finger 1 (S185fs).8 This variant only affects GFI1B-p37 because GFI1B-p32 lacks intact zinc finger 1 
and 2. Thus, S185fs results in loss of GFI1B-p37. Homozygously mutated family members have a severe 
bleeding diathesis, while heterozygous family members are unaffected, indicating that GFI1B-p37 is 
crucial for platelet development. Apparently, the remaining GFI1B-p32 levels in the homozygous 
mutated family members are not sufficient for normal platelet development, suggesting that GFI1B-p32 
is not involved in this process. However, the expression level of GFI1B-p32 is ~5 times lower than that 
of GFI1B-p37.9 Therefore it is possible that the total protein level of GFI1B, independent of the isoform, 
is causing the phenotypes in GFI1B-S185fs patients, instead of absence of GFI1B-p37. So far, GFI1B-p32 
has only been described to regulate erythropoiesis.9 We observed that megakaryoblastic MEG-01 
cells overexpressing GFI1B-p32 are growing at a similar rate as non-transduced cells, in contrast to 
GFI1B-p37 transduced cells which are overgrown by non-transduced cells (Figure 3). This shows that 
GFI1B-p32 does not affect megakaryoblast expansion, and supports the theory that GFI1B-p32 does 
not control megakaryopoiesis. The generation of megakaryocyte differentiation models exclusively 
expressing GFI1B-p32 at a level comparable to the p37 isoform may proof this assumption.
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Figure 1. Molecular mechanism of GFI1B wild type and variants. (A) GFI1B interacts via LSD1 with the CoREST 
complex (LSD1, RCOR1, HDAC1/2, GSE1, HMG20B PHF21A). Proline 2 (P2) and lysine 8 (K8) of GFI1B are crucial this 
interacti on. LSD1 can demethylate H3Kme1/2. However it remains to be investi gated if this is also possible when 
LSD1 is recruited by GFI1B, because H3K4me1/2 and GFI1B bind the same pocket of LSD1. HDAC1/2 can deacetylate 
H3K27ac and H3K9ac. (B) GFI1B-Q287* cannot bind DNA anymore and inhibits wild type GFI1B by sequestering the 
CoREST complex. (C) The mechanism of zinc fi nger 1 (Znf1) missense variants is sti ll unclear. The mutated proteins 
can bind DNA, but the repressive functi on is disrupted. This could be caused by a lost interacti on with a yet to be 
identi fi ed co-factor. 
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Figure 2. Overexpression of Q287* mutated GFI1B-p37 and GFI1B–p32 result in increased MEG-01 expansion. 
Expansion competition cultures of MEG-01 cells retrovirally transduced with empty vector (EV), GFI1B-P37+Q287*-
flag, or GFI1B-p32+Q287*-flag. Fold change of GFP% to GFP% at day 5 (first GFP measurement) is presented on the 
y-axis. Results show mean ± standard error of the mean (n=5).
 
Missense variants
In addition, several GFI1B missense variants (C165F,5 C168F,7 H181Y, and R184P) have been described 
in non-DNA binding zinc finger 1. Most of these variants are of unknown significance as they do not 
necessarily lead to bleedings on their own, although they do affect GFI1B function. Identification of 
additional families will help to better classify these variants. GFI1B variants C165F, C168F and H181Y 
affect zinc coordinating amino acids suggesting that the tertiary structure of zinc finger 1 is disrupted 
by these variants and thereby GFI1B function. Indeed, although the DNA binding domain is still intact, 
C168F, H181Y, and R184P were reported to decrease the transcriptional repression at endogenous 
promoters (Chapter 3).7 The majority of these zinc finger 1 missense variants is associated with a 
bleeding diathesis and/or thrombocytopenia. In contrast, individuals with a heterozygous splice site 
variant resulting in expression of GFI1B-p32 (lacks intact zinc finger 1) instead of GFI1B-p37, do not 
suffer from a bleeding diathesis or thrombocytopenia.7, 8  This indicates that loss of zinc finger 1 in one 
allele is less damaging than missense variants in this region, suggesting that the missense variants are 
not merely loss of function but do somehow interfere with wild type GFI1B or have a changed function. 
Possibly the missense mutated proteins have lost the interaction with a co-(transcription) factor and 
inhibit wild type GFI1B by occupying the target sites or might even have new target sites (Figure 1C). 
Further studies are necessary to unravel the molecular mechanism of these missense variants and 
clarify the function of zinc finger 1. 
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 Finally, a reported homozygous missense variant in zinc fi nger 6 (L308P) may result in a mild 
bleeding diathesis with macrothrombocytopenia and a reducti on in δ-granules,6 indicati ng that the 6th
zinc fi nger is also important for GFI1B and its role in megakaryopoiesis and platelet development. This 
is supported by our observati on that GFI1B without zinc fi nger 6 does not inhibit MEG-01 proliferati on 
like wild type GFI1B (Figure 4). Further studies are required to unravel the molecular mechanism of this 
variant and the normal functi on of zinc fi nger 6.Figure 3
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Figure 3. GFI1B-p32 does not inhibit expansion of MEG-01. Expansion competi ti on cultures of MEG-01 cells 
retrovirally transduced with empty vector (EV), GFI1B-P37-fl ag, or GFI1B-p32-fl ag. Fold change of GFP% to GFP% at 
day 5 (fi rst GFP measurement) is presented on the y-axis. Results show mean ± standard error of the mean (n=5), and 
two-tailed paired t-tests were performed on day 26 to determine stati sti cal signifi cance *P<0.05
Figure 4
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Figure 4. GFI1B without zinc fi nger 6 does not inhibit expansion of MEG-01. Expansion competi ti on culture of 
MEG-01 cells retrovirally transduced with empty vector (EV), GFI1B-fl ag, or GFI1B-fl ag without zinc fi nger 6 (ZF6). 
Fold change of GFP% to GFP% at day 5 (fi rst GFP measurement) is presented on the y-axis. All constructs are in 
GFI1B-p37 isoform context. N=1
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GFI1B REGULATES GENE EXPRESSION BY RECRUITING THE COREST COMPLEX
GFI1B interacts with LSD1 via its N-terminal SNAG domain.10 This interaction can be disrupted by 
introducing a P2A or K8A mutation in GFI1B (Figure 1A). In Chapter 2 we showed that GFI1B-P2A 
and GFI1B-K8A have lost the biochemical function of gene repression and the biological function of 
inhibiting MEG-01 expansion. Furthermore, disruption of the GFI1B-LSD1 interaction with the small 
molecule GSK-LSD1 disrupted the differentiation of primary megakaryoblasts. Together, this indicates 
that the GFI1B-LSD1 interaction plays a crucial role in regulating megakaryoblast proliferation and 
differentiation. 
 GFI1B pull-downs in MEG-01 cells showed that GFI1B associates with LSD1 and other 
components of the CoREST co-repressor complex such as RCOR1 (CoREST), HDAC1/2, PHF21A 
(BHC80), and HMG20B (BRAF35) (Figure 1). The other proteins found, GSE1, RCOR3, and ZMYM2/3, 
are also known LSD1 interactors.11 ZMYM2/3 and PHF21A have not been reported in complex with 
GFI1B before.10 Remarkably, ZMYM3 (binding to GFI1B-Q287*) was identified as the only significantly 
differentially interacting protein between GFI1B and GFI1B-Q287*. Whether the ZMYM3 interaction 
with GFI1B-Q287* is relevant for disease pathogenesis remains to be seen.
 HDAC1/2 and LSD1 are the histone modifying proteins in the CoREST complex. HDAC1/2 bind 
the ELM2 and SANT domain of RCOR1, and deacetylates histone 3 lysines.12 LSD1 consists of a SWIRM 
domain that contributes to protein-protein interactions, the amine oxidase-like (AOL) domain with the 
catalytic activity, and a tower domain interacting with RCOR1. The AOL domain has two subdomains, 
one binds the cofactor flavine-adenine dinucleotide (FAD) and the other recognizes  substrates. Through 
a FAD-dependent oxidative reaction, LSD1 demethylates H3K4me1/2. However, LSD1 can also act as an 
co-activator through binding of the androgen or estrogen receptor and H3K9me1/2 demethylation, or 
demethylate non-histone proteins such as DNMT1 and TP53. In hematopoietic cells, LSD1 is recruited 
to chromatin by transcription factors such as GFI1B, GFI1, TAL1, GATA2 and SALL4.13 
 The SNAG domain sequence of GFI1B and GFI1 mimics the histone 3 tail and binds the same pocket 
in LSD1.14 Interestingly, the SNAG domain has a stronger affinity for LSD1 than histone 3, suggesting that 
GFI1B must be released from LSD1 before H3K4me1/2 demethylation can take place. Furthermore, 
GFI1B-p32 needs to be methylated at lysine 8 for LSD1 and CoREST complex recruitment.9 Whether 
this is also the case for GFI1B-p37 remains to be seen. We did show that lysine 8 is important for the 
LSD1-GFI1B-p37 interaction (Chapter 2). Possibly LSD1 demethylates GFI1B-K8 and is thereby released 
from GFI1B, making the substrate pocket available for the histone 3 tail. The methyl transferase that 
methylates GFI1B-K8 is still unknown. 
 The dynamics and role of different members of the CoREST complex in combination with GFI1B 
is not exactly clear. Based on current knowledge GFI1B could recruit the CoREST complex to DNA via 
the SNAG domain-LSD1 interaction, after which HDAC1 and HDAC2 first deacetylate the histone 3 tail. 
RCOR1 recognizes hypoacetylated histone 3, bridging LSD1 with nucleosomal substrates.11 RCOR1 and 
HMG20B can also bind DNA (non specifically),15, 16 stabilizing the complex which might be enough for 
GFI1B to release LSD1 and opening the LSD1 substrate pocket for H3K4me1/2. In addition to DNA, 
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HMG20B also interacts with PHF21A.16 PHF21A binds unmethylated H3K4 and stabilizes the associati on 
of LSD1 with chromati n, consequently promoti ng the acti vity of LSD1 as a transcripti onal repressor. 
Binding of PHF21A to demethylated H3K4 might be important for LSD1 to mediate demethylati on of the 
neighbouring nucleosome.17
 There is also data which suggests that some CoREST complex components inhibit LSD1 functi on, 
for example PHF21A18 and RCOR3.19 RCOR3 inhibits LSD1 demethylati on acti vity and competes with 
RCOR1. In line with this, LSD1 and RCOR1 silencing suppressed erythro-megakaryocyti c diff erenti ati on 
in fetal liver hematopoieti c progenitors, while RCOR3 silencing sti mulated diff erenti ati on of these cells.19
Furthermore, HMG20B silencing causes spontaneous erythroid diff erenti ati on in mouse fetal liver 
cells. In contrast to silencing of LSD1 and GFI1B, which inhibits erythroid diff erenti ati on.20 Altogether 
this suggests that there are diff erent CoREST complexes at work during erythro-megakaryocyte 
development. ChIP sequencing of GFI1B, CoREST complex components, and histone modifi cati ons 
could identi fy the combinati ons of factors at GFI1B target genes and their epigeneti c acti ons during 
megakaryopoiesis. 
LSD1 inhibitors to investi gate the GFI1B-CoREST complex dynamics. 
LSD1 is overexpressed in approximately 60% of the acute myeloid leukemia (AML) cases. Recent 
publicati ons suggest that LSD1 contributes to leukemia development and propagati on by inducing an 
arrest in myeloid diff erenti ati on and promoti ng proliferati on. A number of phase I/II clinical trials are 
ongoing to investi gate the safety and effi  cacy of LSD1 inhibitors in AML. Overall these compounds appear 
to exert a promising anti -leukemic eff ect by inhibiti ng proliferati on and restoring myeloid diff erenti ati on 
in AML cells. There is an increased effi  cacy for leukemia subtypes carrying MLL and AML1 (RUNX1) 
rearrangements, NPM1 variants, and erythroid/megakaryoblasti c diff erenti ati on block.21
 Most LSD1 inhibitors have been designed by modifying the structure of tranylcypromine 
((±)-trans-2-phenylcyclopropylamine; abbreviated 2-PCPA), an anti depressant originally developed to 
target monoamine oxidase A and B, which are structurally related to LSD1. Tranylcypromine derivati ves 
use LSD1’s catalyti c machinery to covalently modify FAD and irreversible inacti vate LSD1, with the 
assumpti on that these LSD1 inhibitors block the histone demethylase acti vity.22, 23 Indeed, H3K4me1/2 
levels are increased upon LSD1-inhibitor treatment in diff erent cell types.24, 25 In contrast, two separate 
studies treati ng either THP1 or HEL cells with tranylcypromine derivati ves OG86 or NCD38 showed 
unchanged H3K4me1/2 levels (LSD1 target), and increased H3K9ac and/or H3K27ac levels (HDAC1/2 
targets).26, 27 This could suggest that LSD1 rather functi ons as a scaff olding protein instead of a 
demethylase in these leukemia cell lines, and that the HDAC acti vity of the CoREST complex is more 
important than LSD1’s demethylase acti vity. It would be interesti ng to investi gate if H3K4me1/2 levels 
are unchanged aft er LSD1 inhibitor treatment because LSD1 is mainly recruited by GFI1B or GFI1 in 
these cell lines. This could be possible because the SNAG domain of GFI1B and GFI1 binds the same 
pocket as the histone 3 tail, making it impossible for LSD1 to demethylate H3K4me1/2 when recruited 
by these transcripti on factors. Additi on of an LSD1 inhibitor in this scenario would not induce changed 
H3K4me1/2 levels.
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 Furthermore, multiple studies in leukemia cell lines have shown that tranylcypromine derivative 
LSD1 inhibitors (OG86, NCD38, T-3775440, GSK-LSD1) inhibit the interaction with the SNAG domain 
proteins GFI1B and GFI1.26-28 Of note, NCD38 also slightly reduced the interaction between LSD1 and 
RUNX1.26 Upon OG86 treatment in THP1 cells, LSD1, RCOR1, and GFI1 are released from chromatin, 
suggesting that GFI1 requires the CoREST complex for stable chromatin binding, as has been reported 
for SNAI1 (another SNAG-domain protein).27 In contrast, HEL cells treated with NCD38 showed no 
change in the amount of GFI1B binding, suggesting that GFI1B stably interacts with chromatin without 
the CoREST complex.26 Additional studies are therefore needed to validate the stability of GFI1B and 
GFI1 on chromatin without the CoREST complex. In summary, LSD1 has a scaffolding function in addition 
to its demethylase activity, and LSD1-inhibitors can target both these activities making them ideal to 
study GFI1B function. 
TARGETS AND PATHWAYS EXPLAINING PHENOTYPES IN GFI1B-RELATED 
BLEEDING AND PLATELET DISORDERS.
Patients with inherited dominant-negative GFI1B variants often suffer from a bleeding disorder with 
macrothrombocytopenia, a reduction in α- and δ-granule numbers, platelet CD34 expression, and high 
numbers of dysmorphic megakaryocytes in the bone marrow. The multiple defects suggest that GFI1B 
is involved in many processes during megakaryopoiesis. Insight into downstream GFI1B pathways could 
further our understanding of platelet formation and provide new therapeutic targets for (inherited) 
thrombocytopenia. 
GFI1B targets identified in cell lines and Gfi1b-null mice
Only a few direct GFI1B targets have been identified in megakaryopoiesis so far. These include RGS18,29 
FERMT3, and TLN1.30 Interestingly, inherited FERMT3 variants cause defective platelet aggregation 
resulting in a bleeding diathesis.31 Rgs18 is a GTPase activating protein (GAP) that binds activated 
G-proteins and stimulate their GTPase activity, thereby terminating G-protein signaling. GATA1, a known 
interaction partner of GFI1B, is reported to repress RGS18 in erythroid cells.29 It would be interesting 
to study whether GATA1 and GFI1B repress RGS18 together in erythropoiesis and megakaryopoiesis. 
FERMT3 and TLN1 encode for Kindlin3 and Talin1, respectively. Kindlin3 and Talin1 are cytoskeletal 
proteins that bind cytoplasmic tails of integrins, particularly the β3 subunit (CD61) of  the αIIbβ3 integrin 
complex (CD41/CD61), which is the fibrinogen/fibronectin receptor and crucial for platelet aggregation. 
These interactions lead to activation of the integrin molecule, thereby greatly increasing their affinity for 
ligands. Furthermore, Kindlin3 and Talin1 stimulate megakaryocyte differentiation likely by remodeling 
the cytoskeleton. Interestingly, preliminary results from Singh et al. showed that Rgs18 interacts with 
Kindlin3 and Talin1 in megakaryocytes, which suggests the existence of a cytoskeletal associated signaling 
network downstream of GFI1B which may synergistically drive megakaryopoiesis.30 These studies are in 
line with work of Beauchemin et al. showing that Gfi1b-null cells have a poor response (cell spreading) 
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to integrin acti vati on. For instance integrin β3 is upregulated leading to more αIIbβ3 (CD41/CD61) 
complex on the membrane. Surprisingly, Gfi 1b-null megakaryocytes were unresponsive to fi brinogen 
and fi bronecti n, suggesti ng that internal signaling is disturbed. In additi on, PAK4 which regulates acti n 
cytoskeleton and microtubule expression is strongly increased in Gfi 1b-null cells. Inhibiti on of type 
II PAKs (e.g. PAK 4) completely rescued the responsiveness of Gfi 1b-null megakaryocytes to integrin 
acti vati on, but not their ability to form proplatelets. The disturbed proplatelet formati on in Gfi 1b-null 
megakaryocytes is at least parti ally due to a of lack α-tubulin. Because of this the cells are incapable to 
polymerize β-tubulin into microtubules.32  
Aff ected pathways in GFI1B-Q287* iPSC-derived megakaryocyti c cells
To identi fy GFI1B regulated pathways crucial in megakaryopoiesis, we generated induced pluripotent 
stem cell (iPSC) lines from an individual with the dominant-negati ve GFI1B-Q287* variant and a 
healthy volunteer. These cells were diff erenti ated towards megakaryocytes and their proteomes were 
compared.  In GFI1B-Q287* iPSC-derived megakaryocyti c cells we observed a down-regulati on of 
IFN-γ signaling proteins compared to control cells. IFN-γ and its downstream eff ector STAT1 sti mulate 
megakaryocyte diff erenti ati on (polyploidizati on) and platelet producti on,33, 34 so it would be interesti ng 
to further validate if GFI1B regulates IFN-γ signaling pathways. Furthermore, GFI1B-Q287* iPSC-derived 
megakaryocyti c cells revealed signifi cantly increased protein levels of the enti re minichromosome 
complex (MCM2-7), which is required for DNA replicati on and cell cycle progression. Several studies 
including our own (Chapter 2) have shown that MCM proteins are down-regulated upon polyploidizati on 
and further megakaryocyte diff erenti ati on.35, 36 Thus, failure of down-modulati on of DNA-replicati on 
associated genes as a consequence of GFI1B-Q287* might contribute to the lack of polyploidizati on 
in the GFI1B-Q287* iPSC-derived megakaryocyti c cells. Furthermore, the transcripti on factor MEIS1 
showed consistent expression in GFI1BQ287* iPSC-derived megakaryocyti c cells, while it was never 
detected in control iPSC-derived cells. MEIS1 is a key player in megakaryocyte diff erenti ati on and forced 
MEIS1 expression in CD34+ cells results in larger and more colonies in CFU-MK assays.37 The increased 
MEIS1 expression might therefore contribute to the increased proliferati on observed for GFI1B-Q287*
iPSC-derived megakaryocyti c cells. MEIS1 was earlier indenti fi ed as a GFI1B target gene in murine 
erythrocyti c cells, but specifi cally not in murine megakaryocyti c cells.38 Therefore, it would be interesti ng 
to investi gate whether MEIS1 is a GFI1B target in human cells. To validate these candidate genes and 
identi fy more GFI1B target genes in iPSC-derived megakaryocytes, our research group plans to perform 
ChIP sequencing of GFI1B, CoREST complex components, and histone modifi cati ons. Finally, rescue 
experiments may be performed to determine whether deregulati on of these genes by GFI1B-Q287* 
can explain the increased proliferati on and disturbed diff erenti ati on of iPSC-derived megakaryocytes.
Aff ected pathways in GFI1B-Q287* primary platelets
With platelets representi ng the fi nal stage of megakaryopoiesis, we generated proteome profi les 
of primary platelets from control and GFI1B-Q287* individuals. In line with the reported α-granule 
CHAPTER 5
130
deficiency,1 α-granule proteins such as VWF, THBS1, and PF4, showed markedly reduced levels in 
GFI1B-Q287* platelets. However, from our data in Chapter 2 it was not possible to conclude whether 
this is caused by a defect in generation of these proteins, the formation of α-granules, or trafficking 
of the α-granules to proplatelets. Megakaryocytes of GFI1B-Q287* patients contained a few poorly 
developed α-granules,1 and expression of proteins involved in formation of α-granules was unchanged 
or even increased in the platelets of GFI1B-Q287* patients. As described above, Gfi1b-null cells have 
defective microtubule formation and proteins associated with the gene ontology term cytoskeleton 
were underrepresented in platelets of GFI1B-Q287* patients. This could be supportive for the theory of 
affected α-granule trafficking causing reduced α-granule numbers in platelets of GFI1B-Q287* patients. 
 In addition to decreased α-granule proteins, many other proteins were deregulated.  Gene 
ontology terms associated with down-regulated proteins in GFI1BQ287* platelets were related to platelet 
functions, including wound healing, adhesion, cytoskeleton, and vesicle secretion. Proteins elevated in 
GFI1B-Q287* platelets were particularly enriched for gene ontology terms on more basic cell processes, 
such as mitochondrial function, metabolic function, ubiquitination, and RNA processing. These gene 
ontology terms already suggest that the GFI1B-Q287* megakaryocytes were not developed well when 
generating these platelets. This was confirmed by comparing protein profiles of healthy maturing 
megakaryocytes with GFI1B-Q287* patient derived platelets. Around 80% of down-regulated proteins 
in GFI1B-Q287* platelets showed a clear pattern of up-regulation in differentiating megakaryocytes, 
whereas the proteins that showed up-regulation in GFI1B-Q287* platelets were generally down-
modulated during megakaryocyte differentiation (~60%). As platelets represent the terminal stage of 
megakaryocyte maturation, our proteomic data show that the GFI1B-Q287* platelets resemble poorly 
differentiated megakaryocytes. 
Comparing the GFI1B deficient models 
The generated proteomes of primary platelets, iPSC-derived megakaryocytic cells, and normal 
megakaryopoiesis are of great value as they more closely represent what is happening in human 
(patho)physiology compared to the cell line and mice studies reported before. The proteins Talin1, 
Kindlin3, and Rgs18 encoded by the earlier identified GFI1B target genes were detected in iPSC-derived 
megakaryocytic cells and primary platelets. None of the three proteins were differentially expressed 
in iPSC-derived megakaryocytes, and only Talin1 and Rgs18 protein levels were significantly different 
between control and GFI1B-Q287* platelets. Since GFI1B is a repressive transcription factor, one would 
expect direct target genes to be up-regulated in GFI1B-Q287* platelets. In contrast,  Talin1 and Rgs18 
expression was down-regulated. Furthermore, PAK4 was up-regulated and α-tubulin down-regulated in 
Gfi1b deficient mouse megakaryocytes. However, PAK4 was not detected and α-tubulin not consistently 
differentially expressed in iPSC-derived megakaryocytic cells, normal megakaryocytes, or primary 
platelets. In summary the different GFI1B deficient models do not always correlate with what is found 
in GFI1B-Q287* cells and platelets. This could be explained by the differences in cell type or species, but 
possibly also because the dominant negative GFI1B mutation not only inhibits GFI1B function when it 
sequesters the CoREST complex but also other transcription factors relying on this complex.
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CHALLENGES IN CLASSIFICATION OF NEW VARIANTS IN INHERITED 
BLEEDING AND PLATELET DISORDERS.
Due to high-throughput next generati on sequencing approaches many new gene variants have been 
identi fi ed in inherited bleeding and platelet disorders. Standards and guidelines for the classifi cati on 
of new gene variants have been published by the American College of Medical Geneti cs (ACMG) and 
Genomics and the Associati on for Molecular Pathology (AMP),39 and similar recommendati ons have 
been made by EuroGentest and the European Society of Human Geneti cs.40 The classifi cati ons are 
based on evidence such as variant allele frequency in a control populati on, co-occurrence with a known 
pathogenic variant in another gene, in-silico predicti ons on the eff ect of the variant on nucleoti de 
and amino acid level, segregati on of the variant with disease, and functi onal studies. The functi onal 
studies produce strong evidence for either ‘benign’ or ‘pathogenic’ classifi cati on, and are crucial in the 
interpretati on of variants in small families. Therefore it is very important that the functi onal studies are 
carefully validated and reproducible in showing a damaging eff ect on the gene or gene product, and 
preferably model a phenotype of the pati ent. 
 In Chapters 2 and 3 we developed assays to investi gate the damaging eff ect of variants on GFI1B 
functi on. Luciferase reporter assays show whether the biochemical GFI1B functi on of inducing gene 
repression is aff ected by using exogenous promoters. A more physiological model was also developed 
where this same functi on is tested on endogenous GFI1B target promoters. Furthermore we designed 
an expansion competi ti on assay using the megakaryoblasti c cell line MEG-01, which shows the biological 
GFI1B functi on of inhibiti ng cell expansion. Introducti on of the dominant-negati ve GFI1B-Q287* variant 
sti mulates MEG-01 expansion, and therefore models the increased megakaryocyte expansion observed 
in bone marrow of GFI1B-Q287* aff ected individuals. To further validate the expansion assay, we tried 
to identi fy the underlying process (apoptosis or proliferati on) that could explain why MEG-01 cells with 
exogenous GFI1B are overgrown by non-transduced cells, and the opposite occurs with cells expressing 
GFI1B-Q287*. However, we could not detect clear diff erences in apoptosis or the amount of cells in 
S-phase.
 Recently, we also performed the same expansion assay in another megakaryoblasti c cell line called 
CMK. We observed that the CMK cells expressing exogenous GFI1B were much faster overgrown than 
MEG-01 cells with exogenous GFI1B. However, the GFI1B-Q287* transduced CMK cells behaved more 
like empty vector transduced cells, and did not overgrow the non-transduced cells as was observed in 
MEG-01 (Figure 5A). Since the eff ect of exogenous GFI1B is faster and more pronounced in CMK, we 
hypothesized that these cells are overgrown because they undergo apoptosis. By staining the CMK cells 
with Annexin-V, we indeed observed a signifi cant higher percentage of apoptoti c cells in the exogenous 
GFI1B culture. The increased percentage of apoptoti c cells was not observed when introducing the 
pathogenic GFI1B-Q287* variant, or the variants of unknown signifi cance GFI1B-H181Y and GFI1B-
R184P (Figure 5B). Apoptoti c assays in CMK cells could also be used to investi gate the biological 
functi on of GFI1B in a broader context. The advantage for CMK cells being that the phenotype is faster 
presented, however the dominant-negati ve eff ect of GFI1B-Q287* is not visible.
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 For future functional test development, it would be desired to invest in models that show affected 
proplatelet formation or α-granule formation/trafficking because these phenotypes directly cause the 
bleeding diathesis in GFI1B mutated individuals. The increased megakaryocyte expansion observed in 
bone marrow of GFI1B-Q287* individuals and modeled in MEG-01 cells, is further upstream in the 
process of platelet development.  Figure 5
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Figure 5. GFI1B induces apoptosis in CMK cells. (A) Expansion competition cultures of CMK cells retrovirally 
transduced with empty vector (EV), GFI1B-flag wild type, or GFI1B-Q287*-flag. Fold change of GFP% to GFP% at day 
5 (first GFP measurement) is presented on the y-axis. Results show mean ± standard error of the mean (n=3). (B) 
Percentage of Annexin V positive CMK cells 6 days after retroviral transduction with  EV, GFI1B-flag, GFI1B-H181Y-
flag, GFI1B-R184P-flag or GFI1B-Q287*vectors. Results show mean ± standard deviation (n=3). Two-tailed paired 
t-tests were performed to determine statistical significance. *P<0.05 All constructs are in GFI1B-p37 isoform context.
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COLLABORATION OF GFI1B, GATA1, RUNX1 AND FLI1 EXPLAINING THE 
OVERLAP IN PHENOTYPES.
Inherited variants in transcripti on factors GFI1B, GATA1, RUNX1, and FLI1 cause bleeding and platelet 
disorders with thrombocytopenia and granule defects. For variants in GFI1B, GATA1, and RUNX1 
a reducti on of α-granules has been described, in contrast to FLI1 where the α-granules are fused. 
Other overlapping phenotypes are platelet CD34 expression for RUNX1 and GFI1B variants, platelet 
MYH10 expression for RUNX1 and FLI1 variants, and enlarged platelets with hyperproliferati on of 
megakaryocytes for GFI1B and GATA1 variants. This overlap in phenotypes could be explained by the 
fact that the factors regulate each other’s expression and interact to regulate transcripti on (RUNX1 
interacts with GATA1 and FLI1,41, 42 GFI1B interacts with GATA1,43, 44 and chromati n interacti on studies 
have shown many common targets for GATA1, RUNX1 and FLI1).45 To identi fy GFI1B, GATA1, RUNX1, 
and FLI1 co-regulated pathways underlying common phenotypes, our research group plans to compare 
proteome profi les of platelets from pati ents with inherited variants in these transcripti on factors. 
However, it would maybe be more informati ve to use megakaryocyti c cells in which also chromati n 
binding, histone marks, and transcriptomics can be assessed, such as pati ent derived iPSC cells or 
by CRISPR-Cas9 mediated introducti on of the variants in healthy iPSC lines to have a similar geneti c 
background.
 We already studied one overlapping phenotype of GATA1 (V205M, G208S, R216Q, D218G, 
D218N) and GFI1B (Q287*, L308P) variants: the increased megakaryocyte numbers in the bone marrow 
of these pati ents. Since GFI1B and GATA1 repress the anti -apoptoti c protein Bcl-XL together,44 we were 
wondering if disturbed apoptosis is underlying the increased megakaryocyte numbers in these pati ents. 
We studied GFI1B and GATA1 induced apoptosis in the acute megakaryoblasti c leukemia cell line CMK. 
Of note, CMK cells have a GATA1 mutati on preventi ng full length GATA1 expression, resulti ng in sole 
expression of the naturally occurring shorter isoform GATA1s (lacks the N-terminal transacti vati on 
domain, amino acids 1-83). Earlier we showed that GFI1B induced apoptosis, and that this eff ect was lost 
for GFI1B-Q287* (Figure 5B). Overexpression of GATA1 in CMK cells resulted in an increased percentage 
of apoptoti c cells, like what was observed for GFI1B. However, in contrast to GFI1B,  pathogenic variants 
in GATA1 (V205M, R216Q, and D218G) sti ll induced apoptosis like wild type GATA1. This could suggest 
that increased megakaryocyte numbers in the bone marrow of pati ents with inherited GATA1 variants 
are not caused by disturbed apoptosis, in contrast to GFI1B-Q287*. The percentage of apoptoti c cells 
in the CMK culture expressing exogenous GATA1s was decreased compared to the culture expressing 
exogenous GATA1, indicati ng that the N-terminal transacti vati on domain is crucial for apoptoti c functi on 
of GATA1 (Figure 6). These results are in line with an earlier report showing that the region between 
amino acids 54-110, which is parti ally lacking in GATA1s, is required to dampen cell growth.46
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Figure 6. The N-terminal transactivation domain of GATA1 is crucial for its pro-apoptotic function in CMK cells. 
Percentage of Annexin V positive CMK cells 6 days after retroviral transduction with  empty vector (EV), HA-GATA1, 
HA-GATA1s, HA-GATA1-V205M, HA-GATA1-R216Q, and HA-GATA1-D218G vectors. Results show mean ± standard 
deviation (n=3). Two-tailed paired t-tests were performed to determine statistical significance. *P<0.05
FUNCTIONAL CHARACTERIZATION OF THE RS621940 LOCUS ~8 KB 
DOWNSTREAM OF GFI1B.
GFI1B is not only pathologically involved in inherited bleeding and platelet disorders, but also in 
hematological malignancies. For example GFI1B expression is often increased in peripheral blood cells 
from leukemia and MPN patients.47, 48 Also, reduced GFI1B expression and function was associated with 
leukemia development and a worse prognosis for myelodysplastic syndrome (MDS) and acute myeloid 
leukemia (AML) patients.49, 50 This highlights the importance of balanced GFI1B expression, which is 
normally mediated by multiple epigenetic regulators such as GFI1B , GATA1, and TAL1 binding the GFI1B 
promoter and downstream regulatory elements. Up until now, three elements located 12.5 kb, 16 kb 
and 17.5 kb downstream of GFI1B have been identified that likely regulate GFI1B expression. 
 In chapter 4 we investigated whether the clonal hematopoiesis and MPN predisposing G-allele 
of rs621940, located ~8 kb downstream of GFI1B, affects GFI1B expression and auto-repression. The 
rs621940 locus binds many hematopoietic transcription factors in the leukemia cell line K562 including 
ERG1, GATA1/2 and TAL1, and is enriched for the enhancer associated histone mark H3K4me1 (ENCODE 
consortium). In addition, we observed clear GFI1B enrichment at the rs621940 locus in MEG-01 cells. 
Luciferase reporter assays suggest a repressive effect of the rs621940 encompassing element on the 
GFI1B promoter. However, the two rs621940-alleles did not affect GFI1B promoter activity differently 
in these assays. In addition, deletion of this region in K562 cells caused no consistent difference in 
GFI1B expression nor auto-repression. Finally, GFI1B expression from the two rs621940-alleles was not 
consistently different in mononuclear cells of healthy individuals. In conclusion, our studies find no 
evidence that rs621940 affects GFI1B expression nor auto-repression. 
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 The fact that many transcripti on factors bind the rs621940 locus suggests that this region is 
involved in gene regulati on. Furthermore, we identi fi ed 24 proteins that bind diff erenti ally to the two 
rs621940-alleles in MEG01 cells, suggesti ng a functi onal consequence of the polymorphism rs621940. 
Possibly GFI1B is regulated by the rs621940 element in cell types we did not investi gate, or the element 
regulates expression of another gene.
CONCLUSION
Several GFI1B variants have been identi fi ed in individuals with inherited bleeding and platelet disorders. 
Heterozygous GFI1B variants leading to a truncati on of the DNA binding domain are most frequent and 
truly pathogenic. Work in this thesis showed that the truncati ng variant GFI1B-Q287* inhibits wild type 
GFI1B in a dominant-negati ve manner by sequestering the CoREST complex. The proteome studies 
on iPSC derived megakaryocytes and primary platelets from control and GFI1B-Q287* individuals, 
identi fi ed many deregulated pathways and are valuable data sets for future studies into molecular 
pathways driving megakaryopoiesis and platelet formati on. Furthermore, we developed assays that 
show whether new variants have a damaging eff ect on the biochemical and biological functi on of GFI1B. 
The functi onal assays contributed to the classifi cati on of Q89fs, C168F, H181Y, and R184P as variants 
of unknown signifi cance. These variants aff ect GFI1B functi on through protein truncati on or disrupti on 
of zinc fi nger 1, but are not necessarily suffi  cient to cause bleedings on their own. Finally, we identi fi ed 
the rs621940 locus ~8 kb downstream of GFI1B as a putati ve regulatory DNA element. However, in our 
studies we did not fi nd evidence showing that this region regulates GFI1B expression. Further research 
is required to identi fy the functi onal consequence of the clonal hematopoiesis and MPN predisposing 
polymorphism rs621940.
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When a blood vessel is damaged due to injury or surgery a process called haemostasis prevents 
signifi cant blood loss. Blood platelets, or thrombocytes, have a central role in this process by forming a 
plug that stops the bleeding. Platelets are derived from large cells that reside in the bone marrow, called 
megakaryocytes. During megakaryocyte development, or megakaryopoiesis, early megakaryoblasts 
undergo endomitosis to become polyploid. This is followed by cytoplasmic maturati on, during which the 
demarcati on membrane system and α/δ-granules are formed. The δ-granules contain small molecules 
such as calcium, magnesium and adenine nucleoti des (ATP, ADP) that sti mulate platelet aggregati on. 
The α-granules store the proteins needed for coagulati on and haemostasis. Mature megakaryocytes 
generate multi ple, long branching extensions called proplatelets (containing the granules) that elongate 
into the sinusoidal blood vessels of the bone marrow. Finally, the blood fl ow will mediate the release of 
platelets into the blood stream. 
 The above described formati on of platelets is defecti ve in inherited platelet disorders with 
thrombocytopenia and/or thrombopathy resulti ng in a bleeding diathesis. Over 60 genes have been 
found mutated in various types of inherited platelet disorders. However, there are sti ll many pati ents 
that do not receive a molecular diagnosis. In this thesis we investi gated molecular mechanisms and 
downstream pathways of the transcripti on factor GFI1B, which is one of the mutated proteins in 
inherited platelet disorders. Identi fi cati on of molecular pathways relevant for megakaryopoiesis and 
platelet formati on could expand the panel of possibly mutated genes and thereby improve the molecular 
diagnosis success rate of inherited platelet disorders. In additi on, insight in molecular mechanisms and 
pathways can contribute to targeted drug development for thrombocytopenia or thrombopathy, and 
help to understand and hopefully prevent drug-induced thrombocytopenia. 
 GFI1B is crucial for emergence and maintenance of hematopoieti c stem cells, erythropoiesis, 
megakaryopoiesis, and platelet formati on. Loss of Gfi 1b in adult mice blocks terminal megakaryocyte 
diff erenti ati on, and inherited GFI1B variants can cause a bleeding diathesis with macro-thrombocytopenia 
and multi ple platelet and megakaryocyte defects. The phenotypes diff er between the type of GFI1B
variants. The most severe phenotypes are found in pati ents with truncati ng variants resulti ng in loss of 
the full-length GFI1B isoform (p37), the phenotypes caused by dominant-negati ve truncati ng variants 
are milder, and pati ents with missense variants someti mes do not even have a bleeding diathesis. 
Therefore, it is not clear if the reported missense variants are causati ve for all phenotypes. In additi on, 
the molecular mechanism of dominant-negati ve truncati ng and missense variants are unknown.
 GFI1B is a repressive transcripti on factor with an N-terminal SNAG domain that recruits the 
CoREST complex via LSD1. The C-terminus contains six zinc fi ngers of which 3-5 are essenti al for DNA 
binding. In chapter 2 we investi gated the molecular properti es of the heterozygous bleeding-associated 
GFI1B-Q287* variant. This dominant-negati ve variant has lost its DNA-binding functi on, but can sti ll 
interact with the LSD1 containing CoREST complex. The interacti on with LSD1 is crucial for both wild type 
GFI1B and the pathogenic functi on of GFI1B-Q287*. Together with the fact that disrupti on of the GFI1B-
LSD1 interacti on using a small molecule induces GFI1B-Q287* like phenotypes, this strongly suggests 
that dominant-negati ve truncati ng variants like GFI1B-Q287* inhibit wild type GFI1B by sequestering 
the CoREST complex. In additi on, we used GFI1B-Q287* to identi fy GFI1B regulated pathways crucial 
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for megakaryopoiesis and platelet function. To study megakaryopoiesis, we generated induced 
pluripotent stem cell (iPSC) lines from a healthy donor and GFI1B-Q287* patient, and differentiated 
them towards megakaryocytes. By comparing the proteome of healthy and GFI1B-Q287* iPSC-
derived megakaryocytic cells we found that proteins involved in cell division and proteins involved in 
interferon signaling were deregulated. To identify pathways involved in platelet production and function 
we generated proteome profiles of primary platelets from healthy and GFI1B-Q287* individuals. 
GFI1B-Q287* platelets showed reduced expression of proteins implicated in platelet function such 
as α-granule and cytoskeleton proteins, and elevated expression of proteins normally downregulated 
during megakaryocyte differentiation. These findings contribute to our knowledge on GFI1B function in 
both normal megakaryopoiesis and inherited platelet disorders. 
 In chapter 3 we performed a molecular and clinicopathological characterization of eight GFI1B 
variants previously identified in cases with unexplained bleeding and/or platelet defects. All variants 
are located in non-DNA binding domains: the intermediary domain (D23N, Q89fs, G139S), zinc finger 
1 (C168F, H181Y, R184P), the loop between zinc finger 1 and 2 (R190W), or zinc finger 2 (G198S). We 
developed a cell expansion assay to show the effect of variants on GFI1B function. This assay together 
with the clinicopathological characterization classified Q89fs, C168F, H181Y, and R184P as variants of 
unknown significance (VUS). They affect GFI1B function through protein truncation or disruption of zinc 
finger 1, but are not necessarily sufficient to cause bleedings on their own. Still, their identification and 
documentation will help to distinguish pathological from non-pathological GFI1B variants and increase 
our understanding of GFI1B functional domains. 
 In addition to inherited platelet disorders, GFI1B also has a pathological role in myeloid 
malignancies. For example, GFI1B expression levels are often upregulated in peripheral blood cells 
from patients with leukemia and myeloproliferative neoplasms (MPN). Also, reduced GFI1B expression 
and function was associated with leukemia development and a worse prognosis for myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML) patients. This highlights the importance of 
balanced GFI1B expression, which is normally mediated by multiple epigenetic regulators such as 
GFI1B, GATA1, and TAL1 binding the GFI1B promoter and downstream regulatory elements. Up until 
now, three elements located 12.5 kb, 16 kb and 17.5 kb downstream of GFI1B have been identified that 
could regulate GFI1B expression.  
 In chapter 4 we investigated whether the clonal hematopoiesis and the MPN-associated 
polymorphism rs621940, located ~8 kb downstream of GFI1B, affects GFI1B expression. Studies from 
the ENCODE consortium showed that many epigenetic regulators bind the rs621940 locus in K562 
cells, including GATA1 and TAL1. In addition, we observed clear GFI1B binding to the rs621940 locus 
in MEG-01 cells. Pull-down experiments using DNA-sequences with either rs621940-allele followed 
by protein identification using mass spectrometry detected 24 differentially bound proteins in MEG-
01 cells, but GFI1B was not among these. Luciferase reporter assays using the GFI1B promoter and 
a GFI1B downstream region encompassing rs621940, suggest that the rs621940 locus inhibits the 
GFI1B promoter. This effect was stronger for the C-allele than the G-allele. However, there was no 
significant difference in GFI1B auto-repression or GATA1-mediated stimulation between the rs621940 
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C- and G-allele. Also, deleti on of a 1.6 kb fragment encompassing rs621940 in K562 cells did not alter 
GFI1B expression or GFI1B auto-repression. Absolute GFI1B expression did not diff er between the 
rs621940[CC] and rs621940[CG] samples in primary peripheral blood mononuclear cells from healthy 
donors. Finally, the eff ect of rs621940 on allelic GFI1B expression in mononuclear cells was analyzed. 
Also, targeted deep RNA sequencing did not detect consistent diff erences between rs621940 alleles 
on allelic GFI1B expression. These studies fi nd no evidence that rs621940 aff ects GFI1B expression 
or GFI1B auto-repression. This calls into questi on whether the G-allele of rs621940 predisposes for 
myeloid transformati on through altered GFI1B expression. 
 In summary, we showed that inherited GFI1B variants with disturbed DNA binding inhibit wild type 
GFI1B by sequestering the CoREST complex. Our proteome studies on iPSC derived megakaryocytes and 
primary platelets from control and GFI1B mutated individuals, identi fi ed many deregulated pathways 
and are valuable data sets for future studies specifying GFI1B regulated pathways.  Furthermore, our 
studies showed that GFI1B zinc fi nger 1 missense variants disturb GFI1B functi on, but do not necessarily 
cause bleedings on their own. Publicati on of these variants contributes to improved molecular diagnosis 
of pati ents with inherited platelet disorders. Finally, we identi fi ed the rs621940 locus as a possible 
regulatory DNA element, but further studies are required to identi fy the functi onal consequence of 
rs621940. Possibly GFI1B is regulated by the rs621940 element in cell types we did not investi gate, or 
the element regulates expression of another gene.
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Wanneer een bloedvat beschadigd is door een verwonding of operati e zal hemostase voorkomen dat er 
te veel bloed verloren gaat. Bloedplaatjes, of trombocyten, hebben een centrale rol in dit proces door 
een prop te vormen die de bloeding stopt. Bloedplaatjes worden gevormd vanuit grote voorlopercellen 
in het beenmerg, genaamd megakaryocyten. Tijdens de ontwikkeling van megakaryocyten, of 
megakaryopoiese, ondergaan onrijpe megakaryoblasten endomitose waardoor ze polyploïd worden. 
Dit wordt gevolgd door rijping van het cytoplasma waarbij het demarcati e membraan systeem en α- en 
δ-granulen gevormd worden. De δ-granulen bevatt en moleculen zoals calcium, magnesium en adenine 
nucleoti den (ADP, ATP) die bloedplaatjes aggregati e sti muleren. De α-granulen bevatt en eiwitt en 
belangrijk voor bloedstolling en hemostase. Uiteindelijk zullen rijpe megakaryocyten meerdere lange 
vertakte uitstulpingen genaamd proplaatjes door de wand van kleine bloedvaten in het beenmerg 
steken. De proplaatjes bevatt en de bovengenoemde granules. Door de kracht van de bloedstroming 
worden de uiteindelijke bloedplaatjes afgescheiden van de proplaatjes uitstulpingen. 
 Het hierboven beschreven proces van bloedplaatjesvorming is verstoord in pati ënten met 
erfelijke bloedplaatjes aandoeningen, wat resulteert in een verhoogde bloedingsneiging met te weinig 
bloedplaatjes (trombocytopenie) en/of slecht functi onerende bloedplaatjes (trombopathie). Meer dan 
60 genen zijn gemuteerd gevonden bij verschillende erfelijke vormen van bloedplaatjesaandoeningen. 
Echter, er zijn nog steeds veel pati ënten waarbij de onderliggende mutati e niet gevonden wordt. In dit 
proefschrift  hebben we onderzoek gedaan naar de moleculaire eigenschappen van de transcripti efactor 
GFI1B, welke één van de gemuteerde eiwitt en is in erfelijke bloedplaatjes aandoeningen. Identi fi cati e 
van moleculaire paden relevant voor megakaryopoiese en bloedplaatjesvorming kan de groep van 
mogelijk gemuteerde genen vergroten en daarmee de moleculair-geneti sche diagnose verbeteren 
bij erfelijke bloedplaatjesaandoeningen. Verder zal inzicht in de moleculaire mechanismen en paden 
bijdragen aan het identi fi ceren van doelen voor gerichte therapie-ontwikkeling voor trombocytopenie/
trombopathie. Daarnaast kan dit ook van belang zijn bij het begrijpen en misschien voorkomen van 
medicati e-geïnduceerde trombocytopenie. 
 Het GFI1B eiwit is cruciaal voor het ontstaan en behouden van hematopoieti sche stamcellen, 
erytropoiese, megakaryopoiese, en bloedplaatjesvorming. Verlies van Gfi 1b in volwassen muizen 
blokkeert de terminale diff erenti ati e van megakaryocyten, en erfelijke GFI1B varianten kunnen 
resulteren in een verhoogde bloedingsneiging met trombocytopenie, en meerdere bloedplaatjes- en 
megakaryocyt-afwijkingen. De ernst van de bloedingsneiging hangt af van het type mutati e. De meest 
ernsti gste bloedingsneigingen worden gevonden bij pati ënten waarbij de grootste isovorm van GFI1B 
(genoemd p37) niet meer tot expressie komt. De fenotypen van dominant-negati eve varianten die niet 
in staat zijn DNA te binden zijn iets milder, en pati ënten met missense varianten buiten het DNA-bindend 
domein hebben soms niet eens een duidelijk verhoogde bloedingsneiging. Voor de gerapporteerde 
missense varianten is het dan ook niet alti jd duidelijk of zij verantwoordelijk zijn voor alle fenotypen. 
Daarnaast is nog onbekend hoe gemuteerd GFI1B de megakaryocyt- en plaatjesontwikkeling verstoort. 
 GFI1B is een represserende transcripti efactor met een N-terminaal SNAG domein welke het 
CoREST eiwitcomplex rekruteert via het LSD1 eiwit. De C-terminus van GFI1B bevat zes zink vingers 
waarvan zink vinger 3-5 essenti eel zijn voor DNA binding. In hoofdstuk 2 hebben we het moleculaire 
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mechanisme van de heterozygote GFI1B-Q287* variant onderzocht. Deze dominant-negatieve variant 
heeft zijn DNA-bindende functie verloren, maar kan nog steeds een interactie aangaan met LSD1 en 
de rest van het CoREST complex. Ons onderzoek toont aan dat het wegvangen van LSD1 door mutant 
GFI1B-Q287* een belangrijke rol speelt bij de pathogenese. Daarnaast induceert chemische verstoring 
van de GFI1B-LSD1 interactie in primaire megakaryoblasten fenotypen welke ook gevonden zijn in 
GFI1B-Q287* muteerde megakaryocyten. Samen laten deze experimenten zien dat dominant-negatieve 
truncerende varianten zoals GFI1B-Q287*, wild type GFI1B remmen door het CoREST complex weg 
te vangen. Verder hebben we GFI1B-Q287* gebruikt om GFI1B gereguleerde biologische paden te 
identificeren die belangrijk zijn voor megakaryopoiese en bloedplaatjesfunctie. Om megakaryopoiese 
te bestuderen hebben we geïnduceerde pluripotente stamcel (iPSC) lijnen gemaakt van een gezonde 
donor en een GFI1B-Q287* patiënt, en deze in de megakaryocytaire richting gedifferentieerd. Door 
de volledige eiwit expressieprofielen (proteoom) van gezonde en GFI1B-Q287* megakaryocyten 
te vergelijken, hebben we gevonden dat eiwitten met een rol in celdeling en interferon signalering 
gedereguleerd waren. Om paden te identificeren die belangrijk zijn voor bloedplaatjesproductie en 
-functie hebben we een proteoom gegenereerd van bloedplaatjes afkomstig van gezonde controles en 
een GFI1B-Q287* patiënt. GFI1B-Q287* bloedplaatjes lieten een verlaagde expressie zien van eiwitten 
belangrijk voor bloedplaatjesfunctie zoals α-granulen and cytoskeleteiwitten, en een verhoogde 
expressie van eiwitten die normaal laag zijn in rijpe megakaryocyten. Deze bevindingen dragen bij aan 
onze kennis over GFI1B functie in normale megakaryopoiese en erfelijke bloedplaatjes aandoeningen.
 In hoofdstuk 3 hebben we een moleculaire en clinicopathologische karakterisatie gedaan 
van acht GFI1B varianten die eerder gevonden zijn in casussen met onverklaarbare bloedingen 
en/of bloedplaatjes defecten. Alle varianten bevinden zich in niet-DNA bindende domeinen: het 
intermediaire domein (D23N, Q89fs, G139S), zink vinger 1 (C168F, H181Y, R184P), de lus tussen zink 
vinger 1 en 2 (R190W), of in zink vinger 2 (G198S). Wij hebben een assay ontwikkeld die het effect 
van varianten op GFI1B functie kan laten zien. De resultaten van deze functionele test heeft samen 
met de clinicopathologische karakterisatie, varianten Q89fs, C168F, H181Y, en R184P geclassificeerd 
als “variants of unknown significance” (varianten met onbekende significantie, VUS). Deze varianten 
beïnvloeden GFI1B functie door een truncatie of verstoring van zink vinger 1, maar zijn op zichzelf 
niet per se voldoende om een verhoogde bloedingsneiging te veroorzaken. De karakterisering van 
deze varianten zal bijdragen aan een verbeterde pathologische classificatie van GFI1B varianten (zeker 
wanneer ze vaker gevonden worden) en onze kennis vergroten over de functionele GFI1B domeinen.
 Naast erfelijke bloedplaatjesaandoeningen heeft GFI1B ook een pathologische functie in 
myeloide maligniteiten. Zo is GFI1B expressie vaak verhoogd in bloedcellen van patiënten met 
leukemie en myeloproliferatieve neoplasmen (MPN). Daarnaast is verlaagde GFI1B expressie en/
of functie geassocieerd met leukemie ontwikkeling en een slechte prognose voor patiënten met 
myelodysplastich syndroom (MDS) en acute myeloide leukemie (AML). Dit benadrukt dat een goed 
gereguleerde GFI1B expressie cruciaal is. Normaal gesproken wordt dit gerealiseerd door binding van 
verschillende regulatoren zoals GFI1B, GATA1 en TAL1 aan de GFI1B promoter en verder weg liggende 
regulatoire DNA elementen. Tot nu toe zijn drie regio’s 12.5 kb, 16 kb en 17.5 kb stroomafwaarts van 
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GFI1B gevonden die waarschijnlijk GFI1B expressie reguleren. In hoofdstuk 4 hebben we onderzocht 
of het single nucleoti de DNA polymorfi sme rs621940, welke 8 kb stroomafwaarts van GFI1B ligt en 
geassocieerd is met klonale hematopoiese en MPN, GFI1B expressie beïnvloedt. Studies van het 
ENCODE consorti um in K562 cellen (erytroleukemie cellijn van een chronisch myeloide leukemie (CML) 
pati ënt) hebben aangetoond dat veel regulatoire eiwitt en zoals GATA1 en TAL1  rondom rs621940 aan 
DNA binden. Daarnaast tonen wij in hoofdstuk 4 een duidelijke GFI1B binding aan rondom rs621940 
in MEG-01 cellen (megakaryocyt leukemie cellijn van een CML pati ënt). Vervolgens hebben we in 
MEG-01 cellen 24 additi onele eiwitt en geïdenti fi ceerd die binden rondom rs621940 en voorkeur 
hebben voor één van de twee allelen. GFI1B zat echter niet bij deze diff erenti eel bindende eiwitt en. 
Luciferase reporters assays die het eff ect laten zien van de rs621940 regio op GFI1B promoter acti viteit, 
suggereren dat de rs621940 regio de GFI1B promoter remt. Dit eff ect was sterker voor het C-allel dan 
het G-allel. Echter, er was geen signifi cant verschil in GFI1B repressie of GATA1 sti mulati e van de GFI1B 
promoter tussen het rs621940 C- en G-allel. Ook resulteerde deleti e van een 1.6 kb fragment rond het 
rs621940 locus niet in een consistent eff ect op GFI1B expressie of GFI1B auto-repressie in K562 cellen. 
In primaire perifere mononucleaire bloedcellen van gezonde donoren verschilde GFI1B expressie niet 
tussen de rs621940[CC] and rs621940[CG] monsters. Daarnaast was er in de rs621940[CG] monsters 
geen consistent verschil in allel-specifi eke GFI1B expressie gedetecteerd tussen het C- en G-allel. Onze 
experimenten hebben geen bewijs geleverd dat rs621940 GFI1B expressie of GFI1B auto-repressie 
beïnvloedt.  Deze data trekken de theorie dat het G-allel van rs621940 predisponeert voor myeloide 
transformati e door GFI1B expressie te veranderen in twijfel. 
 Concluderend kan gesteld worden dat de in dit proefschrift  beschreven hoofdstukken bijdragen 
aan een beter begrip van de functi e van normaal en gemuteerd GFI1B bij de ontwikkeling van 
megakaryocyten en bloedplaatjes.
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“Do what you like, and like what you do. “ Dit stond op mijn favoriete T-shirt en de door mijn moeder 
geschreven kaart voor het behalen van mijn master. In dit laatste hoofdstuk wil ik graag iedereen 
bedanken die deze periode “leuk” heeft  gemaakt. 
 Ten eerste wil ik Bert bedanken voor zijn vertouwen in mij, zeker wanneer ik dit zelf niet meer 
had. Je moti verende speeches en oneindig enthousiasme zorgden ervoor dat ik alti jd weer vol positi eve 
energie onze maandevaluati es uitkwam. Tijdens deze gesprekken kon ik in het begin je vele ideeën en 
theorieën nog alleen maar volgen, maar nu ben ik zo ver dat ik echt mee kan doen en jou af en toe 
iets kan uitleggen. Jouw enthousiasme was niet alleen wetenschap gerelateerd. Je kon ook alti jd trots 
vertellen over je eigen/oppas kinderen, klusjes rondom het huis, en vakanti es (inclusief foto’s en google 
maps om alles te visualiseren). Ook wanneer ik weer eens toe was aan “vitamine sea”, wist je alti jd veel 
mooie plekken die ik na het surfen kon bezoeken in bijvoorbeeld de Algarve of op Lanzarote. Dit samen 
heeft  ervoor gezorgd dat ik me vertrouwd en veilig voelde op de afdeling, en daar wil ik je heel erg voor 
bedanken.      
 Joop, heel erg bedankt voor al je input, en je terugkerende vragen naar de (klinische) relevanti e 
van ons onderzoek. Jouw streven naar effi  ciënti e is een belangrijke tegenhanger voor Bert zijn 
enthousiasme. Daarnaast creëer jij met je humor een informele werksfeer die ik heel pretti  g vind.
 Saskia, zonder jou had ik het allemaal nooit afgekregen. “Je hebt er weer één afgeleverd.”, zoals je 
zelf al zei. Heel erg bedankt voor het beantwoorden van al mijn vragen, en de vele experimenten die je 
hebt gedaan. Ik vond het een super fi jne samenwerking, en daarnaast ook erg gezellig buiten het lab bij 
de vierdaagse feesten, promoti e feestjes, en labuitjes.
 Anne, het was heel fi jn dat ik op een lopende trein mocht stappen en in het begin even bij jou 
mocht kijken hoe het allemaal werkt. Daarnaast was het ook alti jd erg gezellig op onze tripjes naar 
bijvoorbeeld de EHA in Wenen, Sanquin in Amsterdam, en de RIMLS PhD retreats. Heel veel succes 
verder in Boston.  
 Maaike, toen ik dreigde alleen over te blijven op de AIO kamer kwam jij gelukkig. Ik bewonder 
jouw doorzetti  ngsvermogen en positi eve “can do” instelling heel erg. Je hebt in deze drie jaar al zoveel 
nieuwe dingen jezelf eigen gemaakt en deze geïmplementeerd in het lab, nu moet je ze alleen nog gaan 
gebruiken. Bedankt voor de fi jne samenwerking, je moti verende insteek als ik het even niet meer zag 
zitt en dit laatste jaar, en de vele andere gesprekken. Heel veel succes verder met het afronden van je 
PhD, huis en “body by Bo”.         
 Florenti en, ik wil jou vooral bedanken voor al onze ti jd buiten het lab. Jij bent wel mijn maatje 
geworden hier in Nijmegen. Samen hockeyen, naar ASH in San Diego, Down the Rabbit hole, of andere 
concerten en festi vals. Op het lab was het vaak te gezellig als jij er was. Dus toen je nog alleen op 
donderdag kwam werken, plande ik deze dag maar niet te vol met experimenten want we moesten 
natuurlijk ook nog de vele series (Game of Thrones, Lucifer) en de hockey opstelling bespreken. 
 Leonie, van stage begeleider naar collega ging eigenlijk heel natuurlijk. Misschien omdat er een 
jaartje tussen zat, maar ook zeker omdat jij jezelf nooit boven andere stelt. Ik vond het alti jd erg gezellig 
om naast je te zitt en, en zal zeker onze trip naar de EHA Wenen nooit vergeten.
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Thessa en Ruth heel erg bedankt voor jullie hulp en gezelligheid de afgelopen jaren. Samen met Saskia 
zijn jullie de kern van onze moleculaire onderzoeksgroep en super waardevol.   
 Verder zijn er nog mensen in onze onderzoeksgroep met wie ik maar kort heb samengewerkt. 
Gorica, ik wil je graag bedanken voor de fijne gesprekken die we hebben gehad. Je was altijd oprecht 
geïnteresseerd, en ik hoop dat het snel weer beter met je gaat. Saskia L. en Maarten bedankt voor jullie 
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